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Role of Kappa-Opioid Receptors in Stress-Induced Behaviors 
 
Abstract 
 
The development of anxiety and mood disorders often coincides with exposure to 
stress.  Accumulating evidence indicates that both corticotropin-releasing factor (CRF) 
and dynorphin, the endogenous ligand for the kappa-opioid receptor (KOR), can 
mediate the effects of stress.  My dissertation research utilized laboratory animals to 
investigate the role of KORs in stress-induced increases in the acoustic startle 
response, a metric often used to study stress effects in humans.  Using wild-type mice, I 
first demonstrated that systemic administration of a KOR antagonist produced an 
anxiolytic-like effect on acoustic startle following central (intracerebroventricular) 
infusion of CRF.  Immunohistochemical analysis revealed that KOR blockade 
decreased c-Fos cell counts in the dentate gyrus of the hippocampus in both vehicle- 
and CRF-treated mice, and reduced CRF-induced increases in the ventral tegmental 
area (VTA).  Within the VTA, reductions were predominantly in dopaminergic neurons.  
KOR antagonist pretreatment also produced anxiolytic-like effects on footshock-
potentiated startle, a model that quantifies context-specific fear conditioning.  To 
complement the antagonist studies, we developed constitutive knockout mice that lack 
KORs throughout the brain (KOR
-/-), and conditional KOs that lack KORs only within 
dopaminergic neurons (DAT-KOR
lox/lox).  Initial characterization demonstrated that these 
two mutant lines did not differ from controls in hearing, vision, weight gain, and iv 
 
locomotor activity.  KOR
-/- mice were similar to controls in unconditioned anxiety-like 
behavior, but DAT-KOR
lox/lox mice displayed nominal decreases in anxiety-like behavior 
in the open field and light/dark box.  Unexpectedly, KOR ablation did not affect CRF-
induced increases in startle in either mutant line.  Importantly, however, KOR antagonist 
treatment did not alter CRF-induced increases in startle in KOR
-/- mice, suggesting that 
KOR antagonist effects in wild-type mice are due to blockade of KORs.  These findings 
raise the possibility that differences in KOR antagonist and KOR
-/- studies may be 
related to brief KOR blockade during adulthood versus a lack of KORs during the entire 
lifespan.  In the footshock-potentiated startle paradigm, KOR
-/- mice were comparable to 
littermate controls, whereas DAT-KOR
lox/lox mice showed attenuated effects of 
footshock.  My findings confirm a role for KORs in fear and anxiety-like behavior in 
rodents, and implicate KORs expressed on dopaminergic neurons in modulating 
important aspects of stress-related behavior.v 
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Chapter 1 
 
Introduction 
 
Anxiety disorders represent an increasingly prevalent form of psychiatric illnesses, the 
effects of which can be debilitating.  The neurobiological basis of these disorders is not 
understood.  When functioning normally, the stress response is an adaptive process 
that maintains homeostasis.  However, prolonged stress or over-activation of the stress 
response is implicated in the development of myriad health issues including anxiety and 
depressive disorders (Kessler, 1997; Heim and Nemeroff, 1999).  Corticotropin-
releasing factor (CRF) is an important mediator of the stress response, and this peptide 
regulates hormonal, autonomic, and behavioral consequences of stress (Dunn and 
Berridge, 1990; Bale et al., 2002).  In animals, CRF induces a stress-like state when 
administered into the central nervous system (CNS) (Sutton et al., 1982) and leads to 
behavioral signs analogous to those seen in people with depressive and anxiety 
disorders (Dunn and Berridge, 1990; Owens and Nemeroff, 1991; Koob et al., 1993), 
suggesting that it plays an important role in the negative consequences of stress.  
Indeed, dysregulation of CRF function is thought to underlie human depressive and 
anxiety disorders (Nemeroff, 1992; Owens et al., 1993; De Souza, 1995).  As such, 
investigations into the activation of CRF signaling and downstream effects may provide 
insight into the mechanisms by which stress can trigger psychiatric illness.   
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Accumulating evidence links the kappa-opioid receptor (KOR) system with CRF-induced 
effects.  This system comprises KORs and their endogenous ligand dynorphin (Chavkin 
et al., 1982).  Like activation of the CRF system, activation of the KOR system has been 
implicated in the negative consequences of stress in rodents such as learned 
helplessness, drug seeking, and memory deficits (Pliakas et al., 2001; Newton et al., 
2002; Mague et al., 2003; McLaughlin et al., 2003a; McLaughlin et al., 2006b; Carey et 
al., 2009).  Recently, it has been demonstrated in mice that CRF-induced aversion and 
anxiety-like behavior are dependent on dynorphin and KOR activation (Bruchas et al., 
2009; Land et al., 2009; Knoll et al., 2011). These effects were attributed to KOR 
signaling in the dorsal raphe nucleus (DRN) and amygdala (AMY) respectively.  These 
regions work within a network of interconnected structures, which together contribute to 
behavioral output. 
 
The mesocorticolimbic system, comprising the ventral tegmental area (VTA) and its 
dopaminergic outputs to the nucleus accumbens (NAc), hippocampus (HIP), bed 
nucleus of the stria terminalis (BNST), prefrontal cortex (PFC), and AMY is one neural 
circuitry that integrates CRF and KOR effects.  Each component of this system has 
been implicated in stress and co-expresses CRF receptors (CRF-Rs) and KORs (De 
Souza et al., 1985; Mansour et al., 1995; Dautzenberg and Hauger, 2002).  Although 
the mesocorticolimbic system has not traditionally been studied for its role in depression 
and anxiety (Nestler and Carlezon, 2006), it is becoming increasingly clear that this 
circuit is involved in key aspects of these disorders (Pliakas et al., 2001; Barrot et al., 
2002; Barrot et al., 2005).  Antagonism of KORs within the NAc reduces depressive-like 
behavior (Newton et al., 2002; Shirayama et al., 2004) while NAc infusions of a KOR 3 
 
agonist into this region induce anhedonia (Muschamp et al., 2011b), a core symptom of 
depression.  Anxiety disorders are highly comorbid with depression, as over half of 
patients with lifetime major depression also meet the criteria for an anxiety disorder 
(Kaufman and Charney, 2000; Kessler et al., 2003).  Many treatments for depression 
are also effective in treating anxiety disorders (Ballenger, 1999), suggesting common 
genetic or neuroanatomic components.  As such, the mesocorticolimbic system may be 
a site of KOR activation that plays an important role in regulation of both depressive- 
and anxiety-like behavior.  The goals of this dissertation work are to further delineate 
the general role of KORs in mouse models of stress-induced behaviors, and to test the 
hypothesis that KORs within the mesocorticolimbic system play a particularly important 
role in regulating anxiety-related behavior.  An increased understanding of the systems 
mediating stress-induced illness may provide new opportunities for developing improved 
treatments for anxiety disorders.  
 
This chapter first provides background on stress and introduces CRF and its role in 
anxiety-and depressive-like behaviors.  The KOR system is introduced with focus on its 
role in stress-induced behavior and interactions with CRF.  The neural circuits 
underlying stress and anxiety are then described, with particular emphasis on the VTA 
and its target structures.  The chapter ends with a summary of the primary behavioral 
paradigms used to investigate the hypothesis that stress-related activation of KORs 
within the mesocorticolimbic system mediates anxiety-like behaviors as measured by an 
increase in the acoustic startle response. 4 
 
1. Anxiety   
Mental illnesses are the most common health problem today, with up to half of 
Americans meeting the diagnostic criteria for a disorder at some point in their lifetime.  
Anxiety disorders have a lifetime prevalence of 28.8% (Kessler et al., 2005b) and affect 
more than 40 million Americans in a given year (Kessler et al., 2005a).  Signs (objective 
metrics visible to an observer) and symptoms (subjective metrics described by the 
patient) of anxiety disorders include feelings of apprehension or dread, trouble 
concentrating, excessive worrying, insomnia, and pounding heart.  These effects make 
anxiety disorders the leading cause of workplace disability in the United States (Kessler, 
2000) and cost America an estimated $42.3 billion in 1990 (Greenberg et al., 1999), a 
price that has been increasing each year.  The fact that the neurobiology of anxiety 
disorders is poorly understood contributes to difficulties in the development of new 
treatments that are safer and more effective than present medications, which tend to 
have many side effects including sedation and abuse liability (Woods et al., 1992).  
Because stress is a major trigger for psychiatric disorders including anxiety, new 
insights might be gained from the study of stress-regulated neural circuits.  
 
2. Background on stress systems 
2.1 Effects of stress   
Endocrinologist Hans Selye defined stress as “the rate of wear and tear in the body” 
(Selye, 1956).  The concept of stress focuses on the notion that internal or external 
factors can negatively impact psychological and physical well-being.  Acutely, stress 
leads to involuntary hormonal (e.g., increased free fatty acid generation, inhibition of the 
immune system), autonomic (e.g., increased heart and breathing rate, increased blood 5 
 
flow to the brain and muscle), and behavioral (e.g., feelings of anxiety and fear, 
heightened vigilance) changes—often collectively called “the stress response”—that 
prepare the body to maintain homeostasis in response to a real or perceived threat.  
This adaptive response is generally protective in the short term (Keay and Bandler, 
2001).  However, severe or sustained stress often coincides with development of 
anxiety disorders, clinical depression, and drug abuse (Kessler, 1997; Kendler et al., 
1999; Pine et al., 2002; Volkow and Li, 2004; Fox et al., 2007; Koob and Kreek, 2007).  
In laboratory settings, stress paradigms often trigger depressive- and anxiety-like 
behaviors in model organisms.  Discrete types of stress (stressors) including footshock, 
maternal deprivation, and restraint induce depressive-like behaviors (e.g., increased 
immobility in the forced swimming test [FST]) (Platt and Stone, 1982; Aisa et al., 2008) 
and elevations in brain reward thresholds (Zacharko and Anisman, 1991).  More natural 
stressors also produce similar outcomes: as an example, subordinate mice in a chronic 
social defeat stress (CSDS) paradigm—an ethologically relevant stressor involving daily 
exposure to an aggressor—show anxiogenic-like responses such as spending less time 
in the lit area of a light/dark box and the open arms of an elevated plus maze (EPM) 
(Keeney and Hogg, 1999; Slattery et al., 2012), as well as decreases in social 
interaction (SI) with other mice (Avgustinovich et al., 2005; Berton et al., 2006).  Other 
ethologically-relevant forms of stress, such as resident-intruder stress and neonatal 
stress induced by maternal separation, also subsequently produce depressive-like 
effects in the FST (Wood et al., 2012), as well as in the SI test (Aisa et al., 2008; Marco 
et al., 2009).  These studies demonstrate how models of stress in rodents may enable 
valuable insights into the mechanisms of stress-induced illness in humans. 
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2.2 Corticotropin-releasing factor (CRF) 
CRF, first described by Vale and colleagues (1981), is the principal regulator of the 
stress response (Spiess et al., 1981; Majzoub, 2006).  It is part of a family of peptides in 
mammals also including urocortin 1 (UCN1), urocortin 2 (UCN2) and urocortin 3 (UCN3) 
(for review, see Reul and Holsboer, 2002).  The actions of these peptides are mediated 
through two cognate G-protein-coupled receptors, CRF-R1 and CRF-R2 (for review, see 
Dautzenberg and Hauger, 2002; Eckart et al., 2002).  CRF can activate both receptors, 
although it has greater affinity for CRF-R1 over CRF-R2.   UCN1 can also activate CRF-
R1, whereas CRF-R2 binds all UCNs with high affinity.  CRF-Rs are predominantly 
linked to the Gs-alpha subunit, which activates adenylate cyclase and cAMP-dependent 
pathway signaling.  However, CRF-Rs also appear capable of coupling to multiple other 
G proteins, including Gi and Gq/11, and thus can regulate multiple signaling cascades 
(Grammatopoulos et al., 2001; Blank et al., 2003) in a brain region-specific manner. 
 
CRF produced by cells in the paraventricular nucleus of the hypothalamus (PVN) 
triggers hormonal stress responses by activating the hypothalamic-pituitary-adrenal 
(HPA) axis, which leads to the release of adrenocorticotropic hormone (ACTH).  In turn, 
ACTH stimulates glucocorticoid release from the adrenal glands, which produces 
subsequent metabolic and cardiovascular changes.  Both CRF-containing neurons and 
CRF receptors are found throughout brain regions implicated in behavioral and 
autonomic responses, suggesting that CRF can also have direct effects in these 
regions, independent of HPA axis activation (Swanson et al., 1983; Merchenthaler, 
1984; Sakanaka et al., 1987; Koob et al., 1993; Dautzenberg and Hauger, 2002).  
Central CRF administration in laboratory animals has been shown to produce 7 
 
autonomic and behavioral effects that mimic acute stress responses, including 
increased heart rate and arterial pressure, and decreased food intake and reproductive 
behavior (Dunn and Berridge, 1990).  However, the downstream effects following 
receptor activation are not fully understood.  Further investigation into the systems that 
are responsive to CRF may provide new insights into how stress affects behavior. 
 
2.2.1 CRF in depression and anxiety 
CRF is also implicated in the detrimental consequences of prolonged stress.  Indeed, 
hypersecretion of CRF has been hypothesized to be the primary contributing factor in 
the development of depressive and anxiety disorders (Nemeroff, 1992; Owens et al., 
1993; De Souza, 1995).  In humans, major depressive disorder has been associated 
with higher levels of cerebrospinal fluid CRF (Nemeroff et al., 1984; Widerlov et al., 
1988; Arato et al., 1989; Kasckow et al., 2001), and CRF levels are also elevated in 
patients with post-traumatic stress disorder (PTSD) (Bremner et al., 1997a; Baker et al., 
1999).    
 
CRF-Rs can be found throughout the brain, including within elements of the 
mesocorticolimbic system (e.g., VTA, NAc, AMY) (De Souza et al., 1985; Millan et al., 
1986; Van Pett et al., 2000; Dautzenberg and Hauger, 2002).  Given this distribution, 
CRF can directly modulate brain circuits implicated in anxiety and depressive 
responses.  Exogenous administration of CRF induces anxiety and depressive-like 
behavior in laboratory animals, enabling studies of cause-effect relationships between 
stress and behaviors that reflect the signs of psychiatric illness.  For example, socially 
housed nonhuman primates exhibit depressive-like behaviors such as huddling and 8 
 
wall-facing after intracerebroventricular (ICV) CRF infusion (Kalin, 1990; Strome et al., 
2002).  In rodents, CRF also precipitates depressive- and anxiety-like behaviors such as 
increased immobility in the FST, suppression of exploratory behavior in a novel 
environment, potentiation of acoustic startle responses, and reduction of social 
interaction (Britton et al., 1982; Dunn and File, 1987; Liang et al., 1992; Swiergiel et al., 
2008).  Similarly, mice overexpressing CRF throughout their lifespan show evidence of 
anxiety-like behavior such as decreased open arm time in the EPM, reduced time in the 
light compartment of a light/dark box, and decreased locomotor activity in their home 
cage (Stenzel-Poore et al., 1994; van Gaalen et al., 2002).  Another way of elevating 
CRF levels is through knockout (KO) of CRF binding protein, which normally binds free 
CRF and inactivates it.  Similar to the effects of administration and overexpression of 
CRF, ablation of CRF-BP produces an anxiogenic-like phenotype in the EPM (Karolyi et 
al., 1999).  Together, these findings provide strong evidence for a role of CRF in the 
development of stress-induced illness. 
 
In contrast to the effects of CRF-R activation, CRF-R antagonists have antidepressant 
effects in humans and antidepressant-like effects in laboratory animals (Zobel et al., 
2000; Griebel et al., 2002).  In non-human primates, administration of the CRF-R1 
antagonist antalarmin decreases anxiety and fear behavior and increases exploratory 
and sexual behavior when animals are exposed to stressful stimuli (Habib et al., 2000).  
CRF-R1 antagonists also reduce anxiety-like responses in rodents (Britton et al., 1986; 
Deak et al., 1999), and rats infused with CRF-R1 antisense oligonucleotides display 
anxiolytic-like behavior in the EPM following social defeat (Liebsch et al., 1999).  
Similarly, mice lacking CRF-Rs display decreased anxiety-like behavior indicated by 9 
 
more time spent in the open arms of the EPM and light compartment of the light/dark 
box compared to controls (Smith et al., 1998; Timpl et al., 1998).  The role of CRF-R2 in 
anxiety is less clear, since there have been reports of both increases and decreases in 
anxiety-like behaviors mediated through this receptor.  For example, selective systemic 
activation of CRF-R2 with UCN3 in rats resulted in increased open arm exploration (an 
anxiolytic-like effect) in the EPM (Valdez et al., 2003), whereas CRF-R2 KO mice show 
increased anxiety in both the EPM and open-field tests (Bale et al., 2000; Kishimoto et 
al., 2000).  However, UCN2 activation of CRF-R2 in mice increased anxiety-like 
behavior in the EPM, and a selective CRF-R2 antagonist reduced anxiety-like behavior 
(Pelleymounter et al., 2002).  This apparent discrepancy may be due to differences in 
CRF-R2 actions depending upon species, brain region, or cell type.  
 
A connection between CRF and mood disorders has also been established by 
examining the effects of standard antidepressant drugs.  In rats, chronic treatment with 
the tricyclic antidepressant (TCA) imipramine decreased levels of CRF mRNA within the 
PVN (Brady et al., 1991).  Similar effects were produced by antidepressant drugs with 
different mechanisms of action, including fluoxetine (a selective serotonin reuptake 
inhibitor [SSRI]) and phenelzine (a monoamine oxidase inhibitor [MAOI]) (Brady et al., 
1992; Fadda et al., 1995; Aubry et al., 1999).  Interestingly, in studies where short-term 
treatments were also investigated—regimens that do not produce full therapeutic 
efficacy—these drugs did not affect CRF mRNA (Brady et al., 1991; Brady et al., 1992; 
Aubry et al., 1999), suggesting antidepressant effects may rely at least in part by 
reductions of CRF in the brain.  In addition to producing changes in baseline CRF 
levels, antidepressants also attenuate the effects of stress on CRF.  Stress-induced 10 
 
increases in CRF RNA in the PVN were reduced by venlafaxine, a serotonin and 
norepinephrine reuptake inhibitor (SNRI), and tranylcypromine, an MAOI.  Furthermore, 
chronic stress-induced increases in CRF mRNA in the PVN were blocked by chronic 
venlafaxine (Stout et al., 2002).  In humans, it was shown that an antidepressant 
reduces cerebrospinal fluid CRF levels compared to pretreatment levels in treatment 
responders (Heuser et al., 1998).  These data suggest standard antidepressants, 
despite having myriad mechanisms of action, may share a common ability to decrease 
stress-induced CRF mRNA production.  Likewise, CRF mRNA is also decreased by 
anxiolytic drugs (Skelton et al., 2000).  These studies collectively demonstrate a link 
between CRF and depression and anxiety, and provide a strong rationale for studies of 
CRF as a method to provide new insights on the affective consequences of stress.  
Understanding the systems downstream of CRF-R activation may promote an improved 
understanding of the progression from stress exposure to states of disease and illness. 
 
3. Kappa-opioid receptor (KOR) system  
3.1 KOR localization 
Endogenous opioid systems play an important role in stress, reward processing, and 
mood regulation.  These systems consist of the neuropeptides endorphins, enkephalins, 
and dynorphins and their cognate receptors (mu, delta and kappa respectively).  
Biologically active peptides for all receptors are derived from inactive prohormones that 
are post-translationally processed.  The dynorphin family of peptides derives from 
processing of prodynorphin (Pdyn) into seven major products (see Bruijnzeel, 2009; 
Schwarzer, 2009) that preferentially bind to and activate KORs (Chavkin et al., 1982), 11 
 
although with differing potency (James et al., 1984).  These dynorphin peptides, along 
with KORs, make up the KOR system. 
 
The brain distribution of dynorphin has been assessed by quantifying mRNA and 
peptide signals in mammals including rat, mouse, and human.  These studies indicate 
high overlap across species.  Moderate to high levels of dynorphin mRNA expression 
have been detected in brain areas implicated in depression and anxiety including the 
PVN, AMY, HIP, BNST and NAc of rodents (Morris et al., 1986; Merchenthaler et al., 
1997; Lin et al., 2006).  A similar expression profile exists in human brain (Simonin et 
al., 1995; Zhu et al., 1995; Hurd, 1996; Nikoshkov et al., 2005), suggesting the KOR 
system plays a conserved role in rodents and humans.  Studies of dynorphin protein 
localization demonstrate that expression overlaps with Pdyn mRNA-positive regions and 
their targets (Khachaturian et al., 1982; Vincent et al., 1982; Weber et al., 1982; Weber 
and Barchas, 1983; Code and Fallon, 1986; Fallon and Leslie, 1986) confirming that 
mRNA is translated into dynorphin peptides throughout the brain, particularly in stress-
responsive brain regions. 
 
There is a tight correspondence between dynorphin and KOR localization.  KOR mRNA 
is expressed at high levels in the VTA, substantia nigra (SN), NAc, caudate putamen 
(CPu), hypothalamus, and AMY (Meng et al., 1993).  This is consistent, for the most 
part, with receptor autoradiography indicating high levels of binding in the NAc, CPu, 
hypothalamus and AMY (Mansour et al., 1987, 1988).  However, an exception to this 
general rule is observed within the midbrain: there is high expression of KOR mRNA in 
the VTA and SN despite low levels of KOR expression in these areas.  It is proposed 12 
 
that KORs are synthesized in the VTA and SN, and then transported via receptor 
trafficking to terminals in the NAc and CPu, respectively (Mansour et al., 1995).  Indeed, 
electron microscopic immunohistochemistry has shown KORs localized to presynaptic 
dopamine (DA) terminals in dynorphinergic regions where they are involved in the 
regulation of DA transmission (Donzanti et al., 1992; Svingos et al., 1999).  Given this 
distribution, KOR activation has the potential to modulate mesocorticolimbic circuits 
involved in stress and anxiety, as will be described in more detail below. 
 
3.2 KOR signaling 
KORs are G protein-coupled receptors (GPCRs) that mainly interact with inhibitory Gα 
subunits (Law et al., 2000).  Activation of KORs by endogenous or synthetic agonists 
produces inhibition of adenylate cyclase activity as seen in cell lines (Lawrence and 
Bidlack, 1993), spinal cord (Attali et al., 1989) and brain membranes including striatum, 
HIP, AMY and cerebellum (Konkoy and Childers, 1989, 1993).  KOR agonists can also 
decrease cell excitability and neurotransmitter release through G proteins by inhibiting 
voltage-gated calcium currents (Gross et al., 1990; Tallent et al., 1994; Rusin et al., 
1997; Hjelmstad and Fields, 2003) or activating G protein-coupled inwardly-rectifying 
and voltage-dependent potassium channels (Henry et al., 1995; Simmons and Chavkin, 
1996).  KOR activation has also been shown to inhibit phospholipase C (Misawa et al., 
1990) and activate mitogen activated protein kinase (MAPK) pathways in neurons and 
astrocytes (Belcheva et al., 2005).  The MAPK family includes several kinases that 
respond to a variety of cell stimuli.  These pathways regulate diverse functions such as 
proliferation, differentiation, apoptosis, and gene expression.  MAPK activation by KORs 
has been shown to occur through G protein-dependent and -independent mechanisms.  13 
 
For example, extracellular-signal related kinase (ERK) activation (Belcheva et al., 1998; 
Bohn et al., 2000; Belcheva et al., 2005) and c-Jun N-terminal kinase (JNK) (Kam et al., 
2004) were shown to be G protein-dependent while p38 MAPK increases were arrestin-
dependent but G protein-independent (Bruchas et al., 2006).  This variety of KOR 
effectors enables differential responses according to receptor location, 
microenvironment, and binding partners.  These signaling mechanisms allow for rapid 
effects on cell excitability and transmitter release that may underlie acute stress effects, 
as well as delayed effects such as gene expression which may play a role in conditions 
of chronic stress (Knoll and Carlezon, 2010).  
 
3.3 Behavioral effects of KOR agonists and antagonists 
KOR agonists are similar to other opioid agonists in that they produce analgesia 
(Pasternak, 1980; McLaughlin et al., 2004), but have reduced abuse potential as 
compared to mu-opioid receptor (MOR) agonists (Fraser and Rosenberg, 1964; Tang 
and Collins, 1985).  Consequently, KOR agonists seemed ideally suited as a non-
addictive pain treatment.  Unfortunately, studies in humans revealed that selective KOR 
agonists produced dysphoria, anxiety, and abnormal behavior along with 
psychotomimesis at higher doses (Pfeiffer et al., 1986), which hindered their 
development as therapeutics (Carlezon et al., 2009).  These KOR agonist-induced 
psychological effects are in opposition to the euphoria induced by MOR agonist, 
suggesting an antagonistic role of the KOR system in the brain—an “anti-reward” 
system—to that of MORs (Koob and Le Moal, 2008).  For example, when rodents are 
trained to associate a KOR agonist with a distinct chamber of a multi-chamber place 
conditioning apparatus, they later avoid this chamber when allowed access to the entire 14 
 
apparatus (Iwamoto, 1985; Shippenberg and Herz, 1987; Zhang et al., 2005).  This type 
of conditioned place avoidance (CPA) behavior is interpreted as evidence for a drug-
induced negative mood (aversive) state (Carlezon, 2003).  In contrast, MOR agonists 
produce conditioned place preference (CPP) in that rodents prefer the drug paired side 
and spend more time in this chamber during the test session (Rossi and Reid, 1976).  
KOR agonists also elevate brain reward thresholds (Todtenkopf et al., 2004; Carlezon 
et al., 2006; Tomasiewicz et al., 2008; Dinieri et al., 2009), indicating anhedonia, and 
increase immobility in the FST (Mague et al., 2003; Carlezon et al., 2006), an effect that 
is opposite to that of antidepressants (Porsolt et al., 1977a; Detke et al., 1995) and often 
interpreted to indicate a prodepressive-like effect.  These KOR agonist effects resemble 
behaviors observed following stress or CRF treatment, suggesting a common 
mechanism of action. 
 
KOR agonists also attenuate the effects of drugs of abuse including cocaine, nicotine, 
and amphetamine, further supporting the idea of a KOR mediated “anti-reward” system.  
KOR agonists block the activating and rewarding effects of cocaine (Suzuki et al., 1992; 
Heidbreder et al., 1993; Heidbreder et al., 1995; Zhang et al., 2005), attenuate cocaine-
induced decreases in brain reward thresholds (Tomasiewicz et al., 2008; Dinieri et al., 
2009), and reduce cocaine intravenous self-administration (Glick et al., 1995; Negus et 
al., 1997).  It is thought that rewarding properties of drugs of abuse are attributable to 
their common ability to elevate extracellular concentrations of DA in the NAc (Wise and 
Rompre, 1989); therefore, reducing DA transmission may decrease their acute effects 
and abuse liability.  Drugs of abuse also increase release of striatal dynorphin (Hanson 
et al., 1988; Sivam, 1989; Smiley et al., 1990) which may modulate DA release through 15 
 
presynaptic activation of KORs in the NAc (Svingos et al., 1999) to counteract the 
rewarding effects of drugs.  Indeed, systemic and intra-NAc administration of KOR 
agonists decrease DA levels in the NAc  (Di Chiara and Imperato, 1988; Spanagel et 
al., 1992; Carlezon et al., 2006) which is also postulated as a mechanism for their 
aversive effects (Carlezon and Thomas, 2009).  Interestingly, similar to drugs of 
abuse—but opposite to KOR agonists—both stress and anxiogenic drugs can increase 
DA in the NAc; however, chronic or intense stress can decrease DA in the NAc and 
inhibit CRF-induced increases (Abercrombie et al., 1989; Sorg and Kalivas, 1991; 
McCullough and Salamone, 1992; Imperato et al., 1993; Young et al., 1993; Tidey and 
Miczek, 1996; Ghiglieri et al., 1997; Gambarana et al., 1999; Yadid et al., 2001; Lemos 
et al., 2012b).  This change corresponds with a switch from appetitive to aversive 
responses following NAc CRF infusions, and may represent one aspect of the 
mechanism for the induction of depressive-like behavior following stress (Lemos et al., 
2012b). 
 
Studies involving pharmacological blockade of KOR signaling have predominantly used 
three selective KOR antagonists: nor-binaltorphimine (norBNI), GNTI (a norBNI 
derivative), and/or JDTic, a structurally dissimilar compound (Béguin and Cohen, 2009).  
These antagonists all share the unique ability to antagonize KORs in vivo for an 
extended period of time (generally 3 weeks or more) following a single injection (Endoh 
et al., 1992; Jones and Holtzman, 1992; Carroll et al., 2004; Beardsley et al., 2005).  
This sustained effect may be due to a phenomenon termed biased agonism or ligand-
directed signaling, a mechanism by which a ligand can simultaneously act as an agonist 
and an antagonist at different functions mediated by the same receptor (Urban et al., 16 
 
2007; Melief et al., 2011).  For KOR antagonists, the duration of action correlates with 
JNK pathway activation and disrupting JNK activation using inhibitors or mice lacking 
the JNK-1 isoform blocks the long lasting effects of KOR antagonist (Bruchas et al., 
2007b; Melief et al., 2010; Melief et al., 2011).  However, the mechanism of JNK 
activation and JNK-mediated inactivation of the KOR is not known.  KOR antagonists 
block KOR agonist effects and have antidepressant- and anxiolytic-like effects on their 
own.  For example, these antagonists decrease immobility in the FST (Mague et al., 
2003; Beardsley et al., 2005; Carr et al., 2010) similar to standard antidepressants 
(Cryan et al., 2002).  Administration of norBNI and JDTic produces anxiolytic-like effects 
in the EPM and fear-potentiated startle (Knoll et al., 2007), and the irreversible KOR 
antagonist DIPPA produces anxiolytic-like effects in novelty-induced hypophagia and 
defensive burying tests in rats (Carr and Lucki, 2010), suggesting that KOR activation is 
necessary for the acquisition and/or expression of anxiety-like behavior.  Anxiolytic-like 
effects are also observed in Pdyn-deficient mice which show increased center 
exploration in an open field and spend more time in the lit compartment of a light/dark 
box (Wittmann et al., 2009), both anxiolytic-like effects.  However, other studies indicate 
existing lines of constitutive KOR-KO mice do not differ from controls in the open field 
and light/dark box (Simonin et al., 1998; Filliol et al., 2000).  During development, gene 
expression and system functions related to the absent gene may alter to compensate 
for the gene loss.  This is especially relevant in the above case, since the discrepant 
results are from mice with ablation of different elements of the KOR system knocked out 
(Pdyn vs. KOR).  Dynorphin is a potential ligand for other opioid-receptors (Zhang et al., 
1998), and this may underlie compensatory and behavior differences between the two 
KO strains. 17 
 
3.4 KOR system and stress-induced behaviors 
Stressors including forced swimming (McLaughlin et al., 2003a; Land et al., 2008), 
footshock (Beardsley et al., 2005; Redila and Chavkin, 2008), and social defeat 
(McLaughlin et al., 2006b) all activate the KOR system, suggesting it plays an important 
role in stress effects. In CPP tests, the rewarding effects of cocaine become associated 
with the environment in which it was paired, thereby causing a preference for this 
environment during subsequent drug-free exposure.  This effect can be extinguished by 
repeated access to the testing apparatus, and the rapidly reinstated by stress or 
cocaine priming.  Disruption of KOR signaling blocks stress, but not cocaine-primed 
reinstatement (Carey et al., 2007; Redila and Chavkin, 2008; Aldrich et al., 2009), 
suggesting the KOR system plays a specific role in stress-induced effects.  Stress 
exposure can also increase the magnitude of cocaine reward, as measured in the CPP 
test.  Potentiation of cocaine-induced CPP following social defeat and forced swim 
stress is blocked by norBNI and absent in Pdyn and KOR KO mice (McLaughlin et al., 
2003a; McLaughlin et al., 2006a; McLaughlin et al., 2006b; Schindler et al., 2010), and 
activation of KORs mimics the effect of stress (McLaughlin et al., 2006a; Schindler et 
al., 2010), demonstrating that KOR activation is a necessary and sufficient element of at 
least certain stress effects on behavior.  Although this may seem contradictory to 
studies described earlier in which KOR agonists blocked effects of drugs of abuse, this 
is likely due to differences in timing of administration.  In those studies KOR agonists 
were coadministered with the drug of abuse, but in cocaine-induced CPP studies, KOR 
agonist was injected one hour before cocaine testing.  In fact, when the interval 
between KOR agonist and cocaine was reduced, place aversion was observed 
(McLaughlin et al., 2006a).  Prior activation of the KOR system may decrease hedonic 18 
 
state and increase the rewarding effects of cocaine (Negus, 2004; Ahmed and Koob, 
2005) resulting in potentiation of drug effects (i.e., a larger change due to a lower 
hedonic baseline) which would not occur with coadministration (Bruchas et al., 2010).   
 
Dynorphin release is also necessary for stress-induced aversion.  It is known that mice 
will develop a CPA to an odorant that was previously paired with stress.  The avoidance 
behavior is abolished by pretreatment with the KOR antagonist norBNI before stress 
(forced swim or footshock) and absent in Pdyn KO mice (Land et al., 2008), suggesting 
reduced aversions.  Additionally, dynorphin plays a role in stress-induced analgesia, a 
phenomenon in which stress reduces sensitivity to pain.  NorBNI blocks both 
psychological (Takahashi et al., 1990) and physical stress-induced analgesia 
(McLaughlin et al., 2003a; McLaughlin et al., 2006a) including CSDS.  Both norBNI and 
Pdyn gene disruption block stress-induced analgesia observed immediately after the 
first and subsequent days of social defeat (McLaughlin et al., 2006b).  During CSDS 
sessions, rodents display characteristic immobility and social defeat postures, which 
tend to increase progressively (Miczek et al., 2004).  Postures reflecting social defeat 
are reduced in norBNI treated and Pdyn KO mice, suggesting that KOR blockade 
produces signs of stress resilience.  However, these differences are not apparent 
proceeding the first day of stress, revealing that KOR signaling is not necessary for 
initial defeat-induced postures in this paradigm, but instead in the progression of chronic 
stress.   KOR antagonists and KOR system gene disruption also reduce immobility in 
the FST, but primarily not until the second day (Pliakas et al., 2001; Mague et al., 2003; 
McLaughlin et al., 2003a; McLaughlin et al., 2006a).  Thus KOR-dependent behaviors 
likely involve distinct neural circuits and may reflect the differences in immediate actions 19 
 
of KOR activation versus delayed effects such as gene expression changes, which may 
be especially important in animal models involving initially normal (i.e., non-depressed) 
subjects. 
 
3.5 KOR system and CRF interactions 
As described earlier, CRF is the primary regulator of the stress response; when 
centrally administered, it can recapitulate many of the behavioral, hormonal and 
autonomic effects of stress including dynorphin release.  CRF stimulates release of 
dynorphin from spinal cord (Song and Takemori, 1992), hypothalamus (Almeida et al., 
1986; Nikolarakis et al., 1986), globus pallidus and striatum (Sirinathsinghji et al., 1989).  
It also produces increases in KOR phosphorylation—a marker of receptor activation 
(McLaughlin et al., 2003b)—in components of stress and anxiety circuits including the 
striatum, DRN, AMY, HIP, VTA, and NAc that are reduced or absent in norBNI 
pretreated mice and Pdyn KOs (Land et al., 2008).  The fact that CRF and KOR 
agonists produce aversive and anxiogenic-like effects raises the possibility that CRF 
effects may be mediated by the KOR system.  To address this question, Land et al. 
(2008) examined the effect of KOR blockade on CRF-induced CPAs in mice.  In these 
experiments, central CRF administration induced aversion to the context in which mice 
were placed following infusion.  CRF-induced CPA was abolished with norBNI 
pretreatment and in Pdyn KO mice (Land et al., 2008), suggesting that CRF receptor 
activation promotes dynorphin release and subsequent KOR activation to mediate the 
aversive component of stress.  Work I have conducted during my graduate training has 
also identified important interactions between the CRF and KOR systems in rats using 
the 5-choice serial reaction time task (5CSRTT), a test of cognitive behavior analogous 20 
 
to the continuous performance task used to study attention in humans (Beck et al., 
1956; Robbins, 2002).  CRF dose-dependently disrupted numerous performance in the 
5CSRTT, and these deficits were attenuated by systemic administration of JDTic at a 
dose without effects of its own (see Appendix; Van't Veer et al., 2012).  These findings 
further demonstrate that KOR antagonists can prevent acute CRF-related effects, 
including those that degrade performance in tasks requiring attention. 
 
CRF induced anxiety-like behavior is also dependent on the KOR system.  Mice 
administered central CRF avoid the open arms of an EPM, an effect that is abolished 
with prior norBNI treatment or Pdyn gene disruption (Bruchas et al., 2009).  The 
basolateral nucleus of the AMY (BLA) appears critical for this anxiogenic effect, since 
direct injection of norBNI into this region is sufficient to block CRF-induced decreases in 
open arm time (Bruchas et al., 2009).  This is in agreement with other work 
demonstrating anxiolytic-like effects of KOR antagonism in the EPM after direct 
microinfusion into the BLA (Knoll et al., 2011).  Nonetheless, KOR phosphorylation is 
detected in numerous brain structures following CRF treatment (Land et al., 2008), 
suggesting additional areas of interaction.  Anxiety-like behavior is complex and 
involves a circuit of interconnected brain regions, which all contribute to a behavioral 
output; as such, it is unlikely that a single brain region represents the only area in which 
key interactions between the KOR system and CRF occur.  In my dissertation, I focused 
on the VTA and its projection areas as possible sites of stress/CRF and KOR 
interactions, due to the involvement of this region in responsiveness to stress, its role in 
states of motivation and emotion, and its expression of CRF-Rs and KORs. 
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4. Neural circuits 
The following section introduces the stress and fear/anxiety circuits.  Overlap between 
these circuits may represent regions where stress may influence fear and anxiety 
behavior.  
 
4.1 Stress neurocircuitry 
Stress of any type activates the HPA axis, a neural circuit within which the medial 
parvocellular division of the PVN plays a key role (Fig. 1.1).  These neurons contain 
CRF and release this peptide from the median eminence of the hypothalamus into the 
hypophyseal portal system in response to stress (Antoni, 1986).  Activation of CRF 
receptors within the anterior pituitary regulates ACTH release, which acts on the adrenal 
cortices to promote production and release of glucocorticoids.  Many CRF neurons also 
co-express arginine vasopressin (AVP), which amplifies CRF effects on ACTH release 
(Gillies et al., 1982; Whitnall et al., 1987).  Glucocorticoid actions are mediated by two 
receptors: glucocorticoid receptors (GRs) and mineralocorticoid receptors (MRs).  GRs 
are expressed throughout the brain and are highly expressed in the hypothalamus, 
olfactory bulb, HIP and cerebral cortex while MRs are more limited in distribution and 
are predominantly found in areas involved in emotion, memory, and behavior such as 
the septum, HIP, and PFC (Fuxe et al., 1985; Reul and de Kloet, 1985; Ahima and 
Harlan, 1990; Cintra et al., 1994; Morimoto et al., 1996; Viengchareun et al., 2007).  
GRs and MRs regulate hormonal, autonomic and behavior responses to stress via their 
widespread expression (Munck et al., 1984), and trigger a negative feedback loop that 
terminates HPA axis activation.  Glucocorticoids act within the PVN to suppress CRF 
and AVP mRNA levels and, as a result, inhibit ACTH release (Swanson and Simmons, 22 
 
1989; Autelitano et al., 1990).  It has been proposed that other negative feedback 
circuits controlling gene expression and hormone release in the PVN may exist, 
considering the diverse expression of GRs and MRs.  Indeed, lesions of the HIP result 
in elevated glucocorticoids and elevated levels of CRF and AVP, suggesting disruption 
of negative feedback regulation (Herman et al., 1989).  
 
HPA axis regulation is achieved through actions integrated within the PVN.  Afferents 
from cicumventricular organs, brainstem nuclei, and hypothalamic-basal forebrain 
systems can directly activate PVN neurons (Ziegler and Herman, 2002) and relay 
information on the state of the body such as cardiovascular tone, blood oxygenation, 
arousal and osmotic state.  In particular, the BNST sends projections from multiple 
subregions (Dong et al., 2001b; Ziegler and Herman, 2002; Dong and Swanson, 2004), 
suggesting that this region plays a crucial role in regulation of PVN activity.  The BNST 
also integrates information from other stress-responsive brain regions.  Brain mapping 
studies of immediate-early gene (IEG) expression have been used to understand the 
circuits mediating the positive regulation of the stress response.  Stress leads to 
generalized activation of the IEG c-fos in numerous brain regions including the HIP, 
NAc, BNST, AMY, PVN, DRN, CPu, and VTA (Lopez et al., 1999).  The AMY, HIP and 
PFC can regulate the stress response (Herman et al., 2005) despite having sparse or 
no direct connections with the PVN (Gray et al., 1989; Cullinan et al., 1993; Ziegler and 
Herman, 2002).  These regions do send projections to the BNST (Cullinan et al., 1993; 
Canteras et al., 1995; Crane et al., 2003), suggesting this region may represent a relay 
station where limbic information feeds in and is then passed to the PVN (Cullinan et al., 
1993; Herman et al., 2005).  Likewise, other regions with direct input to the PVN relay 23 
 
information from afferent connections.  For example, observed central AMY actions on 
HPA axis function (Beaulieu et al., 1987; Xu et al., 1999) likely rely on indirect 
projections to the PVN via the nucleus of the solitary tract (Schwaber et al., 1982; 
Ziegler and Herman, 2002).  Interestingly, the major limbic components of the hormonal 
stress response have also been implicated in fear and anxiety neurocircuitry.24 
 
Figure 1.1 HPA axis and neuronal inputs.  Stress causes the release of CRF and 
AVP from parvocellular neurons in the PVN that project to the anterior pituitary.  ACTH 
secretion then leads to glucocorticoid synthesis and release from the adrenal cortex.  
Glucocorticoid actions are mediated by GRs and MRs throughout the brain and 
periphery.  Glucocorticoids activate negative feedback loops within the PVN, pituitary 
and HIP denoted with minus signs in the illustration.  Neuronal inputs from the HIP, 
BNST, PFC and AMY regulate HPA axis (red arrows) activity.  Dashed lines represent 
indirect connections to the PVN.  ACTH, adrenocorticotropic hormone; AMY, amygdala; 
AVP, arginine vasopressin; BNST, bed nucleus of the stria terminalis; CRF, 
corticotropin-releasing factor; GR, glucocorticoid receptor; HIP, hippocampus; HPA, 
hypothalamic-pituitary-adrenal; MR, mineralocorticoid receptor; PFC, prefrontal cortex; 
PVN, paraventricular nucleus of the hypothalamus25 
 
Figure 1.1 (Continued) Hypothalamic-pituitary-adrenal (HPA) axis and neuronal inputs 
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4.2 Fear and anxiety neurocircuitry 
There is considerable overlap in the stress circuits described above and those involved 
in fear and anxiety, suggesting that stress and fear responses are related and can affect 
one another (Shin and Liberzon, 2010).  The AMY is the brain region most often 
considered to be at the center of the fear response.  Over 50 years ago, physicians 
surgically treating epileptic patients reported that electrical stimulation of the AMY 
produces feeling of fear and anxiety (Chapman et al., 1954).  Decades later, the 
significance of the AMY became clearer as researchers focused on Pavlovian 
conditioning.  Much preclinical work has elucidated AMY cellular and molecular 
mechanisms in fear as reviewed elsewhere (Davis, 1997; Davis and Shi, 2000).  
Although the AMY is clearly involved in the expression of fear and anxiety behaviors, it 
is embedded within a circuit of highly interconnected brain structures that are known to 
be involved in processes that reflect motivation and emotion.  It is increasingly evident 
that structures with amygdalar afferent and/or efferent projections contribute to normal 
and pathologic anxiety.  Although the AMY is a macrostructure that includes numerous 
sub-regions, most research on fear and anxiety has focused on two: the BLA, and the 
central nucleus of the AMY (CeA) (Davis, 2002).  These regions have different cell 
types and projection patterns (Krettek and Price, 1978; Carlsen and Heimer, 1988; Sah 
et al., 2003).  The BLA contains predominantly glutamatergic pyramidal neurons and 
receives input from the cortex, HIP and thalamus.  This integrated information may then 
be passed on to efferent structures including the striatum, HIP, PFC, CeA and BNST.  
The CeA contains predominantly medium spiny (GABA-containing) neurons and is a 
major output center that projects to numerous brain regions involved in specific 
components of fear and anxiety.  A deeper understanding of how these interconnected 27 
 
regions function in isolation as well as in circuits may enable new insights into the 
neurobiology of stress and anxiety responses as well as the pathophysiology of 
psychiatric disorders.  In the following section I focus on the role of the VTA in 
regulating the activity of AMY circuits. 
 
4.2.1 Ventral tegmental area 
Although not implicated in classical theories of depressive illness, the mesocorticolimbic 
system may also play an important role in affective behavior (Nestler and Carlezon, 
2006).  The VTA is the origin of neurons of the mesocorticolimbic DA system which 
project to the NAc, HIP, AMY, PFC and BNST.  Historically, the VTA and its 
dopaminergic projections have been studied primarily in the context of motivation and 
reward (Wise and Bozarth, 1987).  However, accumulating work has led to greater 
recognition of the role of this system in aversion as well (Salamone, 1994; Pezze and 
Feldon, 2004; Carlezon and Thomas, 2009).  Aversive stimuli can increase DA neuron 
population activity (Valenti et al., 2011) and activate the mesocorticolimbic system 
resulting in postsynaptic DA release (Thierry et al., 1976; Abercrombie et al., 1989; 
Imperato et al., 1993; Piazza and Le Moal, 1998; Pascucci et al., 2007) that may 
promote or antagonize stress effects on behavior.  
 
4.2.1.1 Role of DA 
Early studies investigating the effect of systemic dopaminergic drugs on fear 
conditioning found that, in general, DA receptor agonists potentiate fear conditioning 
(Tsuchiya et al., 1996; Borowski and Kokkinidis, 1998; Pezze et al., 2002), whereas 
antagonists have the opposite effect (Hijzen et al., 1995; Inoue et al., 1996; Greba and 28 
 
Kokkinidis, 2000).  These effects were likely due to activation of receptors within and 
postsynaptic to dopaminergic midbrain neurons, the main source of DA in the 
mammalian CNS.  Daily VTA stimulation alone is sufficient to produce fear-like behavior 
in cats (Stevens and Livermore, 1978) and aversive stimuli such as footshock increase 
DA metabolites in the VTA (Deutch et al., 1985), which may indicate increased DA 
release.  Interestingly, these same effects are seen following the presentation of 
auditory cues previously paired with footshock, demonstrating that the VTA responds 
similarly to unconditioned and conditioned stimuli.  When VTA function is disrupted by 
axon-sparing lesions or inhibition of DA neuron activity, fear-potentiated startle is 
reduced without affecting baseline startle (Borowski and Kokkinidis, 1996), suggesting 
specific effects of VTA activation in response to fear-eliciting stimuli.  In rabbits, the 
firing rate of dopaminergic VTA neurons changes depending on whether a conditioned 
stimulus (CS) previously paired with a shock or a neutral stimulus was presented, with 
the majority of neurons showing greater activity to CS-paired compared to unpaired 
presentations (Guarraci and Kapp, 1999).  These changes in firing rate may transfer to 
subsequent changes in excitability and function of innervated target regions.  Together, 
these data indicate that DA release and activation of DA-receptor expressing neurons 
contribute to the expression of fear- and anxiety-like behavior in rodents.  However, how 
these changes in DA release can lead to anxiety-like behavior is not fully understood. 
 
There is some evidence that the VTA to NAc projection is involved in the acquisition and 
expression of fear conditioning.  Various stressors have been shown to increase DA 
metabolites or release in the NAc (Abercrombie et al., 1989; Sorg and Kalivas, 1991; 
Imperato et al., 1993; Inoue et al., 1996).  DA levels also rise in response to a CS 29 
 
previously paired with an aversive unconditioned stimulus (US) (Young et al., 1993; 
Wilkinson et al., 1998; Pezze et al., 2002).  During conditioning trials, DA release is 
higher during CS-US pairings than when the US is presented alone suggesting the NAc 
is important for CS-US associations (Pezze and Feldon, 2004).  Further, during test 
trials where the CS no longer predicts the US, DA release decreases (Wilkinson et al., 
1998).  Thus NAc DA likely encodes the salience of the CS (Horvitz, 2000; Pezze and 
Feldon, 2004). 
 
Although it may seem paradoxical that aversive and fear-eliciting stimuli lead to similar 
increases in NAc DA as observed following rewarding stimuli (including drugs of abuse, 
food, and sexual behavior; Wise and Rompre, 1989), the perception of reward versus 
aversion may also rely on concurrent activation of other circuits that provide input to the 
NAc, thereby affecting the ways in which neural signals are integrated and gated (West 
et al., 2003).  For example, the ability for intra-NAc CRF to induce anxiety-like behavior 
may rely on the balance between DA and acetylcholine release in this region (Chen et 
al., 2012).  Importantly, distinct DA pathways are recognized for reward, aversion, and 
salience (Lammel et al., 2011).  Whereas DA release within subregions of the NAc may 
encode salience, aversive responses may be encoded, at least in part, by mesocortical 
neurons.  The PFC is an important site in modulating conditioned fear responses, 
although the precise mechanism is unclear (Pezze and Feldon, 2004).  Both stimulation 
and blockade of DA within the PFC have been shown to reduce the expression of 
conditioned fear which may reflect an inverted U-shaped relationship between fear 
expression and DA activity (Abercrombie et al., 1989; Imperato et al., 1992; Sorg and 
Kalivas, 1993; Dazzi et al., 2001; Feenstra et al., 2001; Bassareo et al., 2002; Pezze et 30 
 
al., 2003).  Depletion of DA within the PFC also produces negative effects including 
impairment of extinction learning and anxiogenic-like effects (Espejo, 1997; Fernandez 
Espejo, 2003).  Conversely, neuropeptide S increases DA in the PFC (Si et al., 2010), 
an effect that may underlie its ability to reduce stress-related anxiety.  Together, these 
data indicate that manipulations in DA may affect fear and anxiety-like behavior in 
region specific ways. 
 
A small number of studies in human subjects have supported preclinical findings and 
demonstrated a role for the NAc in anxiety.  In a case report of a patient undergoing 
deep brain stimulation (DBS) surgery for obsessive compulsive disorder, 
macrostimulation of the ventral NAc induced feelings of fear and panic, which were 
coincident with stimulation (Shapira et al., 2006).  This effect is in contrast to the use of 
NAc DBS for the treatment of anxiety and obsessive-compulsive disorder (OCD).  
Indeed, this patient continued to receive DBS as treatment at contacts separate from 
those which induced “panic” (Shapira et al., 2006).  In other studies, anxiety and OCD 
symptoms were significantly relieved in 3 patients implanted with NAc DBS stimulators 
(Sturm et al., 2003), and depression and anxiety rating  improved in patients with 
treatment-resistant depression comorbid with anxiety (Bewernick et al., 2010; 
Bewernick et al., 2012).  DBS at high frequencies is thought to inhibit activity in the 
targeted region and produce effects similar to lesion (Blond et al., 1992; Benazzouz and 
Hallett, 2000), but is also capable of increasing neuronal activity at the site of 
stimulation (Montgomery and Gale, 2008).  Thus positive effects of DBS may be due to 
functional inactivation of NAc while inductions of fear may result from activation.  Since 
DBS may cause antidromic activation (Nowak and Bullier, 1998), these differences may 31 
 
also rely on excitatory and inhibitory inputs to the site of stimulation which are 
heterogeneous in the NAc (Heimer et al., 1997).  Regardless of mechanism, these 
studies identify the NAc and its inputs as key components in anxiety circuitry in humans 
and support the use of rodent models to investigate the mechanisms of fear and 
anxiety. 
 
4.3. KOR effects in the mesocorticolimbic system 
Insight into how the mesocorticolimbic system is involved in anxiety may come from 
studies of depressive-like behavior.  In humans, depression is highly comorbid with 
anxiety disorders with over half of depressed patients meeting the diagnostic criteria for 
an anxiety disorder (Kaufman and Charney, 2000; Kessler, 2000).  Stress has been 
shown to cause behaviors characteristic of depression such as anhedonia, behavioral 
despair, and dysphoria in rats (Moreau et al., 1992; Pliakas et al., 2001; Land et al., 
2008) that are mimicked by elevating CREB levels in the NAc using viral-mediated gene 
transfer (Pliakas et al., 2001; Barrot et al., 2002).  In contrast, decreasing CREB activity 
in the NAc through expression of a dominant-negative CREB virus leads to 
antidepressant-like effects in rodents (Pliakas et al., 2001; Newton et al., 2002).  
Notably these changes in behavior due to increases or decreases in CREB activity were 
shown to be mediated largely by CREB-induced changes in dynorphin expression.  
Dynorphin has been shown to be a target of CREB induced gene expression in vitro 
(Douglass et al., 1994; Cole et al., 1995; Turgeon et al., 1997) and manipulating CREB 
levels changes dynorphin expression in vivo (Carlezon et al., 1998; Pliakas et al., 2001).  
Administration of norBNI attenuated the behavioral effects of elevated CREB levels 
within the NAc (Carlezon et al., 1998; Pliakas et al., 2001), whereas blockade of 32 
 
endogenous dynorphin actions through direct injection of norBNI into the NAc was 
sufficient to produce antidepressant-like effects (Newton et al., 2002).  It is postulated 
that some features of depression are the result of dynorphin control of 
mesocorticolimbic DA function, either by actions at KORs on VTA cell bodies or 
terminals that project to the NAc (Nestler and Carlezon, 2006).  Given the high 
comorbidity of depressive and anxiety disorders, KOR signaling and control of DA 
function may underlie the pathophysiology of both.  In my dissertation project, I used 
molecular and genetic manipulations to directly determine if stress/CRF and the KOR 
system interact in the mesocorticolimbic system in models of anxiety-like behavior. 
 
In order to probe the relationship between KORs and stress-induced behaviors, I 
subjected mice to stress and then measured the acoustic startle response.  This 
response is a reflectory reaction present in all mammals that is thought to facilitate 
escape from sudden stimuli, and it can be modulated by emotional state such that fear 
and anxiety increase startle whereas pleasure decreases it (Davis, 1979; Schmid et al., 
1995).  The startle reflex has many advantages as a metric, including the fact that it can 
be used in species ranging from humans to mice.  Elevations in the startle reflex are a 
hallmark sign of serious anxiety disorders such as PTSD, and may reflect clinical 
diagnostic criteria such as hyperarousal and hypervigilance (American Psychiatric 
Association, 2000).  I used infusions of CRF or footshocks as aversive stimuli as 
described below, and used acoustic startle as my main behavioral output.  (I did, 
however, use a wide variety of other behavioral procedures when characterizing novel 
lines of mutant mice, as will be described in Chapter 4 of this thesis.) 
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5. Main behavioral paradigms 
5.1 CRF-enhanced startle 
Stress-like states in rodents can be achieved through central administration of CRF.  
One effect of CRF is enhancement of the startle response.  This CRF-enhanced startle 
is a reliable measure with face, predictive, and construct validity.  The startle response 
is a robust reflex in response to an intense acoustic, tactile, or vestibular stimulus 
(Yeomans et al., 2002).  In rodents this response is measured by a full body flinch.  The 
magnitude of this response can be increased when fear-inducing stimuli are presented 
at the time of the startle stimuli or when anxiogenic compounds, such as CRF are 
administered (Swerdlow et al., 1986; Davis, 1993).  It is believed that CRF induces a 
central state of anxiety in rodents since fear-conditioning or administration of 
compounds known to be anxiogenic in humans, such as yohimbine (an α2-adrenergic 
receptor antagonist), result in similar increases in startle amplitude (Morgan et al., 1993; 
Grillon and Davis, 1997).  Furthermore, the CRF-enhanced startle paradigm shows 
predictive validity since compounds that reduce anxiety in humans, such as 
benzodiazepines, reduce the CRF-enhanced startle response in rodents (Swerdlow et 
al., 1986).  It is centrally mediated and not dependent on corticosterone release from 
the adrenal glands, since adrenalectomized rats still show enhanced startle (Lee et al., 
1994).  In the CRF-enhanced startle paradigm, CRF is administered to rodents via 
cannulae directed at the lateral ventricle (Fig. 1.2A), since the CRF peptide does not 
effectively cross the blood brain barrier.  Startle reactivity is then measured using a 
specialized automated system comprising a speaker capable of delivering startle stimuli 
(sudden bursts of white noise), a holder with a metal rod floor that positions the mouse 
directly in front of the speaker, and a load cell upon which the chamber is placed that 34 
 
can quantify the force of the startle response (Fig. 1.2B; white mouse shown for clarity).  
Startle data are measured as the peak to peak response amplitude in the first 100 msec 
following startle stimuli onset.  Sample startle data showing theoretical baseline (Fig. 
1.2C) and potentiated (Fig. 1.2D) startle responses illustrate the increase in (measured 
in arbitrary startle units) seen following central CRF treatment compared to baseline or 
vehicle infusion.35 
 
Figure 1.2 Startle apparatus.  A.  In the CRF-enhanced startle paradigm, mice are 
infused with vehicle (aCSF) or CRF via an intracerebroventricular cannula immediately 
before testing.  B.  The startle apparatus includes a speaker (1) located behind the 
mouse holder that delivers startle-stimuli consisting of bursts of white noise.  The startle 
response is quantified by a load cell (2) beneath the holding cage which converts the 
force of the cage displacement into arbitrary startle units.  In the footshock-potentiated 
startle paradigm, mice are not infused with CRF and are instead given mild footshocks 
delivered via a wiring harness connected to floor rods (3) to induce a fear-like state.  C. 
Hypothetical output data of startle responding showing baseline data before aversive 
experimental manipulation and the potentiated response expected following central 
CRF infusion or footshock. 
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Figure 1.2 (Continued) Startle apparatus
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5.2 Footshock-potentiated startle 
Fear-like states can be achieved through brief presentation of mild shock.  The startle 
response is enhanced immediately after shock, delivered to the feet of rodents (Boulis 
and Davis, 1989; Davis, 1989; Hitchcock et al., 1989; Sasaki and Hanamoto, 2007) or 
arm of humans (Greenwald et al., 1998).  This behavior was originally thought to reflect 
unlearned fear and named “shock sensitization” (Davis, 1989).  Subsequent work, 
however, has shown that this increase in startle is due to rapid contextual conditioning 
(McNish et al., 1997; Richardson, 2000; Risbrough et al., 2009) and is thus a model of 
learned fear.  Footshock has been shown to induce CRF release (Wang et al., 2005), 
while disrupting CRF receptor activation can block the behavioral effects of footshock 
(Ho et al., 2001; Bakshi et al., 2002; Le et al., 2002).  Footshock-potentiated startle is 
abolished in CRF-R1 KO mice and reduced in CRF-R2 KOs (Risbrough et al., 2009).  
Since footshock-enhanced startle also depends on CRF receptor activation, I chose this 
paradigm as a model of learned fear to complement my CRF-enhanced startle studies.  
These studies involve the same basic apparatus as is used for the CRF-enhanced 
startle studies; in this case, however, scrambled footshock is delivered through metal 
rods at the bottom of holding chamber (Fig. 1.2B). 
 
6. Summary 
My working hypothesis is that KORs within the mesocorticolimbic circuit play an 
important role in regulating anxiety-like behavior.  In my first set of studies to address 
this hypothesis, I tested the effects of systemic KOR antagonism in CRF-enhanced and 
footshock-potentiated startle.  This work is described in Chapter 2. 
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Abstract 
Rodent models used in research on psychiatric illness have implicated the KOR system 
in anxiety-like behavior.  KOR antagonists reduce anxiety in models of learned and 
unlearned fear, and block the effects of CRF, a key regulator of the stress response.  
The present studies further characterize interactions of KOR-CRF systems by 
determining if KOR antagonists can affect increases in startle reactivity produced by 
central infusion of CRF.  Mice were administered intraperitoneal (IP) injections of the 
selective and long-lasting KOR antagonist JDTic (10 or 30 mg/kg) immediately following 
surgery to implant a guide cannula directed at the lateral ventricle for delivery of CRF.  
One week later, they were tested for startle responsiveness following 
intracerebroventricular (ICV) administration of CRF (1.0 µg).  JDTic dose-dependently 
attenuated CRF-induced increases in the acoustic startle response without affecting 
baseline startle reactivity.  The persistent ability of JDTic to disrupt KOR function was 
confirmed using the tail-flick assay.  JDTic-induced reductions in startle were 
accompanied by decreases in c-Fos immunoreactivity in the VTA and dorsal HIP.  
Double-labeling experiments in the VTA revealed that JDTic significantly reduced c-Fos 
cell counts in dopaminergic neurons compared to CRF treated controls.  Stress is 
known to increase dopaminergic transmission, and these results indicate that KORs 
may be involved in regulation of this process.  Further, these data indicate KOR 
antagonists may be particularly useful for treating anxiety disorders in which CRF 
systems are dysregulated, such as PTSD. 
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Introduction 
The stress response is an adaptive process that preserves homeostasis and enhances 
the chances of survival.  However, prolonged or uncontrolled stress can precipitate 
psychiatric illness, including anxiety and depressive disorders (Keane et al., 2006; 
Keller et al., 2007; Kessler et al., 2010).  CRF is a brain peptide often considered the 
principal regulator of the stress response (Spiess et al., 1981; Majzoub, 2006).  Its 
effects are mediated through two cognate receptors (CRF-1 and CRF-2) that are found 
throughout the brain including regions implicated in stress and anxiety including the 
AMY, VTA, and NAc (De Souza et al., 1985; Millan et al., 1986; Van Pett et al., 2000; 
Dautzenberg and Hauger, 2002).  Central infusions of CRF induce anxiety-like behavior 
in laboratory animals including potentiation of the acoustic startle response (Swerdlow 
et al., 1986; Liang et al., 1992), a hallmark symptom of PTSD (American Psychiatric 
Association, 2000).  Several studies have reported elevated levels of cerebrospinal fluid 
CRF in PTSD patients (Bremner et al., 1997a; Sautter et al., 2003; de Kloet et al., 
2008), suggesting that blocking CRF receptor actions may be useful therapeutically.  
Indeed, CRF antagonists decrease anxiety and fear behavior in non-human primates 
(Habib et al., 2000) and patients with depression (Zobel et al., 2000).  However, 
development of such drugs for clinical use has been unsuccessful due to setbacks such 
as poor efficacy and unwanted side effects (Zorrilla and Koob, 2010).  Identification of 
neural processes that occur downstream of CRF actions may enable the development 
of improved medications to treat or prevent stress-related illnesses while having fewer 
side effects. 
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KORs are selectively activated by the endogenous opioid dynorphin (Chavkin et al., 
1982).  We have shown previously that systemic KOR antagonism produces anxiolytic-
like effects in tests of learned and unlearned fear (Knoll et al., 2007).  Further, KOR 
antagonist treatment and KOR system KO mice have reduced stress-induced behaviors 
such as analgesia, immobility in the FST, and potentiation of cocaine-induced CPP 
(Takahashi et al., 1990; Menendez et al., 1993a; McLaughlin et al., 2003a).  KOR 
activation has also been suggested to mediate actions of CRF on behavior.  Indeed, 
CRF increases phosphorylation (i.e., activation) of KORs in the brain (Land et al., 2008; 
Bruchas et al., 2009).  Inhibiting KOR action through receptor blockade or using 
dynorphin KO mice reduces effects of CRF on open arm exploration (Bruchas et al., 
2009) and abolished CRF-induced place aversions (Land et al., 2008).  Evidence 
suggests that the stress-related effects of KOR activation are downstream of CRF 
activation since U50,488-induced place aversions—which mimic CRF effects—are not 
blocked by CRF-R antagonism (Land et al., 2008).  If so, it is conceivable that disruption 
of KOR function could mitigate the aversive or maladaptive effects of stress without 
affecting any beneficial (i.e., pro-adaptive or homeostatic) effects. 
 
The brain circuits involved in KOR regulation of stress effects are not well understood.  
Central administration of CRF leads to KOR activation in the NAc, BLA, HIP and DRN 
(Land et al., 2008).  Elevated KOR system function within the NAc and HIP has been 
implicated in depressive-like behavior in rodents.  For example, stress produces 
upregulation of CREB (which regulates dynorphin) (Pliakas et al., 2001; Newton et al., 
2002; Shirayama et al., 2004) and dynorphin expression (Shirayama et al., 2004; 
Chartoff et al., 2009) within these regions.  In contrast, KOR activation within the AMY  
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has been implicated in anxiety-like behavior.  For example, microinfusions of KOR 
antagonists into the AMY produces anxiolytic-like effects: rodents show reduced 
conditioned fear as measured by fear-potentiated startle, increase open arm exploration 
in the elevated plus maze (Knoll et al., 2011), reduced swim stress and CRF-induced 
anxiety-like behavior (Bruchas et al., 2009), and reductions in the stress-related effects 
of nicotine (Smith et al., 2012).  Considering the high comorbidity of depressive and 
anxiety disorders in humans (Kaufman and Charney, 2000; Kessler et al., 2003), and 
the fact that all of these regions receive input from the VTA (Swanson, 1982), there may 
be substantial overlap in the brain circuits that regulate depressive- and anxiety-like 
effects. 
 
The present studies were designed to further characterize how interactions among 
KORs, dynorphin, and CRF regulate behavior.  We quantified anxiety-like behavior in 
mice using the acoustic startle response.  Increases in startle—which likely reflect 
hyperarousal or hypervigilance—are seen in people with anxiety disorders such as 
PTSD (American Psychiatric Association, 2000) and are produced in rodents by central 
infusion of CRF (Liang et al., 1992).  CRF-enhanced startle is generally considered to 
reflect an anxiety behavior in rodents since fear conditioning or administration of 
compounds known to be anxiogenic in humans, such as yohimbine (an α2-adrenergic 
receptor antagonist), produce similar increases in startle amplitude (Morgan et al., 1993; 
Grillon and Davis, 1997).  Furthermore, reductions of CRF-induced increases in startle 
may indicate an anxiolytic effect, since medications that reduce anxiety in humans (e.g., 
benzodiazepines) reduce the CRF-enhanced startle response in rodents (Swerdlow et 
al., 1986; Abduljawad et al., 2001).  In the present studies, mice were given a single  
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injection of the long-acting KOR antagonist JDTic (Carroll et al., 2004) before CRF-
enhanced startle testing.  Mice were then tested in the warm water tail-flick assay to 
ensure KOR blockade, as demonstrated by the ability of JDTic to block the analgesic 
effects of a KOR agonist (McLaughlin et al., 2003a; Van't Veer et al., 2012).  Finally, c-
Fos immunohistochemistry was used to provide an index of neuronal activation 
(Kovacs, 1998) to probe the effects of JDTic on CRF-induced changes in the activity of 
stress-related brain circuits. 
 
Materials and Methods 
Mice: Experiments were performed in 8-10-week-old male C57BL/6J mice (The Jackson 
Laboratory, Bar Harbor, ME).  Mice were individually housed upon arrival and allowed to 
acclimate to the animal care facility for one week prior to surgery.  Mice were 
maintained on a 12:12-h light-dark cycle (0700h lights on) with ad libitum food and water 
available except during testing.  Experiments were conducted during the light phase of 
the daily cycle to avoid startle ceiling effects (Chabot and Taylor, 1992).  Experimental 
protocols were approved by the Institutional Animal Care and Use Committee of 
McLean Hospital and in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals  (National Academies Press, Washington D.C., 
USA, 2011).  
 
Drugs: (3R)-7-Hydroxy-N-[(2S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl]-3-methylbutan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (JDTic) was 
synthesized at Research Triangle Institute (Research Triangle Park, NC).  Trans-(±)-
3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide hydrochloride  
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(U50,488) was purchased from Sigma-Aldrich (St. Louis, MO).  Rat/human CRF was 
purchased from American Peptide (Sunnyvale, CA).  JDTic and U50,488 were dissolved 
in 0.9% saline and administered by intraperitoneal (IP) injection at 10 mL/kg.  The dose 
of U50,488 was based on its salt form.  CRF was dissolved in artificial cerebrospinal 
fluid (aCSF, Harvard Apparatus, Holliston, MA) and infused in a volume of 1.0 µL. 
 
Stereotaxic surgery: Mice were anesthetized with ketamine/xylazine (100 mg/kg, 12.5 
mg/kg, IP) and placed in a stereotaxic instrument (David Kopf Instruments, Tujunga, 
CA) with zygoma ear cups in order to prevent damage to the ear drums.  For each 
mouse, a stainless steel guide cannula (26-gauge, Plastics One, Roanoke, VA) with a 
dummy stylet extending 1.5 mm beyond the end was lowered into the right lateral 
ventricle at the following coordinates, relative to bregma: anteroposterior = -0.2 mm, 
mediolateral = 1.0 mm, and lowered -2.4 mm ventral to the skull (Paxinos and Franklin, 
2001).  Non-acrylic cement permanently secured the cannula to the skull.  The mice 
were allowed to recover for 5-7 days before testing.  
 
Startle testing: Acoustic startle data were collected by measuring the amplitude of the 
startle reflex in response to white noise bursts of various intensities using the Med 
Associates Inc. (St. Albans, VT) Startle Reflex System and Advanced Startle software 
program.  Mice were placed into 8.5 x 7 x 7 cm Plexiglas holders with steel rod floor 
bars attached to a load cell platform contained within a 40 x 64 x 42 cm sound-
attenuating chamber.  The load cell transduces movement into an electrical output that 
is amplified and digitized into arbitrary units by an analog-to-digital converter interfaced 
to a computer.  Startle amplitude was defined as the maximum peak-to-peak voltage  
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occurring within the first 100 ms after the onset of the startle stimulus.  An audio 
stimulator generated 50 msec startle stimuli (1-32 kHz white noise, 1 msec rise-decay) 
that were delivered through high-frequency speakers located 4 cm behind the cages.  
The intensities of the startle stimuli were calibrated before use using customized 
software.  All tests were conducted in darkness.    
 
Following recovery from surgery, mice were given a habituation session to acclimate 
them to the testing chamber and match them into groups with equivalent baseline 
startle.  The habituation session consisted of a 5 min acclimation period followed by 
startle stimuli at 3 decibel (dB) levels (20 each at 80, 90 and 100 dB) presented in a 
pseudo-random order with an inter-stimulus interval (ISI) of 30 sec.  Two days later they 
were given ICV infusions of vehicle (aCSF) or CRF.  The dummy stylet was removed 
and replaced with a 33-gauge infusion stylet (Plastics One) attached to a Hamilton 
microsyringe (10 µl) by polyethylene tubing.  ICV infusions (1.0 µL volume) of either 
vehicle (aCSF) or CRF (0.25, 0.5 or 1.0 µg) were performed over a 2-min period at a 
rate of 0.5 µL/min, with an additional 2 min of diffusion time before the infusion stylet 
was removed and the dummy stylet was replaced.  During the infusion mice were 
placed in clean and empty mouse cages divided in half and were free to move.  After 
the infusion, mice were immediately placed in the startle chambers for a 5 min 
acclimation period followed by a 99-min startle test of 198 startle stimuli (80, 90, or 100 
dB presented in a pseudo-random order with an ISI of 30 sec).  Mice used to examine 
the effects of a KOR antagonist on CRF-enhanced startle received JDTic (10 or 30 
mg/kg, IP) or vehicle (0.9% saline) immediately following surgery, and 7 d later were 
tested as above after administration of 1.0 µg CRF (ICV).  
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Warm water tail-flick assay: The tail-flick assay was used to assess KOR-mediated 
analgesia (Vaught and Takemori, 1979; McLaughlin et al., 2003a).  The test was 
conducted 24 hr following the final startle test session.  Mice were scruffed with their tail 
free and back supported and approximately 1 cm of their tail was submerged into a 52 ± 
1°C warm water bath.  The latency for mice to withdraw their tail from the water was 
timed with a stopwatch.  A maximum time of 15 sec was imposed to prevent damage to 
the submerged tail.  After taking baseline latencies, mice were treated with the KOR 
agonist U50,488 (15 mg/kg, IP), and withdrawal latencies were assessed 30 min later. 
 
Histological verification: Mice were overdosed with pentobarbital (130 mg/kg, IP) and 
transcardially perfused with 0.9% saline (20 mL) followed by 4% paraformaldehyde in 
0.1M phosphate-buffered saline (PBS) (60 mL).  Brains were removed and postfixed 
overnight in 4% paraformaldehyde, and then cryoprotected in 30% sucrose/0.1M PBS 
for 24 h.  Brains were sectioned at 30 µm on a freezing microtome and collected in 0.1M 
phosphate buffer.  Sections were mounted on gelatin-coated slides (Fisher Scientific, 
Pittsburg, PA) and stained with 0.1% cresyl violet.  Mice with incorrect placements (e.g., 
if the tip of the cannula was found to be embedded in brain tissue adjacent to the lateral 
ventricle, rather than being located within the lateral ventricle itself) or signs of infection 
were excluded from analysis. 
 
c-Fos immunohistochemistry:  Separate cohorts of mice were pretreated with an 
effective dose of JDTic (30 mg/kg, IP) or vehicle during surgery as described above and 
allowed to recover for 3 days.  Mice were then given mock ICV infusions on four 
consecutive days to habituate them to the experimental procedure and reduce handling- 
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induced c-Fos expression. The following day at test time, mice received CRF (1.0 µg) or 
aCSF vehicle and were placed back in their home cage for 120 minutes and then 
sacrificed and perfused.  Mouse brain sections (40 µm) were first incubated for 30 min 
in 0.3% H2O2, and then in a blocking solution of 5% normal goat serum (NGS; Vector 
Laboratories, Inc., Burlingame, CA) for 1 h.  Sections were then incubated overnight 
with anti-c-Fos (1:1,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 5% NGS.  
The following morning, sections were first incubated for 1 hr in biotinylated anti-rabbit 
IgG (1:1,000; Vector Laboratories), and then in avidin-biotin complex (ABC) for 1 hr 
(ABC Elite Kit, Vector Laboratories).  C-Fos immunoreactivity was visualized with 3,3’-
diaminobenzidine (DAB).  Photomicrographs of regions of interest were obtained at 40x 
on a Zeiss Axio Scope (Carl Zeiss Inc., Thornwood, NY) using OpenLab software 
(PerkinElmer, Waltham, MA).  The number of labeled cells for each photomicrograph 
was counted using ImageJ software (NIH, Bethesda, MD) and the counts from 3 non-
serial sections per region were averaged for each mouse  
 
For double-labeling with anti-tyrosine hydroxylase (TH), sections were labeled for c-Fos 
as described.  Sections were then incubated in primary antibody to TH (1:10,000; 
Millipore, Billerica, MA) in 5% NGS overnight followed by biotinylated anti-rabbit IgG 
(1:1,000) and ABC for 1 hour each.  TH immunoreactivity was visualized with nickel-
enhanced DAB.  C-Fos, TH and double labeled cells were counted from bilateral 40X 
images of the VTA from 3 non-serial sections using Stereo Investigator software (MBF 
Bioscience, Williston, VT ).  
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Data analysis:  For the CRF dose response, 2-way (CRF x dB level) analysis of 
variance (ANOVA) with repeated measures (dB level) were used to compare the effects 
of increasing doses of CRF to aCSF vehicle.  The effect of JDTic on CRF-enhanced 
startle was analyzed with a 3-way (JDTic x CRF x dB level) ANOVA with repeated 
measures (dB level).  For the tail-flick assay, a 3-way (JDTic x CRF x U50,488) ANOVA 
with repeated measures (U50,488) was used to examine whether JDTic affected 
U50,488-induced antinociception.  Significant interactions in the ANOVAs were further 
analyzed using Bonferroni post hoc tests.  Counts from c-Fos and TH double-labeling 
were analyzed by t-test.  Data are graphed as mean plus standard error of the mean 
(SEM). 
 
Results 
A total of 7 mice were excluded from analysis after histological assessment which 
indicated the tip of the cannula was embedded in brain tissue instead of terminating in 
the lateral ventricle.  All other mice had correct placements (Fig. 2.1). 
49 
 
 
 
Figure 2.1 Representative cresyl-violet stained photomicrograph of an ICV 
cannula tract.  Only mice with cannula tips within the lateral ventricle (LV) were 
included for analysis.  ICV, intracerebroventricular 
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CRF produced dose-dependent increases in startle reactivity (Fig. 2.2).  Prior to CRF 
infusion, mice were given a baseline startle test and were matched into groups with 
equivalent levels of startle (F[3,29]=0.19, NS) across three sound intensities (80, 90, 
100 dB; as expected, there was a main effect of dB (F[2,58]=147.23, P<0.001; Fig. 
2.2A).  Infusions of CRF increased startle amplitude and this increase was dependent 
on an interaction of CRF dose (0.0, 0.5, 1.0 or 2.0 µg) and dB level (80, 90 and 100 dB; 
F[6, 56]=3.35, P<0.01).  Main effects of dB (F[2,58]=196.10, P<0.001) and CRF 
(F[3,29]=4.93, P<0.01) were also observed.  Post hoc analyses of between-subject 
effects at each dB level revealed that 2.0 µg CRF significantly increased startle at all dB 
levels, while 1.0 µg significantly enhanced startle at 80 and 100 dB (P’s<0.05) (Fig. 
2.2B).  In contrast, 0.5 µg had no significant effects.  Increases in startle were sustained 
throughout the 100 min test session (Fig. 2.2C). 
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Figure 2.2 Dose response of CRF on startle amplitude.  Mice were infused with1.0 
µL of vehicle (aCSF) or CRF (0.5, 1.0, or 2.0 µg) and startle amplitude data were 
collected across a 104 min test session.  Startle bursts of 80, 90 or 100 dB were 
delivered every 30 sec throughout the session in a semi-random order.  A. Mice were 
matched into groups showing equivalent levels of baseline startle (n=8-9). B. CRF 
increased startle amplitude in a dose-dependent manner. C. Time course of CRF’s 
effect on startle amplitude across the entire test session.  Data were analyzed by 
ANOVA followed by Bonferroni post hoc tests.  *P<0.05, **P<0.01 compared to aCSF 
control group.  aCSF, artificial cerebrospinal fluid 
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Figure 2.2 (Continued) Dose response of CRF on startle amplitude 
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To study the effects of KOR antagonism on CRF-enhanced startle, mice were infused 
with 1.0 µg of CRF, the lowest dose that significantly increased startle.  During surgery 
to implant the ICV guide cannula, mice were injected with the long-acting KOR 
antagonist JDTic (10 or 30 mg/kg, IP).  Data for each dose of JDTic were analyzed 
separately.  Mice were matched into groups with equivalent levels of baseline startle 
before surgery.  No difference in baseline startle reactivity was observed between aCSF 
and CRF groups following 10 mg/kg JDTic pretreatment, but before CRF infusion 
(F[1,36]=0.50, NS; Fig. 2.3A).  Startle amplitude increased as a function of dB level as 
demonstrated by a main effect of dB (F[2,68]=227.99, P<0.001).  Further, JDTic at 10 
mg/kg had no effect alone on baseline startle (F[1,36]= 0.45, NS).  During the test 
session, mice received 1.0 µL infusions of CRF or vehicle and were immediately tested.  
Data from the test session revealed a CRF x dB interaction (F[2, 68]=7.67, P<0.01; Fig. 
2.3B).  Main effects of dB (F[2,68]=197.73, P<0.001) and CRF (F[1,34]=19.73, 
P<0.001) were also observed.  There were no interactions of JDTic pretreatment (10 
mg/kg) with any other factor, nor a main effect of JDTic.  The effect of JDTic on KOR 
agonist-induced analgesia was tested the following day using the warm water tail-flick 
assay (Fig. 2.3C,D).  Tail withdrawal latencies were collected at baseline prior to IP 
injection with U50,488 (15 mg/kg) and again 30 min following injection.  Tail withdrawal 
latencies depended on both a JDTic x U50,488 (F[1,34]=5.95, P<0.05; Fig. 2.3C) and 
CRF x U50,488 (F[1,34]=4.94, P<0.05; Fig. 2.3D) interaction, whereas no 3-way 
interaction was observed.  When data were collapsed across ICV treatment, post hoc 
within-group analysis demonstrated a significant increase in tail withdrawal latency in 
vehicle but not JDTic pretreated mice (P<0.001).  No differences in baseline tail 
withdrawal latencies were detected in between-group analysis; however, there was a  
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significant difference between vehicle and JDTic pretreatment group latencies following 
U50,488 treatment (P<0.05).  When data from the same studies were collapsed across 
JDTic treatment, analysis revealed no differences between aCSF or CRF treated mice 
either at baseline or following U50,488; however, while aCSF infused mice showed an 
expected increase in latency following U50,488 (P<0.01), this increase was not 
observed in the CRF group.  Since the goal of our study was to prevent CRF-induced 
effects with JDTic pretreatment, we further analyzed the tail-flick data excluding all 
aCSF mice to determine whether a lack of JDTic effect in CRF-enhanced startle may be 
due to insufficient blockade of KORs.  In this analysis, there was a main effect of 
U50,488 treatment (F[1,18]=4.88, P<0.05; data not shown), but no interaction with 
JDTic as would be expected if KOR function was antagonized.  We therefore repeated 
the study using a higher dose of JDTic (30 mg/kg). 
 
Tests at the 30 mg/kg dose of JDTic similarly revealed no effect of JDTic on baseline 
startle reactivity (F[1,37]=0.09, NS; Fig. 2.4A).  Further, there were no differences in 
startle magnitude between aCSF and CRF groups before infusion (F[1,37]=0.01, NS; 
Fig. 2.4A).  As expected, a main effect of dB (F[2,74])=235.37, P<0.001) indicated 
startle amplitude was dependent on dB level at baseline.  In the test session, JDTic 
attenuated CRF-induced increases in startle.  This effect was dependent on dB level, as 
indicated by a JDTic x CRF x dB interaction (F[2,74]=3.93, P<0.05; Fig. 2.4B).  Main 
effects of dB (F[2,74]=262.32, P<0.001) and CRF (F[1,37]=22.71, P<0.01) also 
emerged as well as a JDTic x CRF interaction (F[1,37]=4.97, P<0.05).  Follow-up two-
way ANOVAs at each dB level revealed that CRF effects were dependent on JDTic 
pretreatment at 90 dB (F[1,37]=4.25, P<0.05) and 100 dB (F[1,37]=4.79, P<0.05).  At 80  
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dB, CRF increased startle amplitude (F[1,37]=51.25, P<0.001; however, JDTic failed to 
reduce this response.  Post hoc analyses demonstrated that vehicle pretreated mice 
infused with CRF had significantly higher startle reactivity at 90 and 100 dB compared 
to vehicle and JDTic pretreated mice infused with aCSF (P<0.01) and more importantly, 
to JDTic pretreated mice infused with CRF (P<0.05).  Following the test session, KOR 
agonist-induced analgesia was tested in the tail-flick as above (Fig. 2.4C).  JDTic 
pretreatment reduced U50,488-induced increases in tail withdrawal latency as reflected 
by a JDTic x U50,488 interaction (F[1,37]=11.39, P<0.01).  Vehicle pretreated mice had 
a significant increase in tail withdrawal latency following U50,488 compared to baseline 
(within-subjects post hoc analysis, P<0.001).  This effect was not seen in JDTic 
pretreated mice (P=0.66).  Further, U50,488 significantly increased tail withdrawal 
latencies in vehicle compared to JDTic pretreated mice (P<0.001).  JDTic on its own did 
not have an effect on baseline tail withdrawal latency (P=0.55).  These same effects 
were still observed when aCSF infused mice were removed from the analysis 
(F[1,21]=5.38, P<0.05).  Tail withdrawal latencies were significantly increased in vehicle 
pretreated (P<0.001) but not JDTic pretreated mice (P=0.67) following U50,488 
compared to baseline.  Further, tail withdrawal latencies were significantly higher 
following U50,488 injection in vehicle compared to JDTic pretreated mice (P<0.01).   
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Figure 2.3 Effect of JDTic (10/mg/kg) on CRF-enhanced startle.  Mice were 
implanted with ICV cannulae, administered JDTic (10 mg/kg), and allowed to recover.  
A. Groups were matched for equivalent baseline startle. (n=9-10).  On the test day mice 
received CRF (1µg) or vehicle and were immediately placed in the startle apparatus. B. 
JDTic did not significantly alter CRF-induced increases in startle amplitude at any 
decibel level.  C-D. Effect of JDTic pretreatment on latency to withdraw the tail (in sec) 
in the tail-flick assay at baseline or 30 min after administration of the KOR agonist 
U50,488 (15 mg/kg, IP).  C. U50,488 increased tail withdrawal latencies in vehicle, but 
not JDTic pretreated mice.  D.  Mice infused with aCSF showed an increase in tail 
withdrawal latencies following U50,488, which is absent in CRF infused mice.  Data 
were analyzed by ANOVA followed by Bonferroni post hoc test as appropriate.  *P<0.05 
between group comparison, ***P<0.001 within group comparison.  Veh, vehicle  
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Figure 2.3 (Continued) Effect of JDTic (10/mg/kg) on CRF-enhanced startle 
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Figure 2.4 Effect of JDTic (30/mg/kg) on CRF-enhanced startle.  A. Groups were 
matched for equivalent baseline startle. (n=9-12).  On the test day mice received CRF 
(1µg) or vehicle and were immediately placed in the startle apparatus. B. JDTic 
significantly reduced CRF-enhanced startle at 90 and 100 dB.  C. Effect of JDTic 
pretreatment on latency to withdraw the tail (in sec) in the tail-flick assay at baseline or 
30 min after administration of the KOR agonist U50,488 (15 mg/kg, IP).  U50,488 
increased tail withdrawal latencies in vehicle, but not JDTic pretreated mice.  Data were 
analyzed by ANOVA followed by Bonferroni post hoc test as appropriate.  *P<0.05, 
***P<0.001 
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Figure 2.4 (Continued) Effect of JDTic (30/mg/kg) on CRF-enhanced startle 
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To investigate the effects of JDTic on CRF-induced changes in brain activation, c-Fos 
immunohistochemistry was performed as a marker of neuronal activation.  Mice were 
pretreated with JDTic (30 mg/kg, IP) during ICV surgery and perfused 8 days later 
following aCSF or CRF (1.0 µg) infusion.  Brain regions analyzed are shown in Fig. 2.5. 
and their abbreviations are listed in Table 2.1.  In the VTA, CRF effects depended upon 
an interaction with JDTic (F[1,33]=4.94, P<0.05).  Post hoc analysis revealed that 
JDTic-treated mice had significantly fewer CRF-induced c-Fos immunoreactive cells 
compared to vehicle treatment (P<0.05, Fig. 2.6).  Example photomicrographs show 
reduced c-Fos cell labeling in the JDTic /CRF group compared to the vehicle/CRF group 
(Fig. 2.6A).  In the dDG, a main effect of JDTic was observed (F[1,33]=6.48, P<0.05), 
as JDTic reduced c-Fos cell numbers in both aCSF- and CRF-treated mice (Fig. 2.7).  
Table 2.1 includes the mean number of c-Fos positive cells for all regions analyzed.  P-
values listed are for the JDTic x CRF interaction.  A significant main effect of CRF 
treatment was observed in all regions including the AcbC (F[1,33]=25.82, P<0.001), 
AcbSh (F[1,33]=230.44, P<0.001),  BLA (F[1,33]=56.81, P<0.001), CeA 
(F[1,33]=1290.62, P<0.001), BNST (F[1,33]=1470.55, P<0.001), IL (F[1,33]=109.04, 
P<0.001), Pir (F[1,33]=36,61, P<0.001), DRD (F[1,33]=138.03, P<0.001), dCA1 
(F[1,33]=83.43, P<0.001), dCA2 (F[1,33]=164.55, P<0.001), dCA3 (F[1,33]=288.09, 
P<0.001),  dDG (F[1,33]=67.29,  P<0.001), dStr (F[1,33]=12.90, P<0.001), and VTA 
(F[1,33]=58.51, P<0.001). 
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Figure 2.5 Location of regions of interest analyzed for c-Fos immunoreactivity.  
Areas are demarcated by boxes on representative atlas images of the mouse brain 
(figures 17, 22, 30, 45, 46, 57 and 69 in Paxinos and Franklin (2001)).  Anteroposterior 
distance from Bregma is indicated below each image.  The definitions of abbreviations 
used are located in Table 2.1.  
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Figure 2.5 (Continued) Location of regions of interest analyzed for c-Fos 
immunoreactivity  
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Figure 2.6 Effect of JDTic on c-Fos immunoreactivity in the VTA.  A. 
Representative photomicrographs of c-Fos staining in the VTA at 20x.  Left panels 
represent vehicle pretreated mice while right panels indicate JDTic (30 mg/kg, IP) 
pretreatment.  Top panels are from aCSF infused mice while images in bottom panels 
are from CRF treated subjects. Dorsal is at the top and medial is to the left.  Bar 
indicates 200 µm. Dashed box is representative of area counted at 40x for analysis.  B. 
JDTic significantly decreased CRF-induced increases in c-Fos counts in the VTA. Data 
were analyzed by ANOVA followed by Bonferroni post hoc test. *P<0.05, **P<0.01.  
VTA, ventral tegmental area  
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Figure 2.6 (Continued) Effect of JDTic on c-Fos immunoreactivity in the VTA 
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Figure 2.7 Effect of JDTic on c-Fos immunoreactivity in the dDG.  A. 
Representative photomicrographs of c-Fos staining in the dDG at 20x.  Left panels 
represent vehicle pretreated mice while right panels indicate JDTic pretreatment.  Top 
panels are from aCSF infused mice while images in bottom panels are from CRF 
treated subjects. Dorsal is at the top and medial is to the left.  Bar indicates 200 µm. 
Dashed box is representative of area counted at 40x for analysis.  B. JDTic significantly 
decreased c-Fos counts in the dDG regardless of CRF infusion.  Data were analyzed by 
ANOVA followed by Bonferroni post hoc test. *P<0.05, ***P<0.001.  dDG, dorsal 
dentate gyrus of the HIP 
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Figure 2.7 (Continued) Effect of JDTic on c-Fos immunoreactivity in the dDG 
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     Table 2.1 Effects of JDTic on C-Fos expression after infusion of CRF (1.0 µg, ICV) 
 
Brain Area  Sub-division  Abbr.     c-Fos Cell # (mean ± SEM)  P-value* 
     
IP  Saline  JDTic  Saline  JDTic 
           ICV  aCSF  aCSF  CRF  CRF 
  Accumbens nuclei  Core  AcbC 
 
0.6 ± 0.2  1.5 ± 0.4  13.4 ± 3.2  17.8 ± 4.4  0.549
a 
 
Shell  AcbSh 
 
6.2 ± 1.3  9.9 ± 1.9  52.2 ± 4.1  54.3 ± 3.5  0.793
a 
Amygdaloid nuclei  Basolateral  BLA 
 
5.0 ± 1.8  4.3 ± 1.0  19.5 ± 2.0  18.1 ± 2.3  0.865
a 
 
Central  CeA 
 
4.5 ± 1.3  6.8 ± 1.6  161.0 ± 6.1  164.6 ± 6.0  0.887
a 
Bed nucleus of the stria terminalis  Lateral Division  BNST 
 
10.8 ± 1.8  14.3 ± 2.7  132.7 ± 3.9  135.5 ± 3.7  0.897
a 
Cortex  Infralimbic  IL 
 
24.1 ± 5.4  28.8 ± 4.9  79.2 ± 6.3  83.7 ± 4.3  0.990
a 
 
Piriform  Pir 
 
16.8 ± 6.3  25.2 ± 4.1  97.6 ± 16.8  78.4 ± 12.0  0.221
a 
Dorsal raphe nucleus  Dorsal part  DRD 
 
16.4 ± 2.3  19.3 ± 2.4  50.3 ± 4.0  55.2 ± 2.9  0.727
a 
Dorsal hippocampus  field CA1  dCA1 
 
2.9 ± 1.4  2.3 ± 0.6  43.8 ± 5.9  34.3 ± 5.0  0.279
a 
 
field CA2  dCA2 
 
3.2 ± 1.3  4.9 ± 1.7  34.0 ± 3.0  30.0 ± 2.3  0.204
a 
 
field CA3  dCA3 
 
5.8 ± 1.2  5.9 ± 1.0  27.6 ± 0.9  26.1 ± 1.6  0.533
a 
 
dentate gyrus  dDG 
 
12.2 ± 0.9  10.1 ± 0.9  28.4 ± 2.9  21.8 ± 1.4  0.194
a,b 
Striatum  Dorsal  dStr 
 
0.2 ± 0.1  0.3 ± 0.1  8.3 ± 2.8  8.3 ± 3.3  0.978
a 
Ventral tegmental area     VTA     8.5 ± 1.6  9.5 ± 3.6  40.7 ± 3.5  27.2 ± 3.7  0.033
a 
*p-value for JDTic x CRF interaction 
                a Significant main effect of CRF, p≤ 0.001, 
b Significant main effect of JDTic, P=0.016 
   
Mice were pretreated with vehicle or JDTic (30 mg/kg, IP) before infusion of aCSF or CRF (1.0 µg) n=9-10 per group  
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To identify the cell types affected by JDTic pretreatment, double-labeling experiments 
for c-Fos and TH were carried out in alternate sections of the VTA.  Since the decrease 
in c-Fos cells was only apparent in CRF-treated mice, sections from aCSF-treated mice 
were not processed for immunohistochemistry.  The VTA predominantly consists of 
dopaminergic cells, so an antibody to TH, which labels this neuronal population in the 
VTA, was used to determine if c-Fos reductions were occurring in DA neurons.  JDTic 
significantly reduced the number of c-Fos positive cells that colocalized with TH (Fig. 
2.8). 
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Figure 2.8 Effect of JDTic on c-Fos immunoreactivity in DA cells of the VTA.  A. 
Representative photomicrographs of c-Fos and TH labeling in CRF-infused mice treated 
with saline or JDTic (30 mg/kg).  Arrows indicate c-Fos and TH double-labeled cells 
while arrowheads point to TH alone.  B. The number of TH-positive cells counted for 
saline and JDTic groups did not differ.  C. The percent of TH cells colabeled with c-Fos 
was significantly reduced in mice pretreated with JDTic compared to controls.  Data 
were analyzed by Student’s t-test.  ****P<0.0001 Scale bar indicates 100 µm.  DA, 
dopamine  
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Figure 2.8 (Continued) Effect of JDTic on c-Fos immunoreactivity in DA cells of the 
VTA 
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Discussion 
Central infusions of CRF dose-dependently increased acoustic startle reactivity; doses 
of 1.0 and 2.0 µg CRF significantly increased startle amplitude compared to vehicle.  
Increases in acoustic startle reactivity following 1.0 µg infusions of CRF were nominally 
attenuated by a single pretreatment with the long-lasting KOR antagonist JDTic at 10 
mg/kg and significantly blocked at 30 mg/kg, IP.  This same dose of CRF induced 
neuronal activation throughout the brain as measured by c-Fos immunoreactivity.  
Pretreatment with JDTic (30 mg/kg) blocked CRF-induced increases in c-Fos cell 
counts in the VTA while causing a more general reduction in c-Fos positive cell counts, 
regardless of CRF treatment, in the dDG of the HIP.  These results suggest that KOR 
activation mediates CRF effects on startle and implicates the VTA and dDG in these 
effects. 
 
The general goal of these experiments was to examine the effects of KOR antagonism 
on CRF-enhanced startle and brain c-Fos activation in mice.  After characterizing the 
CRF dose-effect function, we administered CRF at 1.0 µg (ICV) for subsequent studies, 
since this was the lowest of the doses tested to elicit significant increases in startle 
amplitude.  Use of this intermediate dose enabled us to detect both decreases and 
increases in CRF-enhanced startle following JDTic pretreatment.  It also enables us to 
compare our results with those of other reports testing CRF-induced behavioral effects 
in mice including elevated startle (Swiergiel and Dunn, 1999; Risbrough et al., 2004; 
Risbrough and Geyer, 2005; Land et al., 2008; Bruchas et al., 2009), suggesting this is 
an appropriate dose to investigate compounds with anxiolytic-like effects, although  
72 
 
doses lower than 1.0 µg ICV can induce changes in other behavioral tests (see Dunn 
and Berridge, 1990). 
 
Prior to CRF infusion, JDTic pretreatment at either 10 or 30 mg/kg did not have an 
effect on baseline startle responding in mice.  This finding is consistent with previous 
reports indicating lack of effects of JDTic (Knoll et al., 2007) or norBNI (Bortolato et al., 
2005; Tejeda et al., 2010a)—another highly selective KOR antagonist with similar 
pharmacodynamics to JDTic (Munro et al., 2012)—on baseline startle.  Since JDTic 
alone produced no appreciable effects on startle, we sought to determine if KOR 
antagonism would specifically alter CRF responses.  In our initial study, JDTic at 10 
mg/kg did not significantly reduce increases in startle amplitude in response to CRF.  
This likely indicates the use of an insufficient dose of JDTic; indeed, this dose was 
selected on the basis of studies in rats (Knoll et al., 2007).  Because JDTic is a highly 
selective and long-lasting KOR antagonist with a slow onset of action (Carroll et al., 
2004; Beardsley et al., 2005), we administered it at the time of surgery, 7 days prior to 
testing.  This also enabled drug administration during anesthesia, thereby avoiding the 
stress of an IP injection in conscious mice.  Single injections of JDTic have been shown 
to have a duration of action in mice of 14-21 days in a warm water tail-flick assay similar 
to that used in the present work (Bruchas et al., 2007b; Melief et al., 2011), and we 
have reported a similar extended time course in rats (Van't Veer et al., 2012).  Here we 
report that 10 mg/kg JDTic blocks U50,488 effects 8 days following administration; 
however, since the comparison of most interest to us was between the vehicle and 
JDTic groups that received CRF, an analysis of the tail-flick data comparing only these 
groups was performed.  This revealed an effect of U50,488 treatment, but no interaction  
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with JDTic, suggesting that KOR antagonism was insufficient at this time point and may 
explain why JDTic did not significantly attenuate CRF effects.  As such, we conducted 
another study of CRF-enhanced startle following pretreatment with 30 mg/kg JDTic.  
Dose effects of 10 and 30 mg/kg JDTic have been reported in studies of footshock-
induced reinstatement of cocaine administration in rats (Beardsley et al., 2005), 
suggesting that higher doses might be tolerable in mice.  Indeed, 30 mg/kg JDTic 
significantly decreased startle amplitude in CRF treated mice compared to vehicle 
controls at 90 and 100 dB without having any effect on baseline startle.  Further, 
U50,488-induced antinociceptive effects were significantly reduced in JDTic pretreated 
mice, even when excluding the aCSF treated mice.  These data confirm a role for KORs 
in the anxiogenic-like effects of CRF on startle.  It is important to note that the 10 mg/kg 
and 30 mg/kg studies were conducted as entirely separate studies.  We designed the 
studies in this way because we have noted cohort and even seasonal differences in 
baseline and CRF-enhanced startle reactivity.  Indeed, there were some cohort 
differences in CRF-enhanced startle, highlighting the importance of including all of the 
respective control conditions in this second (JDTic, 30 mg/kg) experiment. 
 
The mechanisms by which CRF and KOR systems interact are not fully understood.  
KORs and dynorphin are expressed in brain regions involved in anxiety (Fallon and 
Leslie, 1986; Mansour et al., 1995) which overlap with CRF and CRF-R expression 
(Merchenthaler, 1984; De Souza et al., 1985; Millan et al., 1986; Van Pett et al., 2000; 
Alon et al., 2009).  Stress can elevate dynorphin expression and release (Przewlocki et 
al., 1987; Nabeshima et al., 1992; Shirayama et al., 2004; Chartoff et al., 2009), and 
central CRF can also stimulate dynorphin release (Song and Takemori, 1992) and  
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activate KOR receptors (Land et al., 2008; Bruchas et al., 2009).  These findings 
suggest that at least some CRF effects are mediated by downstream KOR activation.  
To identify circuits in which relevant CRF and KOR interactions may occur, we used c-
Fos immunolabeling as a marker of neuronal activation following CRF infusion in JDTic 
and vehicle pretreated mice.  Our analysis focused on regions implicated in fear and 
anxiety-like behavior in animals and humans, and thus was extensive but not 
exhaustive.  Infusions of CRF increased c-Fos cell counts in all regions analyzed, in 
agreement with other reports of activation within these same areas in rats (Andreae and 
Herbert, 1993; Imaki et al., 1993; Marrosu et al., 1996; Bittencourt and Sawchenko, 
2000).  In contrast, only c-Fos counts within the VTA and dDG were affected by JDTic 
pretreatment. 
 
In the VTA, JDTic specifically reduced increases in c-Fos cell counts following CRF 
infusion, while having no effect on counts in the control (aCSF) condition.  The majority 
of this reduction occurred in TH+ (dopaminergic) neurons, suggesting that the ability of 
JDTic to decrease CRF-enhanced startle may rely on reductions of CRF-induced 
modulation of DA activity (Ungless et al., 2003; Wanat et al., 2008).  Indeed, electrical 
stimulation of the VTA increases startle amplitude while axon-sparing lesions of this 
area reduce fear-potentiated startle (Borowski and Kokkinidis, 1996).  Further, intra-VTA 
infusions of the DA autoreceptor agonist quinpirole, which inhibits DA release, attenuate 
conditioned fear (Borowski and Kokkinidis, 1996; Munro and Kokkinidis, 1997; Nader 
and LeDoux, 1999; Gifkins et al., 2002).  Collectively, these data suggest that 
reductions in CRF-induced VTA activity and subsequent DA release may have 
anxiolytic-like effects including attenuation of CRF-enhanced startle, and provide a  
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rationale for future work that focuses on the role of KORs expressed on VTA DA cells in 
anxiety-related behavior. 
 
In the dDG, JDTic reduced c-Fos labeling regardless of whether mice received ICV 
infusions of CRF or aCSF.  These decreases may represent JDTic-mediated reductions 
in activation within circuits underlying CRF effects on startle.  The startle reflex pathway 
is a simple circuit involving sound input reaching cochlear root neurons via the ear, 
subsequent activation of the caudal nucleus of the pontine reticular formation (PnC), 
and signal output via spinal motoneurons terminating at the neuromuscular junction and 
producing a fast muscle contraction (flinch) (Davis et al., 1982; Yeomans and 
Frankland, 1995).  This response is thought to be modulated at the level of the PnC by 
cortical and limbic inputs.  While the HIP had no direct projections to the PnC, lesions of 
the HIP can alter the acoustic startle reflex (Coover and Levine, 1972; Leaton, 1981; 
Walsh et al., 1986; Mickley and Ferguson, 1989; Caine et al., 1992).  These data 
suggest that while the HIP is not directly involved in the startle reflex, it regulates startle-
relevant circuits.  Indeed, mutant mice with increased startle reactivity show increased 
HIP excitability (Fisahn et al., 2011).  Higher HIP excitability has also been shown to 
correlate with stress-induced anxiety (Mucha et al., 2011).  The present findings 
suggest that JDTic-induced decreases in putative neuronal activation may reduce HIP 
excitability in response to CRF and thus prevent increases in anxiety-like behavior, 
measured here as elevated startle.  Although beyond the scope of the current work, 
electrophysiological studies may provide deeper insight on the mechanisms by which 
KOR antagonism affects this circuitry.  In addition, other behavioral tests—specifically,  
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those that depend more directly on HIP function—may reveal a role for HIP KORs in 
anxiety-related behavior. 
 
The present work confirms a role for KORs in stress-induced behavior by demonstrating 
that CRF-induced elevations of the acoustic startle reflex are attenuated by KOR 
antagonism.  One of the hallmark signs of PTSD is an exaggerated startle reflex, which 
is often persistent and debilitating.  In individuals suffering from PTSD, the CRF system 
is overactive, which is thought to be a primary contributing factor in this disorder 
(Arborelius et al., 1999; Kasckow et al., 2001).  Our results suggest that KOR 
antagonists may be clinically useful to alleviate stress-induced behaviors including 
exaggerated startle and lead to greater improvements in patient treatment.  The next 
chapter describes the role of KORs in another paradigm of stress-induced behavior—
footshock potentiated startle—that similarly uses potentiation of the acoustic startle 
reflex as an index of anxiety-like behavior in mice, in order to extend our findings to a 
more naturalistic stress response.  This paradigm also relies on context conditioning, a 
HIP-dependent task (Phillips and LeDoux, 1992) that will enable further characterization 
of KORs in this region. 
77 
 
Chapter 3 
 
Antagonism of kappa-opioid receptors 
reduces footshock-potentiated startle 
 
Ashlee Van’t Veer
1, F. Ivy Carroll
2, William A. Carlezon, Jr.
1 
 
1Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 
02478; 
2Research Triangle Institute, Research Triangle Park, NC 
 
Author contributions: AVV and WAC designed the experiments.  AVV conducted the 
experiments and analyzed the data.  FIC synthesized and provided JDTic. 
78 
 
Abstract 
Stress is a precipitating factor for depressive and anxiety disorders.  In severe cases, 
exposure to contextual cues associated with traumatic stress is sufficient to trigger signs 
and symptoms of these disorders.  Prior work has shown that some effects of stress 
including dysphoria, anhedonia, and anxiogenic-like behaviors are mediated by the 
KOR system.  Blockade of KOR signaling with KOR antagonists produces 
antidepressant-like effects and anxiolytic-like effects in conditioned and unconditioned 
fear models, and reduces the effects of stress and the stress-related neuropeptide CRF.  
The present studies were designed to extend these findings using footshock-potentiated 
startle, a model of contextual conditioning.  Mice were habituated to the startle 
apparatus and matched into groups with equivalent levels of baseline startle before drug 
treatment and testing.  They were then pretreated with the prototypical, long-lasting 
KOR antagonist JDTic (10 or 30 mg/kg) and tested 24 hr later.  KOR antagonism 
significantly decreased footshock effects on startle.  To identify brain regions that may 
contribute to this effect, c-Fos immunohistochemistry was performed to map neuronal 
activation patterns.  In control mice, footshock induced a small but significant increase 
in c-Fos cell counts in the highly stress-responsive PVN.  However, analysis in the HIP 
and VTA did not reveal changes in neuronal activation following footshock or 
differences in JDTic-pretreated mice compared to controls.  Thus we could not establish 
any associations between behavioral endpoints and neural activation in the brain 
regions studied.  Regardless, this work confirms a role for KORs in stress-induced 
increases in startle.79 
 
Introduction 
Severe or sustained stress often coincides with the development of anxiety disorders 
and clinical depression (Kessler, 1997; Kendler et al., 1999; Pine et al., 2002).  In 
laboratory settings, procedures involving stress exposure often trigger depressive- and 
anxiety-like behaviors in rodents (Platt and Stone, 1982; Zacharko and Anisman, 1991; 
Keeney and Hogg, 1999; Aisa et al., 2008; Slattery et al., 2012).  Stress-like effects can 
also be precipitated by central CRF infusion (Britton et al., 1982; Dunn and File, 1987; 
Stenzel-Poore et al., 1994; van Gaalen et al., 2002; Swiergiel et al., 2008).  CRF is a 
key regulator of the stress response and dysfunction of CRF systems is thought to 
underlie human depressive and anxiety disorders (Nemeroff et al., 1984; Widerlov et al., 
1988; Arborelius et al., 1999; Kasckow et al., 2001).  One clinical sign of these disorders 
is exaggerated startle reactivity, particularly in response to environmental (contextual) 
cues previously associated with stress (Grillon and Baas, 2003; Ray et al., 2009).  In 
rodents, potentiation of the acoustic startle response can be achieved by central 
infusions of CRF (Swerdlow et al., 1986; Liang et al., 1992), although a direct link 
between increased startle and CRF levels has not been established in humans.  
Nevertheless, determining the downstream mediators of stress/CRF effects on startle 
may provide important targets for the development of drugs to alleviate or prevent the 
deleterious effects of stress. 
 
It has been demonstrated that some of the key effects of stress and CRF are mediated 
by the KOR system, which comprises KORs and their endogenous ligand dynorphin 
(Chavkin et al., 1982).  Stress induces the release of dynorphin (Nabeshima et al., 
1992), which activates KORs and produces aversive behaviors (Land et al., 2008).   
80 
 
KOR agonists can mimic the effects of stress (McLaughlin et al., 2006a), suggesting 
KOR activation is a critical step in producing the behavioral consequences of stress.  
Conversely, KOR antagonists are effective at blocking the effects of stress such as 
stress-induced analgesic behavior (Takahashi et al., 1990; McLaughlin et al., 2003a; 
McLaughlin et al., 2006b), learned helplessness (Pliakas et al., 2001; Newton et al., 
2002; Mague et al., 2003), and drug reinstatement (Beardsley et al., 2005; Carey et al., 
2007).  KOR antagonists also produce anxiolytic-like effects in models of learned and 
unlearned fear (Knoll et al., 2007), and can attenuate the anxiogenic-like and dysphoric 
effects of CRF (Chapter 2; Land et al., 2008; Bruchas et al., 2009; Van't Veer et al., 
2012).  Thus disruption of KOR function may diminish the aversive or maladaptive 
consequences of stress exposure. 
 
Fear-like states in rodents can be achieved through brief presentation of mild footshock.  
The context—which may comprise visual, tactile, auditory, and olfactory cues—in which 
footshock occurs becomes associated with this aversive event, and subsequent re-
exposure to the cues alone can potentiate the startle reflex (Boulis and Davis, 1989; 
Davis, 1989; Hitchcock et al., 1989; McNish et al., 1997; Richardson, 2000; Sasaki and 
Hanamoto, 2007; Risbrough et al., 2009).  Increased startle reactivity following shock is 
also observed in humans (Greenwald et al., 1998), suggesting evolutionarily-conserved 
mechanisms.  Footshock has been shown to induce CRF release (Wang et al., 2005) 
while disrupting CRF receptor activation can block the behavioral effects of footshock 
(Ho et al., 2001; Bakshi et al., 2002; Le et al., 2002).  Further, footshock-potentiated 
startle is abolished in CRF receptor knockout mice (Risbrough et al., 2009) suggesting 
CRF signaling and consequent downstream events are necessary for the anxiogenic- 
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like effects of footshock.  Contextual conditioning is thought to depend upon the HIP 
(Kim and Fanselow, 1992; Phillips and LeDoux, 1992; Rudy et al., 2002), a brain area in 
which the KOR antagonist JDTic affects neural activity, as reflected by c-Fos activation 
(Chapter 2).  As such, based on our previous work, we hypothesized that the ability of 
footshock to potentiate the acoustic startle response would be dependent on KOR 
activation in the HIP. 
 
The present studies investigated the effects of KOR antagonism on anxiety-like 
behavior, measured as an increase in the acoustic startle response following 
presentation of footshock (Davis, 1989).  Mice were given a single injection of the long-
acting KOR antagonist JDTic (Carroll et al., 2004) and tested for footshock-potentiated 
startle 24 hr later.  The following day they were again subjected to startle testing in the 
context where footshock occurred.  In these same mice, KOR antagonism was directly 
examined in the warm water tail-flick assay by the ability of JDTic to block the analgesic 
effects of a KOR agonist (McLaughlin et al., 2003a; Van't Veer et al., 2012), to confirm 
long-lasting effects of the drug.  Finally, in a naïve cohort of mice, c-Fos 
immunohistochemistry was used to provide an index of neuronal activation (Kovacs, 
1998) to examine the effects of JDTic on footshock-induced changes in the activity of 
stress-related brain areas. 
 
Materials and Methods 
Mice: Experiments were performed in 8-10-week-old male C57BL/6J mice (The Jackson 
Laboratory, Bar Harbor, ME).  Mice were housed 4 per cage upon arrival and allowed to 
acclimate to the vivarium for one week prior to testing.  Mice were maintained on a  
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12:12-h light-dark cycle (0700h lights on) with ad libitum food and water available 
except during testing.  Experiments were conducted during the light phase of the daily 
cycle to avoid startle ceiling effects (Chabot and Taylor, 1992).  Experimental protocols 
were approved by the Institutional Animal Care and Use Committee of McLean Hospital 
and in accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals  (National Academies Press, Washington D.C., USA, 2011).  
 
Drugs: JDTic  was synthesized at Research Triangle Institute (Research Triangle Park, 
NC).  U50,488 was purchased from Sigma-Aldrich (St. Louis, MO).  JDTic and U50,488 
were dissolved in 0.9% saline and administered intraperitoneally (IP) at 10 mL/kg.  The 
dose of U50,488 was based on its salt form.   
 
Startle testing: The equipment and procedures used here were similar to those 
described in Chapter 2.  Briefly, acoustic startle data were collected by measuring the 
amplitude of the startle reflex in response to white noise bursts of various intensities 
using the Med Associates Inc. (St. Albans, VT) Startle Reflex System and Advanced 
Startle software program.  Mice were placed into 8.5 x 7 x 7 cm Plexiglas holders with 
steel rod floor bars attached to a load cell platform contained within a 40 x 64 x 42 cm 
sound-attenuating chamber.  The load cell transduces movement into an electrical 
output that is amplified and digitized into arbitrary units by an analog-to-digital converter 
interfaced to a computer.  Startle amplitude was defined as the maximum peak-to-peak 
voltage occurring within the first 100 ms after the onset of the startle stimulus.  An audio 
stimulator generated 50 msec startle stimuli (1-32 kHz white noise, 1 msec rise-decay) 
which were delivered through high-frequency speakers located 4 cm behind the cages.   
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The intensities of the startle stimuli were calibrated before use using customized 
software.  All tests were conducted in darkness.       
 
Prior work demonstrates that mild footshock can potentiate the acoustic startle reflex in 
rodents (Davis, 1989; Risbrough et al., 2009).  To determine if KORs are involved in the 
footshock-potentiated startle phenomenon, mice were matched into groups with similar 
levels of baseline startle and were treated with the KOR antagonist JDTic (10 or 30 
mg/kg, IP) or vehicle 24 hr prior to testing.  The footshock-potentiated startle test 
procedure was adapted from Risbrough et al. (2009).  Mice were initially given a 
baseline startle session consisting of a 5 min acclimation period followed by 102 startle 
stimuli, 34 each at 80, 90, and 100 dB.  This test served to habituate the mice to both 
the holding chambers and startle stimuli and to match them into experimental groups 
with equivalent baselines before testing.  During the test session, mice received a 5 min 
acclimation period followed by 27 startle stimuli, 9 each at 80, 90, and 100 dB in a 
pseudo-random order with a 15 sec ISI to assess their baseline startle (startle test).  
Mice then received three sessions of 5 footshocks (shock session).  The footshock 
intensity increased between sessions (i.e., 0.2 mA, session 1; 0.4 mA, session 2; and 
0.8 mA, session 3).  The average ISI between footshocks was 60 sec (30-90 sec).  Mice 
received an additional startle test after each shock session to assess the magnitude of 
startle potentiation elicited by footshock exposure.  Fecal boli were also recorded at the 
end of the test session, as an index of somatic stress (Hall, 1934; Flint et al., 1995; 
Crawley, 2007).  The following day, mice were given a final startle test to probe context 
conditioning in the absence of footshock; fecal boli were again counted at the end of the  
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session.  Mouse holders were thoroughly cleaned with 70% isopropanol wipes at the 
end of each test session.   
 
Warm water tail-flick assay: The tail-flick assay was used to assess KOR-mediated 
analgesia (Vaught and Takemori, 1979; McLaughlin et al., 2003a; Van't Veer et al., 
2012).  The test was conducted 24 hr following the final startle test session.  Mice were 
scruffed with their tail free and back supported and approximately 1 cm of their tail was 
submerged into a 52 ± 1°C warm water bath.  The latency for mice to withdraw their tail 
from the water was timed with a stopwatch.  A maximum time of 15 sec was imposed to 
prevent damage to the submerged tail.  After taking baseline latencies, mice were 
treated with the KOR agonist U50,488 (15 mg/kg, IP), and withdrawal latencies were 
assessed 30 min later. 
 
C-Fos immunohistochemistry:  Separate cohorts of mice were used for c-Fos 
immunohistochemistry.  Mice were placed in the startle chambers for 30 min on four 
consecutive days prior to testing to habituate them to the experimental procedure and 
reduce handling-induced c-Fos expression. On the fourth day, mice received JDTic (30 
mg/kg, IP) or vehicle following the habituation session, immediately before being placed 
back into their home cage.  Mice were tested 24 hr after injection.  The test was 
designed to mimic the first two footshock blocks (0.2 mA and 0.4 mA) received in the 
footshock-potentiated startle test described above, but without the startle stimuli, in 
order to isolate the effects shock.  Briefly, during the 30 min test session, 5 footshocks 
at 0.2 mA were presented 12.5 min after mice were placed in the chambers, followed 
8.5 min later by 5 footshocks at 0.4 mA.  Mice were returned to their home cages and,  
85 
 
120 min later, perfused with 4% paraformaldehyde.  The procedures used for c-Fos 
immunolabeling were identical to those described in Chapter 2.  Briefly, brains were 
postfixed in 4% paraformaldehyde overnight, then transferred into 30% sucrose in PBS 
for cryoprotection.  Mouse brain sections (40 µm) were first incubated for 30 min in 
0.3% H2O2, and then in a blocking solution of 5% NGS (Vector Laboratories, Inc., 
Burlingame, CA) for 1 hr.  Sections were then incubated overnight with anti-c-Fos 
(1:1,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 5% NGS.  The following 
morning, sections were first incubated for 1 hr in biotinylated anti-rabbit IgG (1:1,000; 
Vector Laboratories), and then in ABC for 1 hour (ABC Elite Kit, Vector Laboratories).  
C-Fos immunoreactivity was visualized with DAB.  Photomicrographs of regions of 
interest were obtained at 40x on a Zeiss Axio Scope (Carl Zeiss Inc., Thornwood, NY) 
using OpenLab software (PerkinElmer, Waltham, MA).  The number of labeled cells for 
each photomicrograph was counted using ImageJ software (NIH, Bethesda, MD) and 
the counts from 3 non-serial sections per region were averaged for each mouse  
 
Data Analysis:  Baseline startle was analyzed with a JDTic x dB level ANOVA with 
repeated measures (dB level).  The effects of JDTic on footshock-potentiated startle 
were analyzed with a 3-way (JDTic x dB level x startle block) ANOVA with repeated 
measures (dB level and startle block).  For the tail flick assay, a 3-way (JDTic x shock x 
U50,488) ANOVA with repeated measures (U50,488) was used to examine whether 
JDTic affected U50,488-induced antinociception.  Footshock reactivity was analyzed by 
a 3-way (JDTic x shock x shock intensity) ANOVA with repeated measures (shock 
intensity).  Fecal boli and c-Fos cell counts were analyzed with 2-way (JDTic x shock) 
ANOVAs or t-tests as appropriate.  Significant interactions in the ANOVAs were further  
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analyzed using Bonferroni post tests.  Data are graphed as mean plus standard error of 
the mean (SEM). 
 
Results 
Because of the pharmacodynamics of JDTic, mice received the drug (10 mg/kg, IP) or 
vehicle 24 hr before footshock-potentiated startle testing.  Vehicle and JDTic-treated 
mice did not significantly differ in their preshock baseline startle reactivity across the 
three decibel levels (80, 90 and 100) tested (F[1,54]=0.015, NS; Table 3.1).  Startle 
amplitude increased as a function of dB level as demonstrated by a main effect of dB 
(F[2,108]=196.04, P<0.001).  Following the baseline startle block, mice received 3 
footshock blocks ascending in amplitude (0.2, 0.4 and 0.8 mA) each followed by a 
startle test.  The startle reactivity following each footshock block was compared to the 
baseline for each mouse to calculate footshock potentiation.  Vehicle- and JDTic-treated 
mice that did not receive footshock were also tested to confirm that JDTic had no 
delayed effects on startle reactivity (Table 3.2).  Analysis of shocked mice revealed a 
dB x JDTic interaction (F[2,128]=3.24, P<0.05; Fig. 3.1A).  There was a trend for JDTic 
to decrease startle potentiation at 80 dB (t[32]=1.68, P=0.10), whereas 90 and 100 dB 
were not significantly affected.  JDTic effects were not due to differences in detecting 
the footshock, since reactivity during footshock presentation did not differ between the 
groups (Table 3.3).  The number of fecal boli also did not differ between shocked 
groups (i.e., vehicle- and JDTic-treated), but was significantly increased in shocked 
mice compared to unshocked controls (F[1,54]=33.33, P<0.0001; Fig 3.1B).  One day 
following footshock-potentiated startle testing, mice were returned to the test chamber 
and given another startle test in the absence of footshock.  In this test, JDTic did not  
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affect startle magnitude compared to controls (dB x JDTic, F[2,64]=2.51, NS; data not 
shown).  The ability of the KOR agonist U50,488 to induce analgesia was tested the 
following day to ensure persistent JDTic antagonism of KORs (Fig. 3.1C).  Tail 
withdrawal latencies depended upon a significant JDTic x U50,488 interaction 
(F[1,54]=7.30, P<0.01).   Between-subject analysis indicated vehicle and JDTic mice did 
not differ at baseline, but were significantly different following U50,488 (P<0.01).  
Surprisingly, within-subject effects indicated a significant increase in tail withdrawal 
latency following U50,488 in both vehicle (P<0.001) and JDTic (P<0.05) treated mice, 
although the antinociceptive effects of U50,488 were clearly reduced by JDTic 
treatment.88 
 
Table 3.1 Baseline startle reactivity prior to footshock 
         
 
JDTic (10 mg/kg) 
          dB  Veh no shock  JDTic no shock  Veh shock  JDTic shock 
80  1.23 ± 0.14  1.31 ± 0.15  1.06 ± 0.12  1.28 ± 0.18 
90  2.33 ± 0.42  2.54 ± 0.25  2.58 ± 0.29  2.58 ± 0.35 
100  4.00 ± 0.43  3.65 ± 0.34  4.35 ± 0.35  3.99 ± 0.38 
              
         
         
 
JDTic (30 mg/kg) 
          dB  Veh no shock  JDTic no shock  Veh shock  JDTic shock 
80  0.80 ± 0.10  0.64 ± 0.04  0.69 ± 0.07  0.76 ± 0.06 
90  1.70 ± 0.17  1.69 ± 0.21  1.55 ± 0.14  1.85 ± 0.21 
100  3.42 ± 0.27  3.42 ± 0.34  3.39 ± 0.25  3.29 ± 0.27 
              
          Measures reported as mean ± SEM.  No significant effects of JDTic or shock group 
were observed. 89 
 
Table 3.2 Percent change from baseline in mice that did not receive 
footshock 
             
   
JDTic (10 mg/kg) 
 
JDTic (30 mg/kg) 
              Block  dB  Veh  JDTic     Veh  JDTic 
1  80  -21.16 ± 8.23  -15.14 ± 6.97 
 
-0.42 ± 11.54  -5.52 ± 4.89 
 
90  5.77 ± 9.86  -9.70 ± 7.01 
 
-16.11 ± 8.13  -13.21 ± 6.91 
 
100  -6.95 ± 9.98  6.31 ± 13.56 
 
-1.53 ± 8.32  -18.61 ± 7.15 
             
2  80  -22.74 ± 7.66  -23.51 ± 11.72 
 
-15.37 ± 8.99  -18.63 ± 6.22 
 
90  0.17 ± 12.92  -21.34 ± 6.66 
 
-9.75 ± 12.41  -16.49 ± 7.53 
 
100  -1.93 ± 6.98  -4.68 ± 9.12 
 
-8.5 ± 7.34  -16.83 ± 8.43 
             
3  80  -29.41 ± 8.32  -29.91 ± 7.57 
 
-22.79 ± 8.07  -21.69 ± 4.83 
 
90  3.36 ± 12.08  -23.90 ± 7.92 
 
-11.2 ± 10.35  -11.09 ± 10.12 
 
100  -9.70 ± 6.34  -0.26 ± 10.86 
 
-15.83 ± 6.11  -5.59 ± 9.77 
                    
              Block refers to the startle session following test period where shocked mice received 0.2 mA 
footshock (Block 1), 0.4 mA (Block 2) and 0.8 mA (Block 3). 
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Figure 3.1 Footshock-potentiated startle in mice treated with 10 mg/kg JDTic.  
Mice were matched into groups with equivalent baseline startle and then administered 
JDTic (10 mg/kg) 24 hr before testing.  A. Acoustic startle reactivity to 80, 90, and 100 
dB stimuli was tested following blocks of ascending footshock (0.2, 0.4, and 0.8 mA) 
and compared to baseline preshock levels to calculate potentiation.  Analysis revealed a 
dB x JDTic interaction (P˂0.05).  JDTic reduced footshock-potentiated startle at 80 dB 
although this did not reach significance (P=0.10).  B. Shocked mice produced more 
fecal boli compared to no-shock control mice.  JDTic did not affect fecal boli during the 
test session.  C. Following testing, the warm water tail-flick assay was used to assess 
KOR-mediated analgesia.  The latency for mice to withdraw their tail from a 52°C water 
bath at baseline and 30 min after administration of the KOR agonist U50,488 (15 mg/kg, 
IP) was timed with a stopwatch.  U50,488 increased tail withdrawal latencies in both 
vehicle (Veh) and JDTic (10 mg/kg) treated mice.  Tail withdrawal latencies following 
U50,488 were lower in JDTic mice compared to Veh.  Data were analyzed by ANOVA 
followed by Bonferroni post test as appropriate. * P<0.05, ***P<0.001, **** P˂0.0001 
between group comparisons ^^P<0.01 within group comparison91 
 
Figure 3.1 (Continued) Footshock-potentiated startle in mice treated with 10 mg/kg 
JDTic  
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Table 3.3 Footshock reactivity in JDTic-treated mice 
           
 
JDTic (10 mg/kg) 
           
 
no shock 
 
shock 
            mA  Veh  JDTic     Veh  JDTic 
0.2  0.35 ± 0.02  0.43 ± 0.07 
 
5.65 ± 0.84  4.85 ± 0.60 
0.4  0.49 ± 0.10  0.73 ± 0.27 
 
11.95 ± 0.85  10.81 ± 0.94 
0.8  0.57 ± 0.18  0.48 ± 0.14 
 
11.55 ± 0.85  10.71 ± 0.85 
                 
           
 
JDTic (30 mg/kg) 
           
 
no shock 
 
shock 
            mA  Veh  JDTic     Veh  JDTic 
0.2  0.27 ± 0.03  0.29 ± 0.03 
 
4.69 ± 0.58  5.40 ± 0.51 
0.4  0.25 ± 0.02  0.26 ± 0.02 
 
11.17 ± 0.66  11.08 ± 0.81 
0.8  0.23 ± 0.02  0.21 ± 0.02 
 
11.33 ± 0.61  11.30 ± 0.88 
                 
            Measures reported as mean ± SEM of average reactivity during the presentation of 
footshock.  No significant effects of JDTic were observed. 93 
 
Previously we have shown dose effects of JDTic in blocking another stress-induced 
behavior: CRF-enhanced startle (Chapter 2).  In the present studies, we observed a 
small but significant increase in tail withdrawal latency in JDTic pretreated mice given 
the KOR agonist U50,488; these data, combined with data from Chapter 2 indicating 
that 10 mg/kg JDTic did not block CRF-induced startle, suggest that 10 mg/kg is not a 
sufficient dose to fully antagonize KOR function in mice.  We therefore repeated the 
footshock-potentiated startle test in a separate cohort of mice that received JDTic at 30 
mg/kg, IP.  JDTic treatment did not have an effect on baseline startle amplitude 
(F[1,69]=0.026, NS; Table 3.1).  Analysis of test data from the shocked mice 
demonstrated main effects of startle block (F[2,74]=12.39, P<0.001), dB (F[2,74]=4.67, 
P<0.05) and JDTic (F[1,37]=5.29, P<0.05) but no interactions (Fig. 3.2A).  Mice 
pretreated with JDTic before testing had overall lower levels of startle when collapsed 
across dB level and startle block (P<0.05; Fig. 3.2B).  Footshock increased the number 
of fecal boli during the test session compared to no-shock controls (main effect of 
footshock, F[1,59]=72.75, P<0.0001; Fig. 3.2C) and there was an interaction of JDTic 
with footshock (F[1,59]=6.22, P<0.05).  While JDTic did not affect the number of fecal 
boli produced by unshocked mice, it significantly reduced footshock-induced increases 
(P<0.05; Fig. 3.2C).  Further, the number of fecal boli strongly correlated with 
potentiated startle averaged across dB and startle block (r[63]=0.65, P<0.0001; Fig. 
3.2D).  During the context test on the following day, JDTic-treated mice continued to 
show decreased startle amplitude compared to controls (main effect of JDTic, 
F[1,37]=4.36, P<0.05; Fig. 3.2E&F) regardless of dB level.  There was also a main 
effect of dB (F[2,37]=4.36, P<0.05), with less potentiation seen with increasing dB level 
in both treatment groups (Fig. 3.2E).  The number of fecal boli counted after the context  
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test session did not differ between shocked groups, but was significantly increased over 
no-shock control mice (F[1,46]=13.37, P<0.001; Fig. 3.2G).  In the tail-flick, U50,488 
effects depended on an interaction with JDTic (F[1,76]=479.83, P<0.0001).  Within 
subjects analysis indicated a significant increase in tail withdrawal latency following 
U50,488 treatment in vehicle (P<0.0001) but not JDTic-treated mice (Fig 3.2H).  There 
were no differences between drug treatment groups at baseline, but a significant 
increase in tail withdrawal latency in vehicle compared to JDTic following U50,488 
(P<0.0001). 
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Figure 3.2 Footshock-potentiated startle in mice treated with 30 mg/kg JDTic.  A. 
JDTic treatment significantly reduced footshock-potentiated at all dB levels.  B. Data 
collapsed across block and dB revealed a main effect of JDTic.  C. Footshock 
significantly increased fecal boli compared to no-shock controls.  In shocked mice, 
JDTic significantly reduced the number of fecal boli counted at the end of the test 
session.  D. Average startle potentiation during the test session significantly correlated 
with fecal boli (P<0.0001).  E. JDTic continued to reduce startle reactivity when mice 
were returned to the footshock test chamber 24 hr following testing as revealed by a 
main effect of JDTic treatment (F.).  G. While fecal boli numbers were increased in 
shocked mice compared to controls, JDTic did not affect this measure during the re-test.  
H. Veh mice showed an increase in tail withdrawal latencies following U50,488, which 
was absent in JDTic (30 mg/kg) treated mice.  Data were analyzed by ANOVA followed 
by Bonferroni post test as appropriate. * P˂0.05, *** P˂0.001, ****P<0.0001 between 
group comparisons, ^^P<0.01, ^^^^P<0.0001 within group comparisons96 
 
Figure 3.2 (Continued) Footshock-potentiated startle in mice treated with 30 mg/kg 
JDTic  
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C-Fos immunoreactivity was quantified as an index of neuronal activation to determine 
the effects of JDTic on footshock-induced brain circuit activation.  Mice received 2 sets 
of footshocks (5 each at 0.2 mA and 0.4 mA) across a 30 min test session following the 
same time course as that used in the footshock-potentiated startle paradigm.  The 
session was terminated after 0.4 mA shocks in order to capture the peak effect of JDTic 
on anxiety-like behavior.  Mice receiving footshock had higher reactivity during 
footshock presentation compared to activity during the same test period in no-shock 
controls.  JDTic did not affect this measure (footshock amplitude x shock treatment 
interaction, F[1,32]=29.46, P<0.0001; main effect of footshock amplitude, F[1,32]=26.22, 
P<0.0001; main effect of footshock, F[1,32]=304.41, P<0.0001; Table 3.4).  To verify 
the ability to detect increases in c-Fos labeling following footshock, c-Fos cell counts 
were made in the PVN, a region highly responsive to stress.  In vehicle-pretreated mice, 
footshock induced a significant increase in c-Fos cell counts of this region compared to 
no-shock controls (Fig. 3.3).  Subsequent counts were made in the VTA and CA1, CA2, 
CA3 and dDG subregions of the HIP (Fig. 3.4).  Neither footshock nor JDTic had an 
effect on c-Fos immunoreactivity in these brain regions (Table 3.5).98 
 
Table 3.4 Footshock reactivity in JDTic-treated mice used for 
c-Fos studies 
           
 
No shock 
 
Shock 
mA  Veh  JDTic     Veh  JDTic 
            0.2  0.56 ± 1.40  0.53 ± 0.05 
 
9.18 ± 1.19  7.58 ± 0.69 
            0.4  0.46 ± 0.06  0.37 ± 0.06 
 
13.68 ± 1.02  12.22 ± 0.63 
                 
            Measures reported as mean ± SEM of average reactivity during the presentation 
of footshock.  No significant effects of JDTic were observed.  
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Figure 3.3 Effect of footshock on c-Fos immunoreactivity in the PVN.  A. 
Representative photomicrographs of c-Fos staining in the PVN at 10x in an unshocked 
(left) and shocked (right) mouse.  Scale bar indicates 200 µm. Dashed box is 
representative of area counted at 40x for analysis.  Anteroposterior distance from 
Bregma is indicated at right.  B. Footshock significantly increased c-Fos counts in the 
PVN. Data were analyzed by t-test. *P<0.05.  PVN, paraventricular nucleus of the 
hypothalamus 
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Figure 3.3 (Continued) Effect of footshock on c-Fos immunoreactivity in the PVN 
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Figure 3.4 Location of regions of interest analyzed for c-Fos immunoreactivity.  
Areas are demarcated by boxes on representative atlas images of the mouse brain 
(figures 46 and 57 in Paxinos and Franklin (2001)).  Anteroposterior distance from 
Bregma is indicated below each image.  The definitions of abbreviations used are 
located in Table 3.5. 
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Table 3.5 Effect of JDTic on c-Fos expression after footshock 
 
                  Brain Area  Sub-division  Abbr.     c-Fos Cell # (mean ± SEM)  P-value* 
     
IP  Saline  JDTic  Saline  JDTic 
           condition  no shock  no shock  shock  shock    
Dorsal hippocampus  field CA1  dCA1 
 
13.1 ± 3.9  11.1 ± 2.4  9.6 ± 2.5  8.4 ± 1.3  0.89 
 
field CA2  dCA2 
 
19.8 ± 3.2  15.5 ± 2.4  14.9 ± 2.6  13.6 ± 1.8  0.55 
 
field CA3  dCA3 
 
17.5 ± 3.1  17.7 ± 2.2  14.8 ± 1.8  14.8 ± 1.1  0.94 
 
dentate gyrus  dDG 
 
21.5 ± 0.9  21.6 ± 1.6  19.9 ± 1.1  21.9 ± 2.0  0.56 
Ventral Tegmental Area     VTA     10.0 ± 1.2  11.0 ± 0.9  9.5 ± 1.0  11.5 ± 1.7  0.72 
*p-value for JDTic x CRF interaction 
             
n=8-10 per group 
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Discussion 
The current study examined the role of KORs in footshock-potentiated startle, a model 
of contextual fear learning.  We show that pretreatment with a single injection of JDTic, 
a highly selective KOR antagonist with long-lasting effects (Carroll et al., 2004), can 
reduce footshock effects on startle.  These effects were mild in mice treated with IP 
injections of 10 mg/kg JDTic; the largest difference was observed at the lowest startle 
intensity tested (80 dB) and did not reach statistical significance.  A higher dose of 
JDTic (30 mg/kg) significantly attenuated startle responding following footshock across 
all dB levels and footshock intensities.  Neither dose of JDTic affected baseline startle 
responding or footshock reactivity, indicating specific effects of KOR antagonism on 
stress-induced anxiogenic-like behavior.  These data confirm a role for KORs in 
increases in startle produced by stress. 
 
Footshock reactivity is here defined as the magnitude of the “flinch” response, which 
causes a downward displacement of the load cell beneath the holding cage, during 
footshock delivery.  Prior treatment with JDTic did not affect this measure, suggesting 
both vehicle and JDTic mice experienced the aversive quality of the footshock similarly.  
This may seem surprising since JDTic reportedly blocks stress-induced analgesia 
(McLaughlin et al., 2006b).  However, footshock-induced analgesia specifically is 
usually obtained using higher shock intensities of longer duration over a more extensive 
shock session (Lewis et al., 1980; Lewis et al., 1983; Menendez et al., 1993b).  Thus 
the shock duration, amplitude, and interval between footshock presentations in the 
present study may not have been effective at inducing opioid-mediated analgesia (Ross 
and Randich, 1984).  Considering that vehicle and JDTic-treated mice did not  
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significantly differ in footshock responsiveness, JDTic-induced decreases in potentiation 
cannot be attributed to decreased sensitivity to footshock. 
 
Conceivably, JDTic could produce an apparent anxiolytic-like effect on startle if the drug 
instead increased fear-like states since footshock can produce an inverted U-shaped 
response on startle amplitude (Davis and Astrachan, 1978) as animals begin to freeze, 
a behavior that is incompatible with startle.  We do not believe this to be the case 
considering experiments in which JDTic decreased footshock-potentiated startle, it also 
significantly decreased the number of fecal boli.  If instead this reduction in startle were 
due to increased anxiety-like behavior, an increase in defecation should have been 
observed.  Because fecal boli correlated with average startle potentiation, these data 
suggest that decreased startle reactivity is indicative of a reduced anxiety-like state. 
 
The ability of JDTic to reduce footshock effects was not due to a general decrease in 
startle responsiveness since JDTic alone had no effects on baseline startle.  This is in 
agreement with previous work using these JDTic doses in mice (Chapter 2) as well as 
JDTic and norBNI studies in rat (Bortolato et al., 2005; Knoll et al., 2007; Tejeda et al., 
2010a).  Potentiation of startle following footshock was calculated as the percent 
change in startle amplitude from baseline levels collected at the start of the test session.  
The ASR is an involuntary brainstem reflex that can be modulated by limbic input based 
on affective state (Lang et al., 1990).  Thus aversive stimuli can enhance, whereas 
pleasant stimuli can attenuate, the ASR (Vrana et al., 1988).  The data presented here 
suggest that KOR antagonist treatment does not induce anxiolytic-like effects in non-
stressed animals as measured by the ASR, since JDTic and vehicle mice had  
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equivalent levels of baseline startle.  Instead, JDTic specifically augmented increases in 
startle following an aversive stimulus, indicated by the inability of footshock to increase 
startle up to control levels in JDTic-treated mice.  To induce KOR blockade, mice were 
treated with JDTic 24 hr before the test session, during which potentiation of the ASR 
was elicited immediately after footshock presentation.  Because KORs were 
antagonized before footshock presentation, this experimental design did not allow us to 
distinguish between KOR blockade prior to and following the association of context and 
footshock.  Future studies implementing different KOR treatment times would enable us 
to determine the role of KORs in acquisition, consolidation, and expression of context-
dependent potentiation of startle.  For instance, JDTic could be administered 
subsequent to footshock and prior to follow-up context testing in order to investigate 
expression directly.  Previous work has demonstrated that KOR blockade is effective at 
decreasing stress-induced deficits in novel object recognition when given immediately 
after stress (Carey et al., 2009).  Based on this, would expect reductions in context-
elicited potentiation of startle if JDTic was administered immediately after the test 
session.  Further work on the effects of KORs during specific phases of the test session 
will clarify whether KOR antagonists would be beneficial not only when stress can be 
predicted, but in cases when stress has already occurred. 
 
Previous work has shown that footshock induces a robust increase in c-Fos activation in 
the PVN (Pezzone et al., 1992; Duncan et al., 1996; Li and Sawchenko, 1998).  Here, a 
significant increase in c-Fos cell counts was also observed following footshock in the 
PVN of vehicle-treated mice compared to no-shock controls.  However, this induction 
was not as substantial as others noted in the literature.  Mice were killed 2 hours after a  
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30 min footshock paradigm designed to mimic part of the footshock-potentiated startle 
protocol.  This time point is consistent with numerous studies indicating optimal 
detection of c-Fos 2 hr following an aversive stimulus (Morgan and Curran, 1991), 
suggesting that the time point of tissue collection was not responsible for the minimal 
effects observed.  However, although other studies have collected tissue at a similar 
time point, their shock procedures were longer or more intense, which may result in 
greater c-Fos activation.  The small, statistically significant effects in the present study 
may also be attributed to an increased number of c-Fos positive cells in no-shock 
control mice.  In previous reports, baseline (i.e., no-shock) c-Fos reactivity is minimal in 
the PVN (Li and Sawchenko, 1998; Kwon et al., 2008).  The reasons for this 
discrepancy are not clear.  One possibility is that the mice were housed outside the 
testing room where footshock occurred; under these conditions, it is possible that 
unshocked mice became stressed upon hearing vocalizations of other mice receiving 
footshock, or remaining housed near cages of stressed mice before they were killed for 
the immunohistochemistry studies.  Psychological stress, induced by having a mouse 
witness another mouse receive footshock, has not been shown to induce c-Fos 
expression in the PVN (Kwon et al., 2008), although it is unclear whether these 
psychologically stressed mice had any sensory contact with mice that received 
footshock following the procedure.  There is recent evidence that even indirect contact 
with stress-related cues can cause depressive- or anxiety like behavior in mice (Warren 
et al., 2013), although it remains unclear whether the critical cues are visual, auditory, or 
olfactory.  Regardless, no differences between shocked and unshocked mice were seen 
in any region of the HIP or the VTA, regions in which c-Fos induction following 
footshock have been shown (Smith et al., 1992; Funk et al., 2003; Funk et al., 2006).   
107 
 
The elevated baseline c-Fos levels in the PVN of control mice may correspond with 
higher levels of c-Fos cell counts in other stress responsive regions; therefore, subtle 
increases in c-Fos reactivity might have been too small to detect.  Considering these 
limitations, it is difficult to ascertain whether JDTic truly lacked effect on brain activation 
as measured by c-Fos immunoreactivity, or whether changes were obscured as a result 
of signal-detection problems related to the design or implementation of our studies.  
This question might be resolved in the future using high-power (9.4 Tesla) functional 
imaging techniques—currently under development at McLean Hospital—to investigate 
circuit activation in JDTic-treated mice receiving footshock during brain imaging. 
 
Although we were unable to detect changes in neuronal activation using c-Fos labeling 
in brain regions such as the HIP and VTA following footshock, there are obvious 
candidate brain regions where KOR activation may be affecting footshock-induced 
anxiety-like behavior.  We focused on the HIP and VTA here because we have 
previously identified JDTic-mediated reductions in CRF-induced c-Fos immunoreactivity 
in the dDG and VTA (Chapter 2), which may also be key regions for JDTic effects on 
footshock-potentiated startle, given the critical role of CRF in this response (Risbrough 
et al., 2009).  In addition, the HIP has been specifically implicated in contextual fear 
conditioning using paradigms similar to those used here (Kim and Fanselow, 1992; 
Phillips and LeDoux, 1992; Anagnostaras et al., 1999; Rudy et al., 2002).  However, 
KORs are also highly expressed in the AMY (Mansour et al., 1995) a region critical for 
footshock-potentiated startle (Hitchcock et al., 1989) which sends direct projections to 
the startle pathway (Inagaki et al., 1983; Rosen et al., 1991).  Microinfusions of KOR 
antagonist into the AMY have anxiolytic-like effects in models of conditioned and  
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unconditioned fear (Knoll et al., 2011), and abolish stress-induced increases in anxiety-
like behavior (Bruchas et al., 2009).  In addition, KORs are expressed on terminal inputs 
to the BNST (Li et al., 2012), another brain region often implicated in anxiety (Radke, 
2009; Davis et al., 2010).  The AMY and BNST represent candidate brain regions for 
future studies of c-Fos in the context of footshock-potentiated startle.  
 
The stress response is part of an adaptive mechanism responsible for maintaining 
homeostasis in response to a real or perceived threat; however, intense or sustained 
stress contributes to the pathophysiology of psychiatric disorders.  The present work 
confirms a role for KORs in stress-induced behavior by demonstrating that KOR 
antagonism significantly attenuates footshock-induced increases in context-dependent 
startle reactivity.  This anxiolytic-like profile, in combination with previous work 
demonstrating anti-depressant-like effects of KOR blockade (Newton et al., 2002; 
Mague et al., 2003; Shirayama et al., 2004; Carr et al., 2010), support the development 
of therapeutics targeting the KOR system, particularly in treating comorbid anxiety and 
depressive disorders.  Nevertheless, improved treatments may emerge from a deeper 
understanding of the brain regions and cell types involved in these anxiolytic- and 
antidepressant-like effects.  A limitation of the current study was the use of systemic 
KOR antagonist treatment, which precluded our ability to attribute JDTic effects to any 
particular brain region.  In order to target specific KOR systems, we developed a line of 
floxed KOR mice that enable Cre recombinase (Cre)-induced ablation of KORs in 
specific brain regions or cell populations.  The next chapter describes the generation 
and basic characterization of two mouse lines developed by breeding our floxed KOR 
mice with mouse lines expressing Cre in early embryogenesis (Ella-Cre) or only in DA  
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neurons (DAT-Cre) to produce mice lacking KORs throughout the brain and body or 
lacking KORs specifically in DA neurons, respectively. 
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Abstract 
Brain kappa-opioid receptors (KORs) are implicated in states of motivation and emotion.  
KORs negatively regulate mesolimbic dopamine (DA) neurons, and agonists produce 
depressive-like behavioral effects.  To further evaluate how KOR function affects 
behavior, we developed mutant mice in which exon 3 of the KOR gene (Oprk1) was 
flanked with Cre-lox recombination (loxP) sites.  By breeding these mice with lines that 
express Cre-recombinase (Cre) in early embryogenesis (EIIa-Cre) or only in DA 
neurons (DAT-Cre), we developed constitutive KOR knockouts (KOR
-/-) and conditional 
knockouts that lack KORs in DA-containing neurons (DAT-KOR
lox/lox).  Autoradiography 
demonstrated complete ablation of KOR binding in the KOR
-/- mutants, and reduced 
binding in the DAT-KOR
lox/lox mutants.  Quantitative polymerase chain reaction (qPCR) 
studies confirmed that KOR mRNA was undetectable in the constitutive mutants and 
reduced in midbrain DA systems in the conditional mutants.  Behavioral characterization 
demonstrated that these mutant lines do not differ from controls in metrics including 
hearing, vision, weight, and locomotor activity.  Whereas KOR
-/- mice appeared normal 
in the open field and light/dark box tests, DAT-KOR
lox/lox mice showed reduced anxiety-
like behavior, broadly consistent with previously reported effects of KOR antagonists.  
Sensitization to the locomotor-stimulating effects of cocaine appeared normal in KOR
-/- 
mutants, but exaggerated in DAT-KOR
lox/lox mutants.  Exaggerated sensitivity to cocaine 
in the DAT-KOR
lox/lox mutants is consistent with a role for KORs in negative regulation of 
DA function, whereas the lack of differences in the KOR
-/- mutants suggests more 
thorough compensatory adaptations after constitutive receptor ablation.  These mouse 
lines may be useful in future studies of KOR function. 
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Introduction 
Accumulating evidence indicates that brain kappa-opioid receptors (KORs) and 
dynorphin (DYN), the endogenous ligand that binds at these receptors (Chavkin et al., 
1982), are involved in regulating states of motivation and emotion.  Administration of 
KOR agonists produces depressive (dysphoric) effects in humans (Pfeiffer et al., 1986) 
and depressive-like effects in rodents (for review, see Carlezon et al., 2009; Bruchas et 
al., 2010; Knoll and Carlezon, 2010).  In contrast, KOR antagonists produce 
antidepressant-like effects (for review, see Carlezon et al., 2009; Carlezon and Carroll, 
in-press).  Although the mechanisms through which KORs regulate mood are not fully 
understood, actions upon the mesocorticolimbic dopamine (DA) system appear to play 
a key role.  KORs are expressed on both the cell bodies and terminals of 
mesocorticolimbic (ventral tegmental area [VTA]) DA neurons (Svingos et al., 1999; 
Svingos et al., 2001) and are coupled to G-proteins, such that agonist stimulation 
inhibits cyclic AMP production and modulates potassium and calcium channel 
conductance (Bruchas and Chavkin, 2010).  These processes produce inhibition of DA 
neurons in the VTA (Margolis et al., 2003; Margolis et al., 2006b; Ford et al., 2007) and 
diminished DA release in areas that receive VTA input such as the nucleus accumbens 
(NAc) and prefrontal cortex (PFC), regardless of whether the agonist is given 
systemically (Di Chiara and Imperato, 1988; Devine et al., 1993; Carlezon et al., 2006), 
into the VTA (Margolis et al., 2006b), or into the NAc (Donzanti et al., 1992).  Systemic 
administration of KOR agonists also attenuates cocaine effects on behavior 
(Tomasiewicz et al., 2008) and DA neurochemistry (Maisonneuve et al., 1994; 
Thompson et al., 2000).  KOR antagonists cause small elevations in extracellular 
concentrations of DA in the NAc (Maisonneuve et al., 1994), consistent with a  
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neuromodulatory role of KORs and DYN.  Collectively, these studies suggest that 
manipulations that target KORs may be useful in the study and treatment of debilitating 
disorders characterized by dysregulation of motivation and emotion, such as mood 
disorders and addiction. 
 
There is increasing interest in the development of KOR targeted ligands as therapeutic 
agents.  It has been suggested that KOR antagonists might have a wide range of 
indications, including the treatment of depressive-, anxiety-, and addictive disorders (for 
review, see Carlezon et al., 2009; Wee and Koob, 2010; Tejeda et al., 2012; Carlezon 
and Carroll, in-press).  A general ability to reduce the impact of stress may explain how 
KOR antagonists can have efficacy in such a wide variety of animal models that would 
appear to represent different disease states (Bruchas et al., 2010; Knoll and Carlezon, 
2010; Van't Veer et al., 2012; Carlezon and Carroll, in-press).  It has been suggested 
that partial KOR agonists, which activate KORs with a lower efficacy than DYN and thus 
may lack the dysphoric effects produced by full agonists, could be useful for the 
treatment of conditions characterized by elevated motivation (Carlezon et al., 2009).  
One such condition is mania (Cohen and Murphy, 2008), a hallmark sign of bipolar 
disorder.  Full KOR agonists have long been of interest as non-addictive analgesic 
drugs (Pasternak, 1980) or anti-itch medications (Inan and Cowan, 2004).  Although 
current full KOR agonists produce dysphoric effects that may render them difficult for 
patients to tolerate, recent work suggests that it may be possible to identify new 
generations of these agents that have the desired effects on pain without aversive side 
effects (Bruchas et al., 2011).  As such, a broader understanding of the neurobiology of 
KOR function may facilitate the development of new and improved medications.  
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One strategy to understand the neurobiological significance of KORs is to develop 
mutant mice that lack these receptors.  We generated a line of mice in which exon 3 of 
the KOR gene (opioid receptor, kappa 1 [Oprk1]) was targeted for deletion by flanking it 
with Cre-lox (loxP) recombination sites, thereby enabling conditional (region-specific) 
KOR deletion and allowing the design of new studies that complement work conducted 
in previously reported lines (Chefer et al., 2005).  By breeding these mice with lines that 
express Cre-recombinase (Cre) in early embryogenesis (EIIa-Cre) or only in DA 
neurons (dopamine transporter [DAT]-Cre), we developed constitutive KOR knockouts 
(KOR
-/-) and conditional knockouts that lack KORs in DA-containing neurons (DAT-
KOR
lox/lox).  Here we describe initial characterization of these mice in molecular assays 
to confirm the efficacy of the mutation, as well as in a battery of behavioral tests that 
quantify effects of the mutations on metrics including hearing, vision, weight, locomotor 
activity in an open field and anxiety.  We also examined the effects of acute and 
repeated cocaine on behavior in these mice, for comparison with findings from previous 
reports (Chefer et al., 2005).  These early studies provide a basis for future studies of 
KOR function in these mice. 
 
Materials and methods 
Mice: Mice were group-housed (2-5 mice/cage) and maintained on a 12:12-h light-dark 
cycle (0700h lights on) with ad libitum food and water available except during behavioral 
testing.  Experiments were conducted in male mice 2 to 4 months at the start of each 
experiment and testing occurred during the light phase of the daily cycle.  Mice tested in 
the light/dark box test were also tested 7 d later in the elevated plus maze.  For all of the 
other individual experiments, naïve (previously untested) mice were used.  Some  
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additional tests were performed on the DAT-KOR
lox/lox mice and appropriate controls to 
follow up positive findings in initial screening procedures (see below).  Experimental 
protocols were approved by the Institutional Animal Care and Use Committee of 
McLean Hospital and in accordance with the National Institutes of Health (NIH) policies. 
 
Development of mutant mice: The murine KOR gene (Oprk1) contains 4 exons.  A 
targeting construct was generated in which loxP sites flanked exon 3 of this gene 
(inGenious Targeting Laboratory [iTL], Ronkonkoma, NY).  Protein lacking this region 
would be non-functional as the excision shifts the open reading frame, which ensures 
that subsequent portions of the protein are not translated.  For positive selection of 
homologous recombinants, an FRT-flanked neomycin resistance gene (neo) was cloned 
downstream of exon 3 (Fig. 4.1).  The targeting vector was linearized and transfected 
by electroporation into iTL IC1 C57BL/6NTac embryonic stem (ES) cells.  Recombinant 
ES clones were microinjected into BALB/c blastocytes and resulting chimeras were 
mated with wild-type (WT) C57BL/6 mice to generate F1 heterozygotes.  Correct 
targeting was confirmed by PCR with primers hybridizing to the neo gene (5-
GTACTGTATCAGTAGACATTGG-3) and a flanking primer 3’ to the short homology arm 
(5-CCAGAGGCCACTTGTGTAGC-3).  The neomycin cassette was then removed by 
breeding heterozygous offspring to ACTFLPe mice (Jackson Labs, Bar Harbor, ME).  
Mice that no longer contained the FLPe transgene but retained the loxP sites were 
intercrossed to generate homozygote Oprk1-floxed mice (KOR
lox/lox).  We then crossed 
KOR
lox/lox with mice expressing Cre during early embryonic development (EIIa-Cre; 
Jackson Labs, Bar Harbor, ME), thereby generating constitutive KOR knockouts (KOR
-/-
), and with mice expressing Cre in dopamine transporter-containing cells (DAT-Cre;  
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Parlato et al., 2006), thereby generating conditional knockouts that lack KORs in DA-
containing neurons (DAT-KOR
lox/lox).  Mice were backcrossed to C57BL/6J (7 
generations) before testing.  For experiments, KOR
-/- mice and littermate controls 
(KOR
+/+) were obtained by breeding KOR heterozygous (KOR
+/-) mice.  DAT- KOR
lox/lox 
and littermate controls (KOR
lox/lox) were obtained by breeding floxed KOR mice 
expressing the DAT-Cre transgene with floxed mice lacking the Cre transgene.  
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Figure 4.1 Generation of KOR-deficient mice.  Representative depiction of the wild-
type, targeted, floxed, and KO alleles.  The neo cassette was removed from the 
targeted allele by FLPe-induced recombination.  KO mice were generated by breeding 
to Ella- and DAT-Cre mouse lines to generate constitutive KOs and conditional KOs 
with KORs ablated in DA neurons. DA, dopamine; KO, knockout; KOR, kappa-opioid 
receptor 
 
Ex1 Ex2 Ex3
Wild-type allele 10.2 kb 2 kb 1 kb
Targeted allele
FRT loxP
2.2 kb
neo
Floxed allele
Knockout allele
+FLPe
+Cre 
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Genotyping: Genomic DNA samples obtained from tail biopsies were tested by 
polymerase chain reaction (PCR) to demonstrate recombination at the floxed KOR 
allele using primers annealing immediately upstream of each loxP site and just 
downstream of the floxed region (5-TATTGCTGACCTATCGTGAAC-3, 5-
GAGCTACTGTTTTCATACCATTTA-3, and 5-TTGAGGCTACTAGTTTCCAAAG-3).  
PCR products were run on a 1% agarose gel.  Expected fragment sizes were 399 base 
pairs (bp) for WT DNA, 459 bp for unrecombined DNA and 563 bp for KOs.  PCR 
cycling conditions were 94°C, 45 sec; 60°C, 20 sec; 70°C, 1 min for 40 cycles.  To 
determine whether mice expressed the Cre transgene, genotyping was performed with 
primers to iCre (5-GTGGATGCCACCTCTGATGAAGTCAGGA-3 and 5-
CAATGCGCAGCAGGGTGTTGTAGGCAAT-3). 
 
Autoradiography: Autoradiography was performed using [
3H]U69,593 (PerkinElmer, 
Waltham, MA), a tritiated version of a highly selective KOR agonist (La Regina et al., 
1988), as described previously (Wang et al., 2011).  Mice were killed by decapitation, 
and brains were removed and immediately immersed in isopentane on dry ice.  Coronal 
sections (20 μm) were cut on a cryostat (Leica CM3050 S) maintained at -20°C, thaw-
mounted onto gelatin-dipped slides, and stored at -80°C until processed.  Sections were 
incubated with 5 nM [
3H]U69,593 in 50 mM Tris-HCl buffer (pH 7.4) for 1 hour at 25°C.  
Non-specific binding was assessed in the presence of 10 μM naloxone, a non-specific 
opiate receptor inhibitor. Slides were then rinsed three times (2 minutes each) in cold 50 
mM Tris-HCl buffer, pH 7.4, and once (30 seconds) in deionized H2O, dried under a 
cool stream of air, and exposed to tritium-sensitive storage phosphor screens for 3 
weeks in cassettes.  Radioactive images captured on phosphor screens along with  
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[
3H]microscale standards (GE Healthcare, Buckinghamshire, UK) were visualized using 
a Cyclone Storage Phosphor Scanner (Packard Bioscience), and data were analyzed 
using the OptiQuant program.  Nonspecific binding was subtracted from total binding 
and the resultant values represent specific [
3H]U69,593 binding in fmol/mg as 
determined using [
3H]microscale.  Data are reported as mean values plus standard 
error of the mean (SEM) from three to four sections in each brain. 
 
Quantitative reverse transcription PCR (qPCR): To complement the autoradiography 
studies, we performed qPCR on cDNA synthesized from tissue punches of the NAc, 
caudate putamen (CPu), amygdala (AMY), and midbrain (comprising the VTA plus 
substantia nigra (VTA/SN).  Frozen brains were coronally sectioned on a cryostat (-
20°C) until the rostral NAc was exposed (Bregma 1.70 mm).  Bilateral 1-mm
3 punches 
of NAc tissue were taken and kept on dry ice.  More caudal brain regions of interest 
were sequentially obtained by sectioning until the rostral face of the region was exposed 
and bilateral tissue punches obtained (average tissue weight≈15.0 mg).  To verify the 
location of the tissue punches, 30 μm coronal sections were collected at the beginning 
and end of each punch; these sections were slide mounted, stained with 0.1% cresyl 
violet, and analyzed to verify that the tissue punch location was within targeted brain 
regions.  Total RNA was extracted using PureLink RNA Mini Kit (Invitrogen).  RNA 
quality and quantity were assessed using an RNA 6000 Nano Chip (Agilent, Santa 
Clara, CA) on an Agilent Bioanalyzer 2100.  RNA integrity number (RIN) exceeded 7 for 
all samples, indicating high quality.  500 ng of total RNA was used to synthesize cDNA 
using iScript cDNA Synthesis Kit (BioRad) in a ThermoHybaid iCycler (Thermo 
Scientific).  Primers specific for KOR (Oprk1; 5-TCCTTGGAGGCACCAAAGTCAGGG- 
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3, and 5-TGGTGATGCGGCGGAGATTTCG-3), DAT (Slc6a3; 5-
AATGCCCTGGGCTGGATCATTGC-3 and 5-AATGGCGCAGCGTGAATTGGC-3), β-
actin (Nba; 5-AGTGTGACGTTGACATCCGTA-3 and 5-
GCCAGAGCAGTAATCTCCTTCT-3), and filamin β protein (FlnB; 5- 
TTCACTGTGGGCGTTGCTGC-3 and 5-AAGCATGGCACCACCTTCCG-3) genes were 
designed using NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
and purchased from Integrated DNA Technologies (Coralville, Iowa).  The KOR primer 
set flanked the exon 3 to exon 4 junction.  Melt curve analysis and polyacrylamide gel 
electrophoresis confirmed the specificity of the primers.  The amplicon bp lengths are 
237 (KOR), 178 (DAT), 112 (β-actin), and 176 (FlnB). 
 
The qPCR was run using the iQ SybrGreen Supermix (BioRad).  The reaction was 
carried out on a MyiQ Single Color Real-Time PCR Detection System (BioRad) in a 
volume of 20 µl, with 2.0 µL of 3.0 µM forward and reverse primers, 2.0 µL 
Rnase/Dnase free H2O, 10 µL SybrGreen Supermix, and 4.0 µL cDNA sample diluted 
1:10.  PCR cycling conditions were 95°C for 5 min; 40 cycles at 94°C for 15 sec, 60°C 
for 15 sec, 72°C for 15 sec.  Data were collected at a read temperature of 81°C to 83°C 
for 15 sec depending on the amplicon melt temperatures.  Standard dilution curves 
were generated for each primer in every experiment and on every plate by serially 
diluting (1.00, 0.25, 0.0625, and 0.0156-fold) a master cDNA stock comprising an equal 
mix of cDNA pooled from the brain regions of interest of all control mice.  The undiluted 
master sample was assigned an arbitrary concentration of 1.00.  MyiQ Optical System 
Software (BioRad) was used to analyze the data, and reported values for KOR and DAT 
were normalized to the average of two internal controls: β-actin, and FlnB, neither of  
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which showed group differences in qPCR analyses.  Samples containing no cDNA 
template and samples from cDNA reactions containing no reverse transcriptase were 
run as controls for contamination and amplification of genomic DNA, respectively.  All 
samples were run in duplicate.  In experiments that compared gene expression in the 
NAc, CPu, AMY, and VTA/SN, qPCR reactions for KOR and internal control gene 
analysis were run concurrently with all samples from these regions on the same 96 well 
plate, to ensure identical amplification and measurement conditions. 
 
Cre-recombinase immunohistochemistry: Mice were perfused with 0.9% saline followed 
by 4% paraformaldehyde.  Whole brains were extracted and postfixed in 4% 
paraformaldehyde overnight then transferred to 30% sucrose for cryoprotection.  Brains 
were sectioned at 30 µm and incubated in 0.3% H2O2 for 30 min, then blocked in 5% 
normal goat serum (Vector Laboratories, Inc., Burlingame, CA), for 1 hour.  Sections 
were incubated in primary antibody to Cre-recombinase (1:2,000; Millipore, Billerica, 
MA) in 5% NGS overnight.  The next day sections were incubated in biotinylated anti-
rabbit IgG (1:500; Vector Laboratories, Inc., Burlingame, CA) for 1 hour followed by 
ABC for 1 hour (ABC Elite Kit, Vector Laboratories, Inc., Burlingame, CA).  Cre-
recombinase immunoreactivity was visualized with DAB. 
 
Warm water tail-flick assay: The tail-flick assay was used to assess KOR-mediated 
analgesia (Janssen et al., 1963; McLaughlin et al., 2003a).  Mice were held by the scruff 
and their tails were submerged 1-2 cm in a 52±1°C water bath. The latency for mice to 
withdraw their tail from the bath was timed with a stopwatch to establish baseline  
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withdrawal latency.  Mice were then treated with the KOR agonist (±)U50,488 (15 mg/kg 
IP) and withdrawal latencies were assessed 30 min later.  A maximum tail emersion 
time of 15 sec was used to prevent tissue damage. 
 
Acoustic startle response: Acoustic startle data were collected by measuring the 
amplitude of the startle reflex in response to white noise bursts using the Med 
Associates Inc. (St. Albans, VT) Startle Reflex System and Advanced Startle software 
program.  Mice were placed into Plexiglas cages (8.5 x 7 x 7 cm) with steel rod floors 
attached to load cell platforms contained inside sound and light attenuating chambers 
(40 x 64 x 42 cm).  The load cells are capable of transducing movement into an 
electrical output that is amplified and digitized into arbitrary units by an analog-to-digital 
converter interfaced to a personal computer.  Startle amplitude was defined as the 
maximum peak-to-peak voltage occurring within the first 100 ms after the onset of the 
startle stimulus.  An audio stimulator generated 40 msec startle stimuli (1-32 kHz white 
noise) that were delivered through speakers located behind the cages.  To assess their 
startle threshold mice were allowed 5 min in the chamber to acclimate followed by 100 
startle stimuli, 10 each at 70, 74, 78, 82, 86, 90, 94, 98, and 102 dB in a pseudo-random 
order with an interstimulus interval of 7-23 sec (average of 15 sec). 
 
Weight: To determine if KOR deletion alters body weight, individual mice were weighed 
at weekly intervals beginning at weaning (4 weeks) and continuing until adulthood (8 
weeks). The same scale was used throughout the experiment and mice were only 
included if their exact date of birth was known.  Weights were recorded to 0.1 gm. 
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Visual cliff: Depth perception (visual acuity) was tested in the visual cliff paradigm.  The 
apparatus consisted of a platform 1 meter above the ground with a checkered pattern.  
A clear piece of Plexiglas was placed on the platform and extended 0.5 meters beyond 
the platform edge.  The checkered pattern was also placed on the floor below the 
extending Plexiglas, giving the illusion of an edge.  At this interface was a smooth beam 
(2.54 x 2.54 cm) running the length of the edge.  Mice were placed on the beam and 
allowed to step off to either side.  Choices were recorded as safe if the mouse stepped 
toward the platform side and unsafe if the mouse chose the overhang side.  Each 
mouse was tested for 10 trials. 
 
Activity testing: To determine if KOR deletion alters overall locomotor activity, mice were 
tested in clear Plexiglas open-field arenas (28 x 28 x 20 cm) housed inside dark light 
and sound attenuating chambers (Med Associates Inc., St. Albans, VT, USA).  
Locomotor activity was quantified using an automated system equipped with infrared 
beams.  Beam breaks were recorded and converted into horizontal distance travelled 
(Activity Monitor 5.0; Med Associates Inc.).  The testing period was 1 h.  The amount of 
time mice spent in the 16 x 16 cm interior of the open field (Center Time), a metric 
increased by drugs with anxiolytic effects in people (Prut and Belzung, 2003; Knoll et 
al., 2007), was also quantified, although only the final 45 min of these data were 
analyzed. 
 
Cocaine sensitization: The cocaine locomotor sensitization test paradigm began 
immediately after the initial 1 hr activity test.  The methods were similar to those 
previously described (Chefer et al., 2005).  Briefly, at the same time each day mice  
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were subjected to a 3 hr test which included a 1 hr habituation session (0-60 min), a 1 
hr post saline (10 mL/kg, intraperitoneal [IP]) test session (60-120 min), and a final 1 hr 
post cocaine (15 mg/kg, IP) test session (120-180 min). This procedure was repeated 
daily for 5 consecutive days followed by two days off and a final identical test on day 8. 
 
Cocaine place conditioning: The unbiased place conditioning apparatus consisted of 
opaque Plexiglas chambers with two interchangeable and distinct tactile floor stimuli 
(hole vs. grid) with which cocaine or vehicle injections were paired.  Each chamber 
included a removable guillotine door that allowed the confinement of mice to one half of 
the apparatus.  The experiments proceeded in three phases: habituation (one session), 
conditioning (4 sessions; 2 CS+ and 2 CS-), and preference testing (one session).  The 
habituation session was intended to reduce the novelty of the experimental apparatus 
and injection procedures.  On the first day of the experiment, mice were injected with 
vehicle just prior to being placed in the conditioning chamber for 30 min, where the floor 
was lined with smooth Plexiglas and the entire apparatus was open for exploration.  
During the conditioning phase, mice were injected with vehicle (AM) or cocaine (PM; 
1.25 or 5 mg/kg) just before being confined to one side of the conditioning chamber for 
30 min.  After two conditioning trials (2 saline, 2 cocaine; Days 2–3), a 30-min 
preference test was conducted (Day 4) wherein the test floor was half hole and half grid 
and the entire apparatus was open for exploration.  All conditioning and testing was 
conducted under dim light and scored using an automated system (Noldus EthoVision 
XT).  Percent time in the drug-paired side was calculated based on the automated 
output.  The apparatus was cleaned with 70% isopropyl alcohol between mice. 
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Light/dark box test: The light/dark box test was used as a secondary method of 
quantifying anxiolytic-like effects only when data from the open field suggested group 
differences in Center Time.  New cohorts of mice were used.  The apparatus consisted 
of a box (42 x 42 x 30 cm), one third of which was the dark compartment (2 lux) and two 
thirds of which was the light compartment (380 lux).  An opening (10x5 cm) allowed 
passage between the two sides.  Mice were placed into the dark compartment and 
allowed to move freely in the apparatus for 5 min.  The latency for mice to transition 
from the dark chamber to the light chamber and the total time in the light chamber was 
recorded with EthoVision XT (Noldus Information Technology, Wageningen, 
Netherlands).  The apparatus was cleaned with 70% isopropyl alcohol between mice. 
 
Elevated plus maze: Mice that were tested in the light/dark box were also tested 7 days 
later in the elevated plus maze.  Mice were tested on a plus maze (75 x 75 cm) that was 
elevated 1 m above the floor.  Each arm was 35 x 6 cm connected by a 5 x 5 cm center 
area.  Mice were transferred to the dimly lit testing room at least 1 hr prior to testing.  
Mice were placed onto the center of the apparatus facing a closed arm and activity was 
recorded for 5 min using EthoVision XT.  Total time spent in the open arms and total 
distance traveled (cm) were quantified.  The maze was cleaned with 70% isopropyl 
alcohol between mice. 
 
Data analysis: All data are graphed as mean plus SEM.  Data for each genotype were 
analyzed by two-sample t-tests or ANOVA followed by Bonferroni post hoc tests as 
appropriate.  For the visual cliff and place conditioning experiments, one sample t-tests 
were used to compare the observed data for each genotype to the hypothetical data  
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expected for blind mice or lack of cocaine preference respectively.  Startle threshold 
was calculated as the lowest dB significantly different from no stimulation response 
using separate ANOVAs for each genotype. 
 
Results 
Radioligand binding of [
3H]U69,593 was used to determine whether the floxed construct 
was effective in eliminating functional KORs in KOR-mutant mice.  No detectable 
[
3H]U69,593 binding was present in KOR
-/- mice, whereas autoradiographic mapping in 
WT littermates showed clear distribution of KORs throughout the brain including the 
NAc, AMY, and cortex (Fig. 4.2B).  The distribution is similar to those reported 
previously (reviewed in Mansour et al., 1988).  Quantification demonstrated a significant 
difference in [
3H]U69,593 binding in brain areas of the mesocorticolimbic DA system 
(PFC, NAc, caudate-putamen, AMY, VTA and SN), depicted in Fig 4.2A.  Binding in 
KOR
-/- mice was reduced to background levels in all regions analyzed (P’s<0.05; Fig. 
4.2D).  [
3H]U69,593 binding was visibly similar in both DAT-KOR
lox/lox mice and 
littermates (KOR
lox/lox) (Fig. 4.2C), but quantification showed that DAT-KOR
lox/lox mice 
had reduced binding in the PFC and CPu (P’s<0.05; Fig. 4.2E).  Since KORs are also 
expressed in non-dopaminergic cells, the reductions in any particular region of 
conditional KOs may represent only a fraction of total KORs in that area.  
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Figure 4.2 [
3H]U69,593 binding in KOR KO lines.  A. Representative autoradiograms 
of [
3H]U69,593 binding to KORs in coronal brain sections of a KOR
+/+ mouse at 4 
different levels from rostral to caudal positions depicting regions of interest quantified in 
D,E . B,C. Representative computer-generated pseudocolor autoradiograms of 
[
3H]U69,593 binding in KOR
+/+, KOR
-/-, KOR
lox/lox, and DAT-KOR
lox/lox mice.  Non-specific 
binding (N.S.) was assessed in the presence of naloxone. Note that exposure of 
sections to different screens yields slightly different signals, which were then calibrated 
with the corresponding microscale standards.  D,E. Quantification of specific 
[
3H]U69,593 binding (fmol/mg tissue) from brain regions known to express KORs.  
*P<0.05, ***P<0.001, ****P<0.0001 (n=3-6). AMY, amygdala; CPu, caudate-putamen; 
NAc, nucleus accumbens; PFC, prefrontal cortex; SN, substantia nigra; VTA, ventral 
tegmental area  
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Figure 4.2 (Continued) [
3H]U69,593 binding in KOR KO lines 
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To further confirm the specificity of the deletion, brain dissections (punches) were 
analyzed by qPCR to quantify mRNA levels.  We verified this technique by examining 
KOR and DAT mRNA in KOR
-/- mice (gene x genotype interaction, F[2,9]=39.94, 
P<0.0001).  Post hoc analysis revealed reduced levels of KOR mRNA in heterozygotes 
and no detectable mRNA in KOR
-/- mice compared to KOR
+/+ controls (Fig. 4.3A).  The 
accuracy of the brain punches was verified through analysis of DAT mRNA, which 
showed similar levels among the genotypes.  KOR mRNA levels were reduced in the 
VTA/SN of DAT-KOR
lox/lox mice compared to littermate controls whereas DAT mRNA 
levels were not significantly different (gene x genotype interaction, F[1,6]=20.35, 
P<0.01; Fig. 4.3B).  As expected based on the location of Cre expression (Fig. 4.4), this 
reduction was specific to the VTA/SN and was not observed in other brain regions 
(region x genotype interaction, F[3,18]=8.10, P<0.01; Fig. 4.3C).  
 
Since KOR activation induces analgesia, the tail flick assay was used as a behavioral 
confirmation of KOR deletion.  Baseline tail withdrawal latencies did not differ between 
KOR
-/- or DAT-KOR
lox/lox mice and their littermate controls (Fig. 4.5A).  In KOR
-/- mice, 
tail withdrawal latencies depended upon a drug x genotype interaction (F[1,31]=24.23, 
P<0.0001; Fig. 4.5A).  After U50,488 treatment, KOR
+/+ mice had increased tail 
withdrawal latency compared to their own baseline (P<0.0001) and significantly longer 
latencies than KOR
-/-  mice (P<0.0001). The response to U50,488 was similar to that 
observed in WT mice (increased latency compared to baseline) in DAT-KOR
lox/lox mice 
and did not differ compared to littermate controls (main effect of drug, F[1,21]=24.92, 
P<0.0001; Fig. 4.5B), suggesting that DAT-expressing cells make a minimal 
contribution to the antinociceptive effects of KOR agonists.  While some differences in  
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the baseline and drug responses were noted between the mutant strains, this likely 
represents variability between the individual experiments, since all mice within each 
experiment were tested on the same day.  
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Figure 4.3 Gene expression analysis using qPCR in KOR mutant mice. A. Levels of 
KOR mRNA from punches of the ventral tegmental area and substantia nigra (VTA/SN) 
of mutant mice indicates reduced KOR mRNA in KOR
-/+ mice and no detectable levels 
in KOR
-/- mice compared to controls.  B. Similarly, DAT-KOR
lox/lox mice have significantly 
less KOR mRNA than KOR
lox/lox littermates.  Levels of DAT mRNA were equivalent in 
mutants and controls.  C. KOR mRNA reductions were specific for the VTA/SN in DAT-
KOR
lox/lox knockouts.  *P˂0.05, **P˂0.01, ****P˂0.0001 (n=4). qPCR, quantitative 
reverse transcription polymerase chain reaction 
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Figure 4.4 Immunohistochemistry for Cre-recombinase.  DAT-KOR
lox/lox mice show 
Cre-recombinase immunoreactivity specifically in the VTA and SN.  Scale bar indicates 
400 µm.
SN
VTA 
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Figure 4.5 Warm water tail-flick assay.  Mice were tested at baseline and 30 min 
following the KOR agonist U50,488 (15 mg/kg, IP).  A. U50,488 induced analgesia in 
KOR
+/+ but not KOR
-/- mice.  B. U50,488 significantly increased tail withdrawal latencies 
in both KOR
lox/lox and DAT-KOR
lox/lox knockouts.  ****P˂0.0001 (n=11-17).
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Both strains of the mutant mice appeared normal upon gross examination.  Regardless, 
a series of experiments were conducted to determine whether their basic development 
and senses were intact.  Mice were weighed weekly from age 4 to 8 weeks (Fig. 
4.6A,D) and analysis of mean body weight by time and genotype revealed a main effect 
of weight over time (F[4,84]=388.40, P<0.0001; F[4,64]=535.70, P<0.0001); however, 
both mutants were virtually indistinguishable from their littermate controls.  To determine 
if hearing was affected in KOR-deficient mice, startle threshold was determined in both 
lines (Fig. 4.6B,E).  Startle amplitude increased with increasing sound intensity (dB) but 
did not differ significantly between control and mutant mice in either KOR
-/- or DAT-
KOR
lox/lox mice.  To calculate startle threshold, each genotype was analyzed separately.  
The lowest sound intensity tested that was significantly different from no stimulation 
controls was 86 dB in all groups indicating similar thresholds in control and mutant mice.  
Vision was tested in the visual cliff paradigm (Fig. 4.6C,F).  The percent of safe choices 
over 10 trials was determined for each mouse.  Mutant mice did not differ from controls, 
or show deficits in visual depth perception as indicated by percent safe choices 
significantly above chance (50%; P’s<0.01).  This is consistent with other studies in 
sighted mice, and in contrast to the random (52% safe) choices made by a blind strain 
of mice (C3H/HeJ; Fox, 1965).  Overall, these data indicate that neither constitutive nor 
DA neuron-selective KOR deletion has an effect on body weight or basic sensory 
functions such as hearing or vision.    
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Figure 4.6 Effects of KOR deletion on weight gain and sensory function.  A,D. 
Weight gain in KO mice did not differ from littermate controls. (n=9-14) B,E. Startle 
responding in KO mice did not statistically differ from controls.  Hearing thresholds for 
all genotypes was 86 dB. (n=8-10) C,F. Vision was not affected in either KOR KO line. 
(n=7-9)  #P˂0.05 compared to no stimulation (no stim) condition.  Each genotype was 
analyzed individually.  **P˂0.01, ***P˂0.001, ****P˂0.0001 compared to 50%.
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Activity testing also did not reveal any differences between mutant mice and controls 
(Fig. 4.7A,C).  A more detailed analysis of the activity data suggested some strain 
differences in time spent in the center of the open field.  Although there were no 
significant differences in Center Time when the entire 60-min test period was analyzed 
(not shown), visual inspection of the data indicated high variability during the first 15 
min—a time which mice were most actively exploring the new environment—followed by 
a 45-min period during which group differences emerged.  As such, we re-analyzed the 
Center Time data using only the final 45 min of the test session.  Under these 
conditions, KOR
-/- mice were similar to WT controls in Center Time (main effect of time, 
F[2,28]=6.48, P<0.01; Fig. 4.7B).  However, DAT-KOR
lox/lox mice spent considerably 
more time in the center of the open field (main effect of genotype, F[1,32]=5.45, P<0.05; 
Fig. 4.7D), an anxiolytic-like effect.  To determine whether these mice would show less 
anxiety-like behavior in other paradigms, DAT-KOR
lox/lox mice were tested in the 
light/dark box and elevated plus maze.  DAT-KOR
lox/lox mice had significantly shorter 
latencies to enter the light side of the light/dark box (P<0.05, anxiolytic-like effect; Fig. 
4.8A), although once making this transition the total time in the light side did not differ 
between genotypes (Fig. 4.8B).  Open field and light/dark box effects were not 
attributable to the expression of Cre recombinase alone, since DAT-KOR
+/+ mice did not 
differ from KOR
+/+ littermate controls (Fig. 4.7D,E; Fig. 4.8C,D).  No differences were 
detected in open arm time or open arm entries in the elevated plus maze (Fig. 4.8E-H).  
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Figure 4.7 Open field activity.  A,C. General locomotor behavior was unchanged by 
KOR deficiency. B. Time spent in the center of the open field was not significantly 
different between KOR
+/+ and KOR
-/- mice.  D. DAT-KOR
lox/lox mice spent significantly 
more time in the center than KOR
lox/lox littermates.  *P˂0.05 (n=8-9) n.s., not significant
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Figure 4.8 Effects of KOR ablation in DA neurons on light/dark box and EPM 
behavior.  A. DAT-KOR
lox/lox mice had reduced latencies to first enter the light 
compartment compared to KOR
lox/lox controls.  B. No differences were observed in total 
time spent in the light compartment.  C,D. In the EPM, DAT-KOR
lox/lox mice did not differ 
from KOR
lox/lox controls in the percent time spent in the open arms or percent open arm 
entries.  *P˂0.05 (n=10-11). EPM, elevated plus maze 
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Figure 4.8 (Continued) Effects of KOR ablation in dopamine neurons on light/dark box 
and elevated plus maze behavior 
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Previous results suggest that KOR
-/- mice fail to exhibit cocaine-induced behavioral 
sensitization, but appear pre-sensitized to the locomotor activating effects following the 
first injection of cocaine (Chefer et al., 2005).  To determine whether our lines of mice—
which differ from these previous lines because they were generated by Cre-loxP 
recombination—exhibit a similar behavioral phenotype, mice were tested in a cocaine-
induced behavioral sensitization paradigm.  Both KOR
-/- mice and KOR
+/+ littermates 
developed locomotor sensitization to cocaine and did not significantly differ from one 
another (Fig. 4.9A-C).  Analysis of distance travelled in the 1 hour following cocaine 
treatment revealed a main effect of day (F[5,70]=12.11, P<0.0001; Fig. 4.9C), but no 
interaction with genotype.  Since behavioral sensitization may involve changes in DA 
function (Koff et al., 1994; Valjent et al., 2010), mutant mice lacking KORs specifically in 
DAT-expressing neurons were also tested.  Both DAT-KOR
lox/lox mice and littermate 
controls exhibited locomotor sensitization to daily injections of cocaine, although the 
degree of sensitization was enhanced in the mutants, and depended upon a genotype x 
treatment day interaction (F[5,80]=2.64, P<0.05; Fig. 4.10A-C).  Post hoc analysis at 
each day of testing indicated that DAT-KOR
lox/lox mice had a significantly greater 
response to cocaine at day 8 compared to littermate controls (P<0.05; Fig. 4.10C).  
Control mice expressing DAT-Cre with WT KOR alleles (i.e., lacking loxP sites; DAT-
KOR
+/+) and their littermate controls (KOR
+/+) were tested separately.  Cre expression 
alone was not sufficient to increase sensitization (data not shown). 
142 
 
Figure 4.9 Cocaine-induced locomotor sensitization in KOR
-/- mice.  KOR
-/- mice 
were not significantly different from KOR
+/+ littermates.  A,B. Time course of ambulatory 
distance (cm) in KOR
+/+ and KOR
-/- mice during the first 1 hour of testing and following 
injection of saline (10 mL/kg) and cocaine (15 mg/kg).  Time of injection is indicated by 
a dotted line.  C. Sum of the distance travelled during the 1 hour test period following 
cocaine injection for each test day (n=8). 
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Figure 4.9 (Continued) Cocaine-induced locomotor sensitization in KOR
-/- mice 
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Figure 4.10 Cocaine-induced locomotor sensitization in DAT-KOR
lox/lox mice.  DAT-
KOR
lox/lox mice had greater locomotor sensitization to cocaine than KOR
lox/lox littermate 
controls.  A,B. Time course of ambulatory distance (cm) in KOR
lox/lox and DAT-KOR
lox/lox 
mice during the first 1 hour of testing and following injection of saline (10 mL/kg) and 
cocaine (15 mg/kg).  Time of injection is indicated by a dotted line.  C. Sum of the 
distance travelled during the 1 hour test period following cocaine injection for each test 
day.  *P˂0.05 (n=9). 
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Figure 4.10 (Continued) Cocaine-induced locomotor sensitization in DAT-KOR
lox/lox 
mice 
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To determine whether the DAT-KOR
lox/lox mice would also exhibit enhanced effects in 
other cocaine-induced behaviors, mutant mice were tested in a cocaine conditioned 
place preference paradigm.  Mice were first tested with two conditioning trials of 5 
mg/kg cocaine, the minimum dose we have found to be effective at producing place 
preference in mice (A.J. Bechtholt and A. Van’t Veer, unpublished observations).  At this 
dose, both genotypes displayed a significant preference for the drug paired side in 
contrast to the expected observation of equal time spent on both sides of the apparatus 
if no preference was formed (P’s<0.01; Fig. 11A) and were not different from each 
other.  To determine if a lack of difference in genotypes was due to a ceiling effect on 
preference, a lower dose of cocaine (1.25 mg/kg) was used in a follow-up experiment.  
It was predicted that if DAT-KOR
lox/lox mice were more sensitive to the effects of cocaine, 
the drug might establish a place preference at a dose too low to induce preference in 
WT mice.  However, 1.25 mg/kg cocaine did not establish place preferences in either 
genotype, as indicated by virtually equal amounts of time spent in both sides of the 
testing apparatus (Fig. 11B).   
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Figure 4.11 Cocaine-induced conditioned place preference.  A.  Place preferences 
observed in KOR
lox/lox and DAT-KOR
lox/lox mice did not differ following conditioning with 5 
mg/kg cocaine.  B. Neither genotype developed place preferences to 1.25 mg/kg 
cocaine.  ***P˂0.001, ****P˂0.0001 compared to no preference (50% time on drug 
paired floor) (n=9-10).
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Discussion 
Here we describe the development of two lines of mice with mutations in KOR systems: 
a constitutive line (KOR
-/-) in which KORs are ablated throughout the brain and body, 
and a conditional line (DAT-KOR
lox/lox) in which KORs are lacking in DA-expressing 
cells.  Autoradiography studies confirmed loss of functional KOR protein, as reflected by 
binding of the highly selective KOR agonist [
3H]U69,593.  Binding of this ligand was 
completely absent in the KOR
-/- mice and, as expected, reduced in the DAT-KOR
lox/lox 
mice in brain areas rich in DA cell bodies or terminals while appearing intact in other 
brain areas.  To complement these protein analyses, we used qPCR to confirm loss of 
KOR gene expression throughout the brain in the KOR
-/-mice and in midbrain DA 
systems of DAT-KOR
lox/lox mice.  In an in vivo test of KOR function, we found that the 
KOR agonist U50,488 was completely devoid of antinociceptive effects (McLaughlin et 
al., 2003) in the KOR
-/- mice.  However, there was no such loss of function in the DAT-
KOR
lox/lox mice, suggesting that the antinociceptive effects of KOR agonists are not 
mediated by brain DA systems.  We also tested these mouse lines in a broad battery of 
tests to quantify effects of these mutations on sensory function, growth, and locomotor 
activity.  Compared to littermate controls, both lines of mice gained weight normally 
throughout development and neither line of mice showed any evidence of deficits in 
hearing, vision, or movement in an open field (e.g., lethargy or gross motor 
abnormalities).  Our findings suggest that the mutations we induced do not produce 
non-specific effects that can complicate data interpretation in tests where it is assumed 
that the mutants are normal in each of these domains. 
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While there were no differences in either strain in overall locomotor activity in the open 
field, a more detailed analysis in which activity patterns were quantified revealed some 
differences in the time spent in the center of the field (Center Time).  These differences 
were seen only in DAT-KOR
lox/lox mice; the KOR
-/- mice did not differ from controls.  
Furthermore, Center Time differences were only statistically significant when data from 
the final 45 min of the test session were analyzed.  The strategy of restricting data 
analysis to later portions of a test period is common in these types of screening 
procedures, especially in tests such as the forced swim test (Porsolt et al., 1977b) 
where there is large variability or almost complete overlap among groups in the earliest 
portions of the test session.  Regardless, DAT-KOR
lox/lox mice spent considerably more 
time in the center of the open field.  This type of pattern is often interpreted as reflecting 
an anxiolytic-like phenotype, since drugs with anxiolytic effects in humans produce this 
same effect on Center Time behavior (Prut and Belzung, 2003; Knoll et al., 2007).  
Elevated Center Time in the KOR mutants is also broadly consistent with previous work 
indicating that KOR antagonists have anxiolytic-like effects in rodents (Knoll et al., 2007; 
Carr and Lucki, 2010; Rogala et al., 2012).  To further assess the possibility that 
increased Center Time in the DAT-KOR
lox/lox mice reflects an anxiolytic-like phenotype, 
we ran additional (naïve) cohorts of mice in the light/dark box test.  Latencies to enter 
the light (i.e., anxiety-provoking) side of the apparatus were significantly lower in the 
DAT-KOR
lox/lox mice, also suggesting an anxiolytic phenotype.  However, upon entry, 
the mutant mice were just as likely to spend time in the light side as controls, suggesting 
reductions in passive avoidance behavior (latency to enter the light) rather than active 
avoidance behavior (tendency to escape from the light).  The lack of an anxiolytic-like 
phenotype in the EPM is surprising, but this outcome may reflect the fact that these  
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mice had been used previously in the light/dark box test, which may cause generalized 
reductions in anxiety-related behavior in subsequent tests.  Lack of effects in the EPM 
may also reflect the fact that this test was developed to identify pharmacological 
treatments (e.g., benzodiazepines) with anxiolytic effects (File, 1990; Haller et al., 
2012), and may have a different threshold for identifying the more subtle effects of 
mutations.  Lack of any evidence of an anxiolytic-like phenotype in the KOR
-/- mutants 
suggests more thorough compensatory adaptations occur after constitutive receptor 
ablation, or that under normal conditions activation of KORs in populations of non-DA 
neurons produce anxiolytic effects that offset the anxiogenic effects of KOR activation in 
DA-expressing neurons. 
 
Whereas the KOR
-/- mice appeared to have normal sensitivity to the locomotor-
stimulating effects of cocaine, the DAT-KOR
lox/lox mice had exaggerated sensitivity.  This 
exaggerated sensitivity was most evident when cocaine had been given in a repeated, 
intermittent (daily) regimen, followed by a 2-day period of no treatment: a challenge 
dose of cocaine produced much greater forward locomotion in the DAT-KOR
lox/lox mice 
than in controls.  The process of sensitization to the locomotor-activating effects of 
cocaine is often considered to be important because it is an example of cocaine-
induced plasticity, and the neuroadaptations underlying this process may be related to 
those that contribute to addictive behaviors (Robinson and Berridge, 2000; Carlezon 
and Nestler, 2002).  Considering that the locomotor-stimulating effects of drugs of 
abuse are strongly associated with their ability to elevate extracellular concentrations of 
DA in the NAc (Wise and Bozarth, 1987), these findings are consistent with the 
hypothesis that KORs provide negative regulation of the function of the  
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mesocorticolimbic DA system (Carlezon et al., 2009).  In this context it is surprising that 
the KOR
-/- mice did not show exaggerated sensitization to cocaine, considering the fact 
that they also lack KOR regulation of mesocorticolimbic DA systems.  In addition, it has 
been previously reported that a different line of KOR
-/- mice show exaggerated 
sensitization to the locomotor-stimulating effects of cocaine in a virtually identical 
treatment regimen (Chefer et al., 2005).  While the line of mice used in those previous 
studies and our KOR
-/- mice both have constitutive receptor ablation, there are important 
differences, including the targeting vector and background flanking genes (Chefer et al., 
2005).  Because the rewarding effects also undergo a process of sensitization with 
repeated exposure (Lett, 1989; Piazza et al., 1989; Shippenberg and Heidbreder, 1995); 
we ran additional (naïve) cohorts of the DAT-KOR
lox/lox mice in the cocaine place 
conditioning test.  These mice did not seem more sensitive to either a subthreshold 
dose of cocaine (1.25 mg/kg, IP) that does not establish a conditioned place preference 
in controls, or to a higher dose (5.0 mg/kg) that does establish a place preference in 
controls.  Although these data may indicate that KORs have a more profound regulatory 
influence on the locomotor-stimulating effects of cocaine than on its rewarding effects, 
this interpretation seems unlikely considering that KOR agonists are known to reduce 
the reward-related effects of cocaine (Tomasiewicz et al., 2008).  Rather, this effect may 
be due to a relative lack of sensitivity of the place conditioning test to subtle differences 
in reward—indeed, a common criticism of place conditioning is that dose-effects are “all 
or none” (Bevins, 2005)—or that more drug exposure and/or a period of no treatment is 
needed to reveal differential sensitivity, as was the case in the locomotor sensitization 
studies.  Future studies that utilize other testing procedures, such as the intracranial 
self-stimulation (ICSS) test, may provide more insight on mutation-induced differences  
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in sensitivity to cocaine and other drugs of abuse.  Although the ICSS procedure is very 
time-consuming, it is minimally sensitive to learning deficits (Carlezon and Chartoff, 
2007) and it has effectively identified mutation-related alterations in sensitivity to the 
reward-related effects of cocaine (Roybal et al., 2007; Dinieri et al., 2009; Muschamp et 
al., 2012). 
 
These mouse lines may be useful in future studies of KOR function.  As one example, 
these lines of mice could be bred with lines expressing ligand (e.g., tamoxifen)-
dependent Cre, such that the tissue selective gene excision can be induced at any time 
during development (Feil et al., 2009).  Use of these mice would provide deeper insight 
on the development of long-term compensatory mechanisms that affect the phenotypes 
of the mutants.  Similarly, viral vectors expressing Cre could be micro-infused into 
discrete brain areas (Berton et al., 2006; Graham et al., 2009), enabling an alternative 
method with which to accomplish time- and tissue-selective gene ablation.  Viral vectors 
expressing KORs could also be used in the KOR
-/- mice to “rescue” behavioral 
phenotypes or re-establish sensitivity to drugs that act at KORs.  Such studies are 
beyond the scope of the present report, the goals of which were to characterize these 
mouse lines and to report the development of a novel in vivo tool that should be useful 
for studies modeling the etiology and treatment of psychiatric conditions ranging from 
depression and anxiety (Carlezon et al., 2009; Knoll and Carlezon, 2010) to addiction to 
substances including cocaine (McLaughlin et al., 2003a; Beardsley et al., 2005; Bruchas 
et al., 2010; Wee and Koob, 2010), nicotine (Jackson et al., 2010), and ethanol (Walker 
et al., 2012).  
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Abstract 
 Although there is strong evidence that activation of KORs expressed on midbrain DA 
neurons can produce depressive-like effects including anhedonia and dysphoria, their 
role in anxiety-like effects such as elevated startle (hyperarousal) is not known.  We 
have shown that systemic KOR antagonism produces anxiolytic-like effects in tests of 
conditioned and unconditioned fear.  Considering the high comorbidity of depressive 
and anxiety disorders, the present studies were designed to characterize the role of the 
mesocorticolimbic KOR system in stress-induced anxiety-like behavior.  We examined 
startle reactivity in constitutive KOR KO mice (KOR
-/-) and conditional KOs in which 
KORs are selectively deleted in DA-containing neurons (DAT-KOR
lox/lox) following CRF 
and footshock stressors, both of which potentiate startle in WT mice.  KOR
-/- mice had 
similar levels of CRF-enhanced and footshock-potentiated startle compared to littermate 
controls.  In contrast, KOR ablation restricted to DA neurons was sufficient to reduce 
footshock-potentiated startle, although it had no effect on CRF-enhanced startle.  To 
complement studies in DAT-KOR
lox/lox mice, we ablated KORs specifically in the VTA of 
adult KOR
lox/lox mice by infusing a viral vector expressing Cre directly into this region.  
Surprisingly, startle behaviors in viral vector-treated mice did not differ from that of 
controls.  These data provide support for a role of KORs on midbrain DA cells in the 
manifestation of stress, as well as some evidence that disruption of KOR function 
reduces stress-induced anxiety-like behavior, but they raise questions about why the 
various approaches to KOR ablation yield different results.     
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Introduction 
Although stress is a normal response to adverse events, chronic or severe stress is 
implicated in the development of pathological anxiety, depression, and substance abuse 
(Kessler, 1997; Kendler et al., 1999; Volkow and Li, 2004).  Stress induces the release 
of dynorphin (Chavkin et al., 1982; Przewlocki et al., 1987; McLaughlin et al., 2003a), 
and subsequent activation of KORs, which mediate its effects on behavior (Land et al., 
2008; Bruchas et al., 2009).  Thus KOR agonists mimic stress effects (McLaughlin et 
al., 2006a; Schindler et al., 2010; Bruchas et al., 2011) and produce depressive-like 
behaviors (Mague et al., 2003; Todtenkopf et al., 2004; Carlezon et al., 2006).  
Conversely, KOR antagonists reduce effects of stress (Takahashi et al., 1990; 
Menendez et al., 1993a; McLaughlin et al., 2003a; McLaughlin et al., 2006b; Carey et 
al., 2009; Sperling et al., 2010) and are antidepressant- and anxiolytic-like (Mague et 
al., 2003; Beardsley et al., 2005; Knoll et al., 2007; Carr et al., 2010).  Together, these 
data support the hypothesis that KOR activation plays an important role in the etiology 
of stress-induced anxiety and depressive disorders. 
 
KORs are expressed throughout the brain in humans and rodents, particularly in regions 
associated with anxiety and depressive behavior such as the VTA, NAc, AMY, HIP, and 
BNST (Fallon and Leslie, 1986; Mansour et al., 1995; Hurd, 1996; Peckys and 
Landwehrmeyer, 1999; Li et al., 2012).  Notably, KORs expressed on mesocorticolimbic 
DA neurons play a key role in depressive-like behavior in rodents (Newton et al., 2002; 
Shirayama et al., 2004; Ebner et al., 2010; Muschamp et al., 2011b).  KORs are 
expressed on both cell bodies and VTA terminals including those in the NAc (Svingos et 
al., 1999; Svingos et al., 2001) and activation of KORs inhibits neuronal activity  
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(Margolis et al., 2003; Margolis et al., 2006b; Ford et al., 2007).  As such, KORs can 
regulate both the firing rates of DA neurons as well as DA release from terminals in 
efferent targets (Di Chiara and Imperato, 1988; Donzanti et al., 1992; Devine et al., 
1993; Carlezon et al., 2006; Margolis et al., 2006b).  Conversely, KOR antagonists 
increase extracellular concentrations of DA in the NAc (Maisonneuve et al., 1994) and 
direct injection of KOR antagonist into the NAc is sufficient to induce antidepressant-like 
effects (Newton et al., 2002; Shirayama et al., 2004), suggesting these effects are the 
result of alterations in DA function (Nestler and Carlezon, 2006).  Although the VTA 
sends strong projections to the NAc, it also sends projections to areas such as the AMY 
and BNST, which are more directly implicated in fear and anxiety (Davis et al., 1997; 
LeDoux, 2000; Radke, 2009).  While the role of the mesocorticolimbic DA system in 
anxiety-like behavior has not been thoroughly explored, the high comorbidity of 
depressive and anxiety disorders in humans (Kaufman and Charney, 2000; Kessler et 
al., 2003), suggests that this system may be involved in the pathology of both.   
 
Here we examined anxiety-like behavior in two lines of KOR-mutant mice: one lacking 
KORs throughout the brain (KOR
-/-), and one lacking KORs specifically in DA neurons 
(DAT-KOR
lox/lox).  These lines of mice were tested in two paradigms of stress-induced 
behavior—CRF-enhanced startle and footshock-potentiated startle—that were 
previously demonstrated to be sensitive to systemic KOR antagonism (Chapter 2 and 
3).  As a complementary approach to using DAT-KOR
lox/lox mice, we ablated KORs in 
the VTA of adult floxed KOR (KOR
lox/lox) mice by infusing a viral vector expressing Cre 
into this region before footshock-potentiated startle testing.  This approach enabled 
spatial (i.e., VTA) and temporal (i.e., during adulthood) restriction of KOR ablation.  
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Materials and Methods 
Mice: KOR
lox/lox and KOR-deficient mice were generated and genotyped as described 
previously (Chapter 4).  Briefly, we generated mice in which exon 3 of the Oprk1 gene 
was flanked by loxP sites (inGenious Targeting Laboratory [iTL], Ronkonkoma, NY).  
These KOR
lox/lox mice were then bred to Ella-Cre and DAT-Cre expressing mice to 
generate constitutive KOR KOs and conditional KOR KOs in which KORs are ablated 
from DA neurons respectively.  Experiments were performed in 8-16-week-old male 
mice backcrossed for 7 generations to C57BL/6J mice (Jackson Laboratories, Bar 
Harbor, ME).  Mice were maintained on a 12:12-h light-dark cycle (0700h lights on) with 
ad libitum food and water available except during testing.  Experiments were conducted 
during the light phase of the daily cycle.  Experimental protocols were approved by the 
Institutional Animal Care and Use Committee of McLean Hospital and in accordance 
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals  
(National Academies Press, Washington D.C., USA, 2011) .  
 
Drugs: JDTic was synthesized at Research Triangle Institute (Research Triangle Park, 
NC).  Rat/human CRF was purchased from American Peptide (Sunnyvale, CA).  JDTic 
was dissolved in 0.9% saline and administered IP at 10 mL/kg.  CRF was dissolved in 
aCSF (Harvard Apparatus, Holliston, MA) and infused in a volume of 1.0 µL. 
 
Stereotaxic surgery and microinfusions: Mice were anesthetized with ketamine/xylazine 
(100 mg/kg, 12.5 mg/kg, IP) and placed in a stereotaxic instrument (David Kopf 
Instruments, Tujunga, CA) with zygoma ear cups in order to prevent damage to the ear 
drums.  For each mouse, a stainless steel guide cannula (26-gauge, Plastics One,  
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Roanoke, VA) with a dummy stylet extending 1.5 mm beyond the end was lowered into 
the right lateral ventricle at the following coordinates, relative to bregma: anteroposterior 
= -0.2 mm, mediolateral = 1.0 mm, and lowered -2.4 mm ventral to the skull (Paxinos 
and Franklin, 2001).  Non-acrylic cement (Geristore, Den-mat, Santa Maria, CA) 
permanently secured the cannula to the skull.  The mice were allowed to recover for 5-7 
days before testing.  Drugs were microinfused by removing the dummy stylet and 
replacing it with a 33-gauge infusion stylet (Plastics One) attached to a Hamilton 
microsyringe (10 µl) by polyethylene tubing.  ICV infusions of either vehicle (aCSF) or 
CRF (1.0 µg) were performed over a 2-min period at a rate of 0.5 µL/min, with an 
additional 2 min of diffusion time before the infusion stylet was removed and the dummy 
stylet was replaced.  During the infusion mice were placed in clean and empty mouse 
cages divided in half and were free to move.  After the infusion, mice were immediately 
placed in the startle chambers. 
 
Viral-mediated gene transfer was used in some mice to ablate KORs within the VTA or 
adult mice.  We used an adeno-associated virus (AAV) because it produces stable gene 
expression without notable toxicity (Ahmed et al., 2004); our AAV-GFP (control) and 
AAV-Cre/GFP vectors have been described previously (Berton et al., 2006; Graham et 
al., 2007) and were obtained from S.J. Russo, Mt. Sinai School of Medicine.  KOR
lox/lox 
mice received bilateral injections of AAV-GFP or AAV-Cre/GFP into the VTA at the 
following coordinates, relative to bregma: anteroposterior = -3.3 mm, mediolateral = 
±0.5 mm, and lowered 4.1 mm ventral to the skull (Paxinos and Franklin, 2001) through 
a 27-gauge hypodermic tube attached to a Hamilton syringe (10 µl) by polyethylene 
tubing.  Injections of 0.3 µL per side were made over a 3-min period.  Injectors were left  
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in place for an additional 5 min before being slowly removed.  The incision was closed 
with sutures. 
 
Startle testing:  The equipment and procedures used here were similar to those 
described in Chapters 2 and 3.  Briefly, acoustic startle data were collected by 
measuring the amplitude of the startle reflex in response to white noise bursts of various 
intensities using the Med Associates Inc. (St. Albans, VT) Startle Reflex System and 
Advanced Startle software program.  Mice were placed into 8.5 x 7 x 7 cm Plexiglas 
holders with steel rod floor bars attached to a load cell platform contained within a 40 x 
64 x 42 cm sound-attenuating chamber.  The load cell transduces movement into an 
electrical output that is amplified and digitized into arbitrary units by an analog-to-digital 
converter interfaced to a computer.  Startle amplitude was defined as the maximum 
peak-to-peak voltage occurring within the first 100 ms after the onset of the startle 
stimulus.  An audio stimulator generated 50 msec startle stimuli (1-32 kHz white noise, 
1 msec rise-decay) which were delivered through high-frequency speakers located 4 cm 
behind the cages.  The intensities of the startle stimuli were calibrated before use using 
customized software.  All tests were conducted in darkness.    
CRF-enhanced startle: Following recovery from surgery, mice were given a habituation 
session to acclimate them to the testing chamber.  The habituation session consisted of 
a 5-min acclimation period followed by startle stimuli at 3 dB levels (20 each at 80, 90 
and 100 dB) presented in a pseudo-random order with an ISI of 30 sec.  Two days later, 
mice were infused with CRF (1.0 µg, ICV) and immediately placed in the startle 
chambers for a 5-min acclimation period followed by a 99-min startle test of 198 startle 
stimuli (80, 90, or 100 dB presented in a pseudo-random order with an ISI of 30 sec).   
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KOR
-/- mice used to examine the effects of a KOR antagonist on CRF-enhanced startle 
received JDTic (30 mg/kg, IP) or vehicle (0.9% saline) immediately following surgery, 
and 7 d later were tested as above after administration of 1.0 µg CRF (ICV).  The 
following day, mice were given another baseline startle session and 24 hr later were 
retested after administration of aCSF.  
 
Footshock-potentiated startle: The footshock-potentiated startle test procedure was 
based on a prior report (Risbrough et al., 2009), with minor adaptations to the sound 
intensity (dB) levels, as described in Chapter 3.  Briefly, mice were initially given a 
habituation startle session consisting of a 5-min acclimation period followed by 102 
startle stimuli, 34 each at 80, 90, and 100 dB which occurred 24 hr before the test 
session.  During the test session, mice received a 5-min acclimation period followed by 
27 startle stimuli, 9 each at 80, 90, and 100 dB in a pseudo-random order with a 15 sec 
ISI to assess their baseline startle (startle test).  Mice then received three sessions of 5 
footshocks (shock session).  The footshock intensity increased between sessions (i.e., 
0.2 mA during session 1; 0.4 mA during session 2; and 0.8 mA during session 3).  The 
average ISI between footshocks was 60 sec (30-90 sec).  Mice received an additional 
startle test after each shock session to assess the magnitude of startle potentiation 
elicited by shock exposure.  The following day, mice were given a final startle test to 
probe context conditioning in the absence of footshock.  Mice that received viral vector 
infusions were tested in footshock-potentiated startle 30 d after surgery. 
 
qPCR: We performed qPCR on cDNA synthesized from tissue punches of the VTA 30 d 
following intra-VTA infusion of AAV-Cre/GFP or AAV-GFP vector.  Bilateral 1-mm
3  
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punches of VTA tissue were taken on a cryostat and kept on dry ice.  RNA was 
extracted using PureLink RNA Mini Kit (Invitrogen).  RNA quality and quantity were 
assessed using an RNA 6000 Nano Chip (Agilent, Santa Clara, CA) on an Agilent 
Bioanalyzer 2100.  RNA integrity number (RIN) exceeded 7 for all samples, indicating 
high quality.  500 ng of total RNA was used to synthesize cDNA using iScript cDNA 
Synthesis Kit (BioRad) in a Thermo Hybaid iCycler (Thermo Scientific).  Primers specific 
for KOR (Oprk1; 5-TCCTTGGAGGCACCAAAGTCAGGG-3, and 5-
TGGTGATGCGGCGGAGATTTCG-3), DAT (Slc6a3; 5-
AATGCCCTGGGCTGGATCATTGC-3 and 5-AATGGCGCAGCGTGAATTGGC-3), and 
integral membrane protein 2B (Itm2b; 5- CGCATCGAGAACGTGGACAACC-3 and 5- 
GTGGCATTGAATTCCTCCCCACG-3) genes were used.  Melt curve analysis and 
polyacrylamide gel electrophoresis confirmed the specificity of the primers.  The 
amplicon bp lengths are 237 (KOR), 178 (DAT), and 218 (ITM2B). 
 
The qPCR was run using the iQ SybrGreen Supermix (BioRad).  The reaction was 
carried out on a MyiQ Single Color Real-Time PCR Detection System (BioRad) in a 
volume of 20 µl, with 2.0 µL of 3 µM forward and reverse primers, 2.0 µL Rnase/Dnase 
free H2O, 10 µL SybrGreen Supermix, and 4.0 µL cDNA sample diluted 1:10.  PCR 
cycling conditions were 95
°C for 5 min; 40 cycles at 94
°C for 15 sec, 60
°C for 15 sec, 
72
°C for 15 sec.  Data were collected at a read temperature of 82
°C for 15 sec.  MyiQ 
Optical System Software (BioRad) was used to analyze the data, and reported values 
for KOR and DAT were normalized to ITM2B, which did not show group differences in 
qPCR analyses.  All samples were run in triplicate.   
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Histological verification: Mice were overdosed with pentobarbital (130 mg/kg, IP) and 
transcardially perfused with 0.9% saline (20 mL) followed by 4% paraformaldehyde in 
0.1M PBS (60 mL).  Brains were removed and postfixed overnight in 4% 
paraformaldehyde, and then cryoprotected in 30% sucrose/0.1M PBS for 24 h.  Brains 
were sectioned at 30 µm on a freezing microtome and collected in 0.1M phosphate 
buffer.  Sections were mounted on gelatin-coated slides (Fisher Scientific, Pittsburg, 
PA) and stained with 0.1% cresyl violet.  For AAV infused brains, the region of GFP 
expression was determined with a fluorescence microscope.  Mice with incorrect 
placements or signs of infection were excluded from analysis. 
Data analysis:  The effect of genotype on CRF-enhanced startle was analyzed with a 3-
way (genotype x CRF x dB level) ANOVA with repeated measures (dB and CRF).  
Footshock-potentiated startle was analyzed by 3-way ANOVA (genotype x block x dB 
level) in shocked mice.  Significant interactions in the ANOVAs were further analyzed 
using Bonferroni post hoc tests. 
 
Results 
Following recovery from surgery, mice lacking KORs constitutively (KOR
-/-) or 
specifically in DA neurons (DAT-KOR
lox/lox) were tested in CRF-enhanced startle.  
Baseline startle amplitudes did not differ between KOR
-/- mice and KOR
+/+ littermate 
controls (main effect of dB, F[2,56]=40.97, P˂0.0001; Fig. 5.1A).  CRF-infusion 
significantly increased startle reactivity in both genotypes (F[1,28]=34.87, P˂0.0001) 
and there was not a genotype x CRF interaction observed, indicating that the mutant 
mice displayed normal CRF-enhanced startle (Fig. 5.1B).  Likewise, baseline startle 
responding was dependent on dB level (F[2,70]=45.00, P˂0.0001), but did not differ  
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between DAT-KOR
lox/lox and littermate controls (Fig. 5.1C).  As was the case with the 
constitutive mutants, CRF significantly increased startle responding (F[1,35]=29.22, 
P˂0.0001) that was not dependent on genotype in the conditional mutant line (Fig. 
5.1D), although KOR ablation did tend to cause nominal reductions in CRF effects 
(F[1,35]=1.90,NS). 
 
To determine if the ability of JDTic to block CRF-enhanced startle (Chapter 2) could be 
due to off-target effects unrelated to KOR blockade, KOR
-/- mice were pretreated with 
the drug (30 mg/kg, IP) 7 days before a CRF-enhanced startle test, to match the time 
course of previous work (see Chapter 2).  The following day they were given another 
baseline startle test session and 24 hr later were infused with aCSF and tested again.  
Vehicle- and JDTic-treated groups did not differ in baseline startle responding following 
IP treatment (i.e., before CRF treatment) (main effect of dB, F[2,38]=7.28, P˂0.01; Fig. 
5.1E).  In the test sessions, CRF significantly increased the acoustic startle reflex 
independent of JDTic treatment (F[1,19]=14.15, P˂0.001; Fig. 5.1F), suggesting that 
JDTic effects observed previously were the result of on-target (KOR-specific 
antagonism) effects of the drug. 
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Figure 5.1 Effect of KOR ablation on CRF-enhanced startle.  During habituation 
baseline startle reactivity was compared.  A. No genotype effects were observed 
between KOR
-/- and littermate controls (KOR
+/+).  B. On the test day, mice received CRF 
(1.0 µg) or vehicle and were immediately placed in the startle apparatus. Constitutive 
KOR ablation did not affect CRF-induced increases in startle reactivity (n=14-16).  C. 
DAT-KOR
lox/lox mice had equivalent levels of startle reactivity as KOR
lox/lox controls 
(n=17-20).  D. Ablation of KORs from DA neurons nominally attenuated, but did not 
significantly reduce CRF-enhanced startle.  E. Baseline startle reactivity was not 
affected by JDTic (30 mg/kg, IP) pretreatment in KOR
-/- mice (n=10-11).  F. JDTic did 
not significantly alter CRF-induced increases in startle amplitude at any dB level in 
KOR
-/- mice.  Data were analyzed by ANOVA. 
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Figure 5.1 (Continued) Effect of KOR ablation on CRF-enhanced startle 
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The two lines of KO mice were next tested in footshock-potentiated startle, a paradigm 
in which systemic KOR antagonism was also found to have an anxiolytic-like effect 
(Chapter 3).  Consistent with the results reported in Fig. 5.1 above, KOR
+/+ and KOR
-/- 
did not differ in baseline startle across the 3 startle intensities used (80, 90, and 100) 
immediately preceding footshock presentation (main effect of dB, F[2,36]=15.89, 
P˂0.0001; Fig. 5.2A).  After this baseline session, mice received footshocks of 
increasing intensity (0.2, 0.4 and 0.8 mA) each followed by a startle session that was 
compared to the baseline session to calculate percent potentiation.  Both genotypes 
showed similar reactivity during footshock presentation (Table 1), with increasing 
footshock amplitude increasing this response (F[2,46]=132.03, P˂0.0001).  Footshock-
potentiated startle depended on block (F[2,46]=6.51, P˂0.01), but did not differ between 
KOR
-/- mice and littermate controls (Fig. 5.2D).  When mice were re-tested in the 
context 24 hr later, they still displayed increased startle reactivity above baseline and 
genotype did not affect this response (Fig. 5.2G).   
 
DAT-KOR
lox/lox and KOR
lox/lox controls began the test session with similar baseline startle 
responding (main effect of dB, F[2,36]=15.89, P˂0.0001; Fig. 5.2B).  Likewise, they 
were not significantly different in their response during presentation of footshock (Table 
1).  However, in the test session, footshock-potentiated startle depended on a genotype 
x block interaction (F[2,36]=9.72, P˂0.05).  Post hoc tests revealed that DAT-KOR
lox/lox 
mice had significantly less footshock-potentiated startle following 0.2 mA and 0.4 mA 
footshock blocks compared to littermate controls (P’s˂0.05), but were virtually identical 
after 0.8 mA footshocks (Fig. 5.2E).  A follow-up contextual conditioning test conducted 
24 hr later did not reveal any differences between DAT-KOR
lox/lox mice and controls  
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(Fig. 5.2H) indicating similar levels of anxiety-like behavior when returned to the 
footshock context.  Mice expressing DAT-Cre, but lacking floxed KOR alleles (DAT-
KOR
+/+) mice and controls (KOR
+/+) mice were tested to ensure that decreases in 
footshock-potentiated startle were not simply due to Cre expression alone.  DAT-Cre did 
not affect baseline startle (main effect of dB, F[2,40]=49.59, P˂0.0001; Fig. 5.2C) or 
footshock reactivity (Table 1).  Analysis of potentiation following footshock did not 
reveal any significant differences between DAT-KOR
+/+ mice and KOR
+/+ littermate 
controls (Fig. 5.2F).  Further, no differences were observed during the context test 24 hr 
after footshock-potentiated startle (Fig. 5.2I). 
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Figure 5.2 Effect of KOR ablation on footshock-potentiated startle.  A-C.  Baseline 
startle reactivity in mutant and control mice revealed no genotype differences.  D. 
Constitutive KOR deletion did not affect footshock-potentiated startle (n=8-9).  E. DAT-
KOR
lox/lox mice had significantly reduced potentiation following 0.2 and 0.4 mA blocks of 
footshock compared to KOR
lox/lox controls (n=10).  F. Reductions in footshock-
potentiated startle observed in DAT-KOR
lox/lox mice were not due to DAT-Cre expression 
alone (n=11).  G-I. When mutant mice were re-tested in the footshock context 24 hr 
later, they were indistinguishable from littermate controls.  Data were analyzed by 
ANOVA followed by Bonferroni post test as appropriate.  * p<0.05  
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Figure 5.2 (Continued) Effect of KOR ablation on footshock-potentiated startle 
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Table 5.1 Footshock reactivity in KOR-deficient mice 
           
                       
         
KOR
lox/lox 
 
KOR
+/+ 
                        m
A  KOR
+/+     KOR
-/-     DATCre-     DATCre+     DATCre-     DATCre+ 
                        0.2  7.23 ± 1.13 
 
7.23 ± 1.19 
 
7.75 ± 1.00 
 
6.27 ± 1.18 
 
8.69 ± 1.52 
 
8.52 ± 1.39 
                        0.4  16.99 ± 0.65 
 
14.37 ± 2.15 
 
16.49 ± 0.78 
 
15.14 ± 1.13 
 
16.75 ± 0.71 
 
16.44 ± 0.92 
                        0.8  17.94 ± 0.57 
 
18.04 ± 0.57 
 
17.74 ± 0.56 
 
17.30 ± 0.70 
 
17.69 ± 0.69 
 
16.08 ± 0.84 
                                   
                       
Measures reported as mean ± SEM of average reactivity during the presentation of footshock.  No 
significant effects of genotype were observed.  
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To complement the conditional KO studies, AAV-Cre/GFP was used to ablate KORs 
from the VTA of KOR
lox/lox.  This technique allows for spatial- (i.e., within VTA) and 
temporal- (i.e., during adulthood) specific ablation of KORs in the same system affected 
in the DAT-KOR
lox/lox line of mice.  GFP expression was localized to the VTA when 
examined 30 d after AAV infusion—the time point at which our behavioral studies were 
conducted (Fig. 5.3A).  Further, mRNA levels of the KOR gene were significantly 
reduced in mice receiving Cre vector compared to GFP vector controls (P˂0.05) 
whereas DAT expression was unaffected, suggesting specific Cre-induced reductions 
(Fig. 5.3B&C).  Cre expression did not affect baseline startle (main effect of dB, 
F[2,42]=34.73, P˂0.0001; Fig. 5.3D) or shock reactivity (Table 2).  Footshock-
potentiated startle was not significantly affected by Cre-mediated KOR gene deletion in 
the VTA (Fig. 5.3E) and mice did not differ when re-tested 24 hr later in the footshock 
context (Fig. 5.3F). 
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Figure 5.3 Effect of intra-VTA AAV-Cre/GFP on footshock-potentiated startle in 
KOR
lox/lox mice.  A. AAV-Cre/GFP or control vector (AAV-GFP) was infused into the 
VTA of adult KOR
lox/lox mice and GFP fluorescence was visualized 30 d later to confirm 
injection site.  B. VTA punches were taken from untested AAV infused mice 30 d 
following infusion and processed for qPCR.  mRNA levels of the KOR gene (OPRK1) 
were significantly reduced in KOR
lox/lox mice receiving AAV-Cre/GFP compared to GFP 
control vector.  C. Levels of DAT (Slc6a3) mRNA were equivalent between groups.  D. 
In footshock-potentiated startle experiments, mice were infused with viral vector and 
allowed to recover for 28 d.  Baseline startle reactivity was tested on day 29 and did not 
differ between AAV-Cre/GFP and AAV-GFP infused mice (n=11-12).  E,F. Mice infused 
with AAV-Cre/GFP were not significantly different from controls in footshock-potentiated 
startle 30 d after surgery or when re-tested 24 hr following footshock.  Data were 
analyzed by ANOVA or Student’s  t-test as appropriate. 
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Figure 5.3 (Continued) Effect of intra-VTA AAV-Cre/GFP on footshock-potentiated 
startle in KOR
lox/lox mice. 
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Table 5.2 Footshock reactivity in 
AAV-infused KOR
lox/lox mice 
     
mA  AAV-GFP  AAV-Cre/GFP 
     
0.2  8.67 ± 1.40  8.83 ± 1.99 
     
0.4  15.65 ± 1.75  14.71 ± 2.53 
     
0.8  16.38 ± 0.68  18.32 ± 1.85 
        
     
Measures reported as mean ± SEM of 
average reactivity during the presentation of 
footshock.  No significant effects of viral 
vector were observed.  
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Discussion 
Ablation of KORs specifically in DA neurons produced anxiolytic-like effects in 
footshock-potentiated startle, but similar levels of potentiation following ICV CRF 
compared to controls.  Neither startle measure was affected by constitutive KOR 
deletion, suggesting greater compensation in KOR function during development in these 
KOs compared to conditional KOs.  Ablation of KORs in the VTA using AAV-Cre/GFP 
viral vector microinfused into KOR
lox/lox mice was not sufficient to reproduce the 
attenuation of footshock-potentiated startle observed in DAT-KOR
lox/lox mice.  These 
findings provide support for a role of mesolimbic KORs in the etiology of stress-induced 
anxiety responses under some—but not all—experimental conditions. 
 
We first investigated the role of KOR function in the mutant mice following infusion of 
the anxiogenic peptide CRF.  Neither constitutive nor conditional ablation of KORs 
affected the ability of CRF to enhance startle.  This was unexpected given our previous 
data demonstrating a significant attenuation of CRF-enhanced startle by systemic 
administration of the long-lasting and highly selective KOR antagonist JDTic (Chapter 
2).  There was a nominal reduction of CRF effects in the DAT-KOR
lox/lox mice at the 
highest startle intensities.  This effect was not statistically significant despite the use of 
comparable group sizes as in the JDTic studies, which might indicate that the effects of 
the mutation are weaker than those of pharmacological blockade, or that JDTic effects 
are due to actions at receptors other than KORs.  To determine if the effects of JDTic in 
WT mice might be due to off-target effects unrelated to KORs, we examined the effects 
of the drug on CRF-enhanced startle in KOR
-/- mice.  Importantly, JDTic failed to affect 
CRF-enhanced startle in KOR
-/- mice, indicating that its ability to reduce CRF effects in  
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WT mice is due to specific blockade of KORs.  Therefore, the dissociation between 
genetic and drug studies might be explained by differences between the effects of KOR 
ablation throughout development and acute pharmacological KOR blockade during 
adulthood.  As one example, the neural systems that regulate anxiety-like behaviors 
(Lin et al., 2006; Marchant et al., 2007; Durant et al., 2010) may undergo developmental 
adaptations that can compensate for KOR ablation.  Hence, behavioral phenotypes that 
are seen with pharmacological blockade in a normally-developing animal may be 
masked in constitutive KOR mutant mice. 
 
Although KOR
-/- mice were indistinguishable from KOR
+/+ controls in footshock-
potentiated startle, DAT-KOR
lox/lox mice demonstrated reduced potentiation following 
footshock compared to KOR
lox/lox controls.  This reduction was significant proceeding 
the first two blocks of footshock, but not in the final block.  In our study design, the 
footshock amplitude in the test progressively increases from 0.2 to 0.4 to 0.8 mA.  Thus 
KOR ablation from DA neurons was sufficient to reduce potentiation of startle in 
response to mild-to-moderate footshock stress, but not effective at the highest intensity 
of footshock tested.  This may explain, at least in part, why startle responses in DAT-
KOR
lox/lox mice were not significantly different from those of controls in the CRF-
enhanced startle studies.  The intensity of stress following 1.0 µg CRF infusion may be 
greater than or at least equivalent to the stressful effects of 0.8 mA footshocks that 
likewise were not augmented in DAT-KOR
lox/lox mice.  Potential evidence for this 
stressor ceiling effect comes from c-Fos activation studies in Chapters 2 and 3.  While 
1.0 µg of CRF robustly increased c-Fos cell counts in all regions analyzed, a footshock 
session using 0.2 and 0.4 mA footshocks failed to do so.  Further experiments in which  
177 
 
DAT-KOR
lox/lox mice are infused with a lower dose of CRF (e.g. 0.5 µg) may reveal 
whether this less stressful condition can be overcome in conditional KO mice.  Our c-
Fos expression data and others (Bittencourt and Sawchenko, 2000; Warnock et al., 
2009) also suggest that CRF given ICV is able to activate CRF-Rs throughout the brain.  
Thus if anxiolytic-like effects of KOR ablation in DA neurons were the result of 
decreases in CRF release and CRF-R activation, central infusions of CRF would negate 
these effects by diffusing to and directly activating these receptors.  If this hypothesis is 
true, we may expect DAT-KOR
lox/lox mice to have decreases in mild footshock stress-
induced CRF release in brain regions such as the BNST—into which direct infusions of 
CRF mimic ICV effects (Liang et al., 1992) —compared to KOR
lox/lox controls. 
 
As an alternative to using a breeding strategy to ablate KORs in DAT-expressing 
neurons—which offers spatial but not temporal specificity—we used an AAV-Cre/GFP 
viral vector to specifically ablate KORs in the VTA of adult KOR
lox/lox mice.  This 
approach ensures normal KOR expression during development and thus eliminates 
compensatory changes that may occur when KORs are ablated during this period.  
Infusions of the Cre-expressing vector did not have a significant effect on footshock-
potentiated startle although they produced a slight but nonsignificant reduction following 
the first block of shock, reminiscent of the effect seen in DAT-KOR
lox/lox mice.  There are 
several possibilities as to why Cre viral vector manipulations do not replicate findings in 
DAT-KOR
lox/lox mice.  One possibility is that whereas KOR ablation in DAT-KOR
lox/lox 
mice is restricted to DAT-expressing cells, KOR ablation produced by the Cre vector 
occurs in all infected neurons, regardless of type.  Although the VTA predominantly 
consists of DA neurons, there are also populations of GABAergic and glutamatergic  
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neurons within this region (Margolis et al., 2006a), any of which may express KORs.  
Further, these non-DA VTA cells typically project to the same structures as DA neurons 
(Swanson, 1982).  Because KOR
lox/lox mice were used in combination with a viral vector 
that infects all cell types, KOR expression is ablated at the injection site non-specifically; 
considering that KORs are in presynaptic terminals where they can inhibit GABA and 
glutamate release (Hjelmstad and Fields, 2003; Li et al., 2012), ablation of KORs in both 
DA and non-DA neurons might have counteracting effects.  Use of electrophysiological 
and optogenetic approaches targeting non-DA cells in the VTA in future studies may 
elucidate whether KOR activation in this population opposes KOR activation effects in 
DA cells.  A second possibility is that although KOR mRNA is significantly reduced 30 d 
following Cre infusion, receptors produced before viral vector infusion may still persist at 
the cell membrane.  Studies using a nonreversible KOR agonist suggest that KOR 
turnover requires at least 14 days (McLaughlin et al., 2004).  As proteins are capable of 
lasting for weeks before degradation (Creighton, 1993), it is possible that a reserve of 
KORs at insertion sites may be sufficient to repopulate through the time of testing.  This 
possibility can be addressed in future studies by determining whether binding of 
[
3H]U69,593, a tritiated version of a highly selective KOR agonist is lower in the VTA of 
AAV-Cre/GFP viral vector infused mice compared to AAV-GFP viral vector controls 30 d 
following infusion.  A third possibility is that attenuation of responding may have been 
missed because of a reduced range of potentiation.  Mice infused with control virus 
displayed only modest potentiation following the 2
nd and 3
rd block of footshock (startle 
increases of less than 30% over baseline), in contrast to earlier non-virus infused mice 
whose potentiation was over 50% and as high as 100%.  This reduced potentiation 
might be the result of increases in baseline startle in mice receiving VTA infusions; in  
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fact, we found that startle reactivity was significantly higher in control GFP vector mice 
compared to no-surgery group controls from the studies presented here (data not 
shown).  Because the startle response was not quantified before surgery, it is unclear 
whether these effects were due to microinfusion or strain differences.  Surgery may also 
have disrupted learning processes that account for the minimal conditioning responses.  
While VTA lesions do not affect baseline startle, they have been shown to disrupt 
increases in startle to fear-eliciting cues (Borowski and Kokkinidis, 1996).  Damage to 
the VTA during surgery by the injection cannula or the hydrolic pressure of the infusion 
may account for the nominal increases in startle following footshock in both control and 
experimental groups.  This possibility could be addressed in future studies by using a 
delivery system (such as pulled-glass micropipettes) with a smaller diameter together 
with slower infusion volumes and/or rates.  Yet another possibility is that the effects 
observed in the DAT-KOR
lox/lox conditional KO mice may be due to DAT-expressing 
neurons outside of the VTA, for example in the SN.  Further work using Cre viral vectors 
to ablate KORs in non-VTA DA populations may clarify whether KORs in these regions 
are necessary for stress-induced increases in anxiety-like behavior.  Finally, the effects 
observed in the DAT-KOR
lox/lox conditional KO mice may be unrelated to a lack of KOR 
signaling in adulthood, and instead be a product of developmental changes that occur 
due to the absence of KORs in DA neurons.  In this scenario, ablating KORs from the 
VTA in adulthood would have no effect since development occurred normally.  
Experiments in which VTA KORs are rescued during adulthood in DAT-KOR
lox/lox mice 
may help to determine if KOR disruption alone is sufficient to attenuate footshock-
effects. 
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In the present studies, mice lacking KORs in midbrain DA neurons throughout their life 
exhibited significant decreases in footshock-potentiated startle.  This work confirms 
KOR antagonist and dynorphin KO mouse studies that indicate a role for KOR signaling 
in stress-sensitized behaviors (Knoll et al., 2007; Wittmann et al., 2009; Carr and Lucki, 
2010) and implicates KORs on DA neurons in these effects.  The effect was surprisingly 
weak, considering the effects of the KOR agonist JDTic, and not recapitulated by viral 
vector-induced ablation of KORs within the same region.  Although the viral vector 
studies have numerous important qualifications and limitations, the pattern of results 
observed raises the possibility that KOR blockade in regions not studied in this project 
also play an important role in regulating signs of anxiety that are reflected by the ASR.  
Although beyond the scope of this project, candidate regions for future studies of KOR 
ablation include the AMY (Knoll et al., 2011), BNST (Li et al., 2012), and PFC (Margolis 
et al., 2006b).  In addition, future studies to delineate the specific dopaminergic 
projections augmented by KOR activation may also provide valuable insight into the 
specific function of neural circuits in anxiety-like states. 
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Chapter 6 
 
Conclusions 
 
The underlying neurobiological mechanisms of anxiety disorders are not understood.   
Severe or prolonged stress often coincides with the development of these disorders 
(Kessler, 1997; Heim and Nemeroff, 1999), suggesting that CRF, a key mediator of 
stress effects in the brain, may mediate these responses.  Indeed, dysfunction of the 
CRF system is thought to underlie at least some forms of pathological anxiety 
(Nemeroff, 1992; Owens et al., 1993; De Souza, 1995).  The KOR system has also 
been implicated in the negative consequences of stress and CRF (Pliakas et al., 2001; 
Newton et al., 2002; Mague et al., 2003; McLaughlin et al., 2003a; McLaughlin et al., 
2006b; Land et al., 2008; Carey et al., 2009; Land et al., 2009) making it a promising 
target for therapeutic intervention.  Previous work has demonstrated a role for KORs in 
the mesocorticolimbic DA system in depressive-like behavior (Newton et al., 2002; 
Shirayama et al., 2004; Muschamp et al., 2011b), and because anxiety disorders are 
highly comorbid with depression (Kaufman and Charney, 2000; Kessler et al., 2003), we 
hypothesized that this system may be an important site of KOR activation in the 
development of anxiety-like behavior as well.  My dissertation work investigated the 
general role of KORs in mouse models of stress-induced behavior and tested the 
hypothesis that KORs within the mesocorticolimbic DA system play a particularly 
important role in regulating anxiety-related behavior.    
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1. Summary of findings 
CRF plays a major role in the regulation of the stress response and reproduces the 
behavioral, hormonal, and endocrine consequences of stress.  Disrupting KOR function 
can block effects of CRF, suggesting KOR activation plays an important role in stress-
induced effects (Land et al., 2008; Bruchas et al., 2009).  I first sought to determine if 
KOR antagonism could block anxiety-like effects of CRF by examining enhancement of 
the ASR following CRF infusion.  I found that central infusions of CRF dose-dependently 
enhanced the acoustic startle response in mice, whereas, pretreatment with the KOR 
antagonist JDTic significantly attenuated this effect.  This was not due to non-specific 
reductions in the capacity to respond, because JDTic treated mice had equivalent levels 
of baseline startle as controls.  To identify brain regions that may be involved in the 
effects of JDTic, I quantified c-Fos expression following CRF infusion within areas 
implicated in depressive and anxiety-like behaviors.  While c-Fos immunoreactivity in 
the dDG was decreased in JDTic mice regardless of whether mice received infusions of 
CRF or vehicle, it was specifically reduced in the VTA of JDTic mice following CRF.  
This reduction was due, at least in part, to decreased activation of DA cells in the VTA: 
the percent of co-labeled c-Fos and TH cells was significantly lower following JDTic 
than following vehicle.  All of the other regions studied had increased c-Fos expression 
in CRF compared to aCSF-infused brains, but there were no further effects of JDTic.  
These studies suggest that KORs may alter the function of the mesocorticolimbic 
system to produce beneficial effects on anxiety-like behavior.   
 
The ASR can also be potentiated by brief presentation of mild footshock immediately 
before testing (Davis, 1989).  This behavior likely depends on CRF function, because  
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mice lacking CRF receptors lack footshock-potentiated startle (Risbrough et al., 2009).  
To determine if KOR antagonism would also block footshock effects on startle, I 
systemically administered JDTic proceeding footshock-potentiated startle testing.  As 
was the case in our CRF studies, JDTic produced anxiolytic-like effects in footshock-
potentiated startle without affecting baseline reactivity.  I again performed a 
histochemical analysis of c-Fos immunoreactivity to compare brain activation patterns 
between JDTic-treated mice subjected to footshock and controls.  Footshock induced 
an increase in c-Fos expression in the PVN of control mice; however, no differences 
were observed in any region of the HIP or VTA, areas in which footshock-induced 
increases in c-Fos expression have been reported (Smith et al., 1992; Funk et al., 2003; 
Funk et al., 2006).  Thus I could not establish any associations between behavioral 
endpoints and neural activation in the brain regions studied.  Nevertheless, my 
behavioral data confirm that KOR antagonists can produce anxiolytic-like effects 
following a single injection.  This profile may make them attractive treatments for anxiety 
disorders or preventing the effects of stress when exposure can be predicted.  
 
To complement the work with KOR antagonists, we developed a line of floxed KOR 
(KOR
lox/lox) mice to enable spatial and, ultimately, temporal control of receptor ablation.  
These floxed mice were bred to two Cre-expressing mouse lines (Ella-Cre and DAT-
Cre) to generate constitutive (KOR
-/-) mutants and conditional (DAT-KOR
lox/lox) mutants 
in which KORs are ablated in DA neurons.  While other lines of KOR
-/- mice exist, to our 
knowledge this is the first thorough characterization of a floxed KOR mutant and lines 
derived from such.  Radioligand studies quantifying tritiated KOR agonist binding in 
mutant mouse brains confirmed the absence of functional KORs in KOR
-/- mice and  
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reductions in functional KORs in the VTA and its efferents in DAT-KOR
lox/lox mice.  
Further, brain region-specific qPCR confirmed the absence of KOR mRNA throughout 
the brain in KOR
-/- mice, and reductions within the midbrain (comprising VTA and SNc) 
of DAT-KOR
lox/lox mice.  Neither line was significantly different than controls in metrics 
quantifying weight gain, vision, hearing, or locomotor activity.  Considering previous 
work demonstrating a role for KORs in anxiety-like behavior both here (Chapters 2 and 
3) and by others (Knoll et al., 2007; Bruchas et al., 2009; Wiley et al., 2009; Wittmann et 
al., 2009; Knoll et al., 2011), we next subjected our KOR mutant mice to tests of 
exploratory anxiety-like behavior.  Whereas KOR
-/- mice behaved as WTs in the open 
field, DAT-KOR
lox/lox mice displayed an anxiolytic-like phenotype, spending significantly 
more time than controls in the center area of the enclosure in the later parts of the test 
session.  A separate cohort of these mice was then tested in the light/dark box and had 
significantly shorter latencies to enter the light compartment, although this same cohort 
behaved normally when subsequently tested in the EPM.  These effects are broadly 
consistent with previously reported anxiolytic-like effects of KOR antagonists, 
suggesting that pharmacological and genetic disruption of KOR function can produce 
similar phenotypes under some conditions. 
 
We also investigated the effects of cocaine-induced locomotor sensitization in our 
mutant lines, to determine if they would replicate prior work demonstrating a pre-
sensitized phenotype in a different line of KOR
-/- mice (Chefer et al., 2005).  We treated 
mice with IP injections of cocaine daily from days 1-5 and then again on day 8.  
Surprisingly, our line of KOR
-/- mice had equivalent sensitization to KOR
+/+ littermates.  
The inconsistency of these data with findings reported by other groups may be due to  
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strain differences or flanking gene effects (see Chapter 5 discussion).  However, DAT-
KOR
lox/lox mice appeared similar to controls after the first injection of cocaine, but in 
subsequent days displayed a heightened response to cocaine effects on locomotor 
activity and were significantly different from controls on day 8 of testing.  Additional 
experiments indicated that this was not due to non-specific effects of Cre expression, 
because the behavior of mice expressing Cre but not the floxed KOR gene did not differ 
from that of controls.  To complement these studies evaluating sensitivity to the 
stimulant effects of cocaine, we performed CPP studies to determine if DAT-KOR
lox/lox 
mice would also have increased sensitivity to the rewarding effects of cocaine.  Neither 
DAT-KOR
lox/lox mice nor KOR
lox/lox controls developed CPPs at a sub-threshold dose of 
cocaine, and both developed equivalent CPPs at an effective dose of the drug (Horger 
et al., 1999).  These data are consistent with other work showing no differences in 
cocaine-induced CPP in either KOR or dynorphin KO mice compared to controls 
(McLaughlin et al., 2003a; McLaughlin et al., 2006a; Redila and Chavkin, 2008).  
Although sensitization to the locomotor-stimulating effects of drugs such as cocaine in 
rodents is sometimes used as a proxy for drug reward or drug seeking—an approach 
fraught with conceptual and practical flaws (Sutton and Self, 2000; Ahmed and Cador, 
2006)—the differential effects seen here are likely due to differences in neural 
processes underlying each behavior.  Additionally, 2 days of cocaine administration in 
the CPP studies may not be sufficient to reveal mutation-induced differences in drug 
sensitivity, considering that 6 days of cocaine administration were required to reveal 
significant differences in locomotor sensitization.  Further work investigating CPP in 
mice that receive more drug exposure may clarify whether alternative cocaine treatment 
protocols might induce adaptations that are dependent on the KOR system in DA  
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neurons.  Regardless, this work establishes an association between KORs expressed 
on DA neurons and the development of an important form of cocaine-induced 
neuroplasticity. 
 
I then used the CRF-enhanced and footshock-potentiated startle paradigms to 
determine if genetic KOR ablation would affect stress-induced effects on startle.  KOR
-/- 
mice had normal levels of enhanced startle in response to both CRF infusion and 
footshock and were not significantly different from KOR
+/+ littermates in either paradigm.  
In contrast, whereas the behavior of DAT-KOR
lox/lox mice was normal in the CRF-
enhanced startle test, they had reduced footshock-potentiated startle.  This potentiation 
was significantly lower than controls following 0.2 and 0.4 mA footshock blocks, 
although mutant and control mice had nearly equivalent potentiation during the 0.8 mA 
footshock block.  To complement studies with DAT-KOR
lox/lox mice, in which KORs are 
absent in DA neurons, I infused an AAV-Cre/GFP viral vector into the VTA of adult 
KOR
lox/lox mice to specifically ablate KORs within this region.  Surprisingly, the mice 
were not statistically different from controls in footshock-potentiated startle; however, 
there are several explanations as to why KOR
lox/lox mice given intra-VTA infusions of 
Cre viral vector do not replicate conditional KO results (See discussion in Chapter 5).  
Overall, these data implicate KORs in DA neurons in the manifestation of stress-
induced behaviors such as footshock-potentiated startle, but suggest KORs outside of 
the DA system may also play an important role in regulating signs of anxiety that are 
reflected by increases in the ASR.   
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In total, the work presented in my thesis confirms a role for KORs in the expression of 
anxiety-like behavior in rodents and for the first time suggests that dopaminergic 
neurons are notably involved in some of these effects.  These suggest common 
neuroanatomic substrates for depressive and anxiety disorders, and raise the possibility 
that KOR antagonists would be useful for treating these disorders, particularly when 
they are comorbid. 
 
2. CRF and KOR interactions in the dDG 
In studies examining CRF-induced c-Fos expression, JDTic pretreatment significantly 
reduced c-Fos labeling in both the VTA and dDG of the HIP.  In further work we chose 
to focus on the VTA; however, decreases in HIP activity may be an important 
component of the mechanism through which systemic JDTic reduces anxiety-like 
behavior.  The HIP is positioned to modulate responses to stress and has reciprocal 
connections with key components of fear and anxiety circuitry including the amygdala 
(Pitkanen et al., 2000) and is thus capable of influencing fear and anxiety behavior.  Of 
all brain areas responsive to stress, the HIP appears most vulnerable to its damaging 
effects (McEwen and Magarinos, 2001).  Both acute and chronic stress models have 
been shown to decrease hippocampal neurogenesis in lab animals (Gould et al., 1997; 
Gould et al., 1998; Tanapat et al., 2001), a process implicated in learning and memory 
(Neves et al., 2008).  Further, smaller HIP volumes are seen in PTSD sufferers 
(Bremner et al., 1995; Gurvits et al., 1996; Bremner et al., 1997b; Stein et al., 1997; 
Gilbertson et al., 2002; Villarreal et al., 2002; Bremner et al., 2003; Wignall et al., 2004; 
Bossini et al., 2008) and HIP size correlates with trauma severity such as combat 
exposure (Gurvits et al., 1996) and symptom severity (Stein et al., 1997; Villarreal et al.,  
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2002; Bremner et al., 2003).  It is unclear when these changes in volume take place, 
though one twin study suggests smaller HIP volumes may occur before trauma and be 
a risk factor for pathology (Gilbertson et al., 2002).  Regardless, these maladaptive 
differences in PTSD patients may underlie HIP dysfunction and promote fear and 
anxiety-like behavior. 
 
Preclinical studies demonstrate that the HIP is involved in unconditioned anxiety-like 
responses as lesions of the HIP or inhibition of dorsal HIP function using the indirect 
GABAA agonist midazolam or the direct agonist muscimol produce anxiolytic-like effects 
in the EPM and social interaction tests (Gonzalez et al., 1998; Menard and Treit, 2001; 
Bannerman et al., 2002; Rezayat et al., 2005)..  Studies also suggest a role for the HIP 
in contextual conditioning—anxiety-like behavior induced by the environment where an 
unconditioned stimulus (e.g. footshock) was presented.   In particular, IEG products with 
transcriptional activity, such as c-Fos, may link brief context exposures to cellular 
changes resulting in memory formation (Davis and Squire, 1984; Tischmeyer and 
Grimm, 1999).   Recently, an elegant study demonstrated that activation of a specific 
population of conditioning-responsive neurons (expressing c-Fos during conditioning) in 
the HIP was sufficient to induce anxiety-like behavior outside of the conditioned context 
(Liu et al., 2012).  These finding suggest that the HIP plays a role in anxiety-like 
behavior and likely by linking contextual memory to stress. 
 
In chapter 2, we found increased c-Fos expression, an index of neuronal activity, in the 
dDG and increased anxiety-like behavior following CRF infusion.  These results fit with 
the data described above indicating that increases in HIP activity contribute to anxiety- 
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like behavior.  A closer inspection of the pattern of c-Fos activation revealed that CRF-
induced increases appeared  to be localized to cells of the hilus (Fig 2.7) which includes 
inhibitory interneurons and glutamatergic mossy cells (Amaral, 1978; Seress and Ribak, 
1983); however, despite efforts, the nature of the cell population activated by CRF 
(whether GABAergic or glutamatergic) in the present work is not known.  Considering 
that mossy cells are the predominant cell type in this region and are highly excitable 
(Buckmaster and Schwartzkroin, 1994; Ratzliff et al., 2002) and also that the hilus is 
particularly vulnerable to cell death following stress (Lowenstein et al., 1992; Kotti et al., 
1996; Toth et al., 1997), some effects of stress  may be mediated by CRF-induced 
excitotoxicity in mossy cells, albeit the exact consequences of mossy cell loss are 
unknown.  JDTic treated mice had reductions in CRF-induced increases in c-Fos 
expression in another population of neurons in the dDG—the excitatory granule cells 
(Fig 2.7).  These changes may reflect a mechanism whereby decreased HIP activation 
results in reduced anxiety-like behavior  and may have important consequences in 
paradigms of contextual-conditioning—such as footshock-potentiated startle—in which 
reductions in HIP activity are predicted to affect context-related memory formation or 
retrieval (Holt and Maren, 1999; Barrientos et al., 2002; Corcoran et al., 2005), thus 
reducing future anxiety-like behavior in that context. 
 
How KOR blockade can reduce neuronal activation, as measured by c-Fos expression, 
is unclear although KOR activation has been shown to increase the excitability of 
granule cells in the dDG (Neumaier et al., 1988; McDermott and Schrader, 2011).  
There is also evidence in other brain regions that KOR activation can inhibit GABA 
release (Hjelmstad and Fields, 2003); thus disruption of KOR activation could block  
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decreases in GABA release and produce greater inhibition of efferent targets.  Indeed, 
KORs are expressed in GABAergic interneurons of the CA1 subregion of the HIP 
(Halasy et al., 2000), suggesting the possibility of KOR-induced disinhibition in HIP.  
Additional work to characterize the cell types modulated by CRF and JDTic as observed 
in c-Fos studies using electrophysiological and double-labeling techniques is a 
beginning step to understanding interactions between these two systems in the context 
of anxiety-like behavior.  Further, studies using direct drug injections or conditional KO 
of KORs from the HIP may clarify whether modulation of HIP circuits is necessary for 
CRF-induced anxiogenic-like behavior and attenuation of this behavior by JDTic. 
 
3. Differences among paradigm and genotype results 
3.1 Differences in c-Fos labeling following CRF and footshock  
I used c-Fos immunolabeling as an index of neuronal activation to investigate the 
circuits underlying KOR antagonist effects on CRF-enhanced and footshock-potentiated 
startle.  CRF induced profound brain activation, as every region analyzed contained 
significantly greater c-Fos expression in CRF- compared to vehicle-infused mice.  
These data are in contrast to the effects of footshock, which, in the regions analyzed, 
only increased c-Fos immunoreactivity in the PVN.  The PVN is one of the most stress-
responsive brain regions as evidenced by significant increases in Fos signal following 
various aversive stimuli (Beck and Fibiger, 1995; Duncan et al., 1996; Bhatnagar and 
Dallman, 1998; Funk et al., 2006).  Footshock-related induction of c-Fos expression in 
the PVN narrowly reached significance in my studies, in contrast to the dramatic 
increases observed by others.  This may be due, at least in part, to a ceiling effect 
manifested by exceptionally high levels of c-Fos labeling in control (no-shock) mice (see  
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Discussion in Chapter 3).  Baseline increases in c-Fos expression are evident when 
comparing HIP c-Fos immunoreactivity in mice from my footshock studies to mice from 
my CRF studies.  Although the photomicrographs used for counting were not taken at 
the same time under identical conditions and thus should not be directly compared for 
statistical analysis, it is clear that no-shock mice have greater activation in HIP subfields 
compared to aCSF-infused controls (see Table 2.1 and 3.5).  These data further 
suggest that no-shock control mice may have had higher than expected brain c-Fos 
expression—possibly due to stress (see Chapter 3 Discussion)—which precluded 
observations of footshock induced increases.  Additionally, mice in the footshock study 
were placed into the startle chambers for 30 min and then returned to their home cage 
before perfusion, whereas aCSF mice were returned to their home cage immediately 
after infusion.  Since the HIP is a key substrate for representing spatial memory 
(O'Keefe and Nadel, 1978), this minor procedural difference might have been sufficient 
to trigger context-related activation that obscured effects of footshock.  In an effort to 
mitigate this possibility, I habituated mice to the testing chamber across several days, 
but potential changes to the environment at the time of testing—such as odor or 
temperature—may nonetheless have contributed to HIP activation (Vanderwolf, 1992; 
Deshmukh and Bhalla, 2003; Karlsson and Blumberg, 2004).  Due to the lack of 
expected footshock effects throughout the HIP and VTA, it is difficult to draw 
conclusions from the disparate results of the CRF and footshock c-Fos studies.  It is 
clear that CRF produced an intense activation of c-Fos throughout the brain, suggesting 
it may be a stronger stressor than the footshock protocol.  ICV infusions of CRF can 
activate cognate receptors throughout the brain and induce anxiogenic-like effects for a 
prolonged period of time (Liang et al., 1992; Bittencourt and Sawchenko, 2000; Meloni  
192 
 
et al., 2006).  Because this CRF infusion-induced anxiety-like state is so persistent, it 
likely does not precisely mimic more naturalistic aversive stimuli-induced anxiety-like 
states—such as footshock-potentiation of the ASR—that are likely reduced or 
terminated when the mice are removed from the context.  Nevertheless, my c-Fos 
expression studies demonstrate robust engagement of brain circuits by CRF in contrast 
to subtle and circumscribed brain activation by footshock. 
 
3.2 Distinct results from KOR antagonist studies and genetic manipulations 
I tested KOR
-/- mice expecting to see similar reductions in startle potentiation to those 
observed in systemic KOR antagonist treated mice (Chapters 2 and 3) because KOR 
function is lacking throughout the brain in both cases.  Surprisingly, the behavior of 
KOR
-/- mice was not significantly different from WT littermates in either CRF-enhanced 
or footshock-potentiated startle.  The dissociation between these pharmacological and 
genetic studies might be explained by differences between the effects of KOR ablation 
throughout development and acute KOR blockade during adulthood; in the former case, 
changes in the developmental course of related systems might compensate for KOR 
ablation (see Chapter 5 Discussion). 
 
Mice lacking KORs in DA neurons were also not significantly different from controls in 
CRF-enhanced startle, suggesting that the KOR effects that regulate behavior in this 
paradigm are expressed outside of the mesocorticolimbic system.  In contrast, KOR 
activation within DA neurons mediates, at least in part, footshock effects on startle, as 
indicated by a significant reduction of footshock-potentiated startle in DAT-KOR
lox/lox 
mice.  This pattern of effects might indicate that distinct regions of KOR activation within  
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circuits regulate CRF versus footshock effects.  An intense aversive stimulus (0.8 mA) 
overcame the reductions in startle potentiation in DAT-KOR
lox/lox mice following lower 
footshock intensities (0.2 and 0.4 mA), which may indicate that high levels of shock 
engage additional neural systems and/or alternative coping mechanisms.  As discussed 
earlier, 1.0 µg CRF produces a robust increase in c-Fos activation throughout brain 
systems involved in stress and anxiety-like behavior, suggesting it is a powerful 
anxiogenic stimulus.  Thus, it is possible that conditional KO mice administered CRF 
were in a state most comparable to that produced by 0.8 mA footshocks and as a result, 
did not have reductions in CRF-enhanced startle; lower doses of CRF may reveal 
reductions in DAT-KOR
lox/lox mice compared to controls.  On the other hand, systemic 
KOR antagonism was capable of decreasing footshock effects throughout the test 
session, suggesting that KORs outside of the DA system can also modulate footshock-
induced behavior.  Collectively, my pharmacological and genetic studies indicate a role 
for KORs both within and outside the midbrain DA system in the anxiogenic-like effects 
of CRF and footshock. 
 
While we chose to focus on the midbrain DA system; it is clear that this is not the only 
system to underlie KOR affects on anxiety, as stress leads to robust KOR activation in 
non-DA nuclei including the serotonergic DRN (Land et al., 2008).  As one example, 
activation of KORs in the DRN, which sends serotonin (5HT)-containing projections to 
forebrain areas critical for modulating fear and anxiety responses (Lowry et al., 2005), 
reduces 5HT release (Tao and Auerbach, 2002) and modulates stress-induced aversion 
(Land et al., 2009).  Whether the 5HT-system works independently or interplays with 
other stress-responsive systems including DA is not entirely clear.  The aversive effects  
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of KOR-mediated decreases in 5HT are attributable to projections from the DRN to the 
NAc, an area also rich in DA.  Thus, the anxiolytic-like effects of systemic JDTic in 
response to stress (Chapters 2 and 3), may rely on both inhibition of decreases in 5HT 
as well as modulation of DA systems, effects that may convergence within the same 
substrates.  Further, the DRN sends direct projections to the striatum and activation of 
5HT receptors in the striatum increases extracellular concentrations of DA (Benloucif 
and Galloway, 1991; Benloucif et al., 1993), raising the possibility that KOR antagonist 
effects may reduce DA activity in this region indirectly through modulation of 5HT 
systems.  Additional studies to further characterize the role of KORs in systems other 
than DA may clarify their role in anxiety-like behavior and the nature of interactions 
among these modulators.  
 
As an alternate approach to our genetic manipulation that ablated KORs in DA neurons 
(DAT-KOR
lox/lox mice), adult KOR
lox/lox mice were infused with a viral vector expressing 
Cre into the VTA to ablate KORs in this structure.   These mice were then tested in 
footshock-potentiated startle to determine whether they replicated the anxiolytic-like 
effects observed in DAT-KOR
lox/lox mice.  Unexpectedly, Cre vector-infused mice were 
not significantly different from GFP vector-infused controls.  There are several 
explanations as to why this manipulation may not have produced a phenotype (see 
Chapter 5 Discussion), including the possibility that stress-induced KOR activation in 
VTA neurons may not underlie the anxiogenic-like effects of footshock.  Considering 
that KORs in all DAT-expressing neurons (not just the VTA) were ablated in our 
conditional KOs, targeted ablation of KORs in DA neurons outside of the VTA may 
reproduce the anxiolytic-like effects observed in DAT-KOR
lox/lox mice.  These regions  
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include the SN, rostral linear nucleus, and periaqueductal gray (Phillipson, 1979; Hasue 
and Shammah-Lagnado, 2002) all of which express DAT (Shimada et al., 1992; Fujita 
et al., 1993) and thus would lack KORs in DAT-KOR
lox/lox mice.  In some mice, we 
observed a greater spread of the Cre viral vector that included infection of the SN 
bilaterally.  These mice displayed similar behavior to controls, suggesting that if extra-
VTA neurons are responsible for the anxiolytic-like effects it is likely not those in the SN.  
Regardless, further studies to ablate KORs specifically from the SN, rostral linear 
nucleus and periaqueductal gray are necessary to clarify the role, if any, of KORs in 
these regions on stress-induced anxiety-like behavior. 
 
4. Potential mechanisms 
4.1 KOR effects outside of the VTA 
KOR antagonist effects in CRF-enhanced startle were not replicated in DAT-KOR
lox/lox 
mice, suggesting a role for KORs expressed in other regions and/or non-dopaminergic 
cells.  Indeed, stress produces KOR activation in the AMY and DRN, regions implicated 
in anxiety-like and aversive behavior (Bruchas et al., 2009; Land et al., 2009; Knoll et 
al., 2011).  The work of other groups has provided an elegant mechanism that explains 
how KOR activation produces aversive effects.  This work implicates KORs expressed 
on terminals of axon projections from the DRN to the NAc (Land et al., 2009).  Stress 
induces KOR-dependent activation of p38 MAPK in DRN serotonergic neurons, which is 
necessary and sufficient to induce a negative affective state (Bruchas et al., 2007a; 
Land et al., 2009; Bruchas et al., 2011).  These effects are hypothesized to result from 
inhibition of serotonergic neurons, considering that KOR activation in DRN slice 
preparations induces p38 MAPK-dependent activation of G-protein-coupled inwardly  
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rectifying potassium channels (GIRKs) and presynaptic inhibition of excitatory 
neurotransmission resulting in decreased serotonergic neuron excitability (Lemos et al., 
2012a).  KORs are also expressed in other stress responsive brain regions that are 
highly interconnected with the mesocorticolimbic system including the BNST, HIP and 
septum; however, the role that KORs within these regions on stress and anxiety-related 
behavior has not been thoroughly examined.  Future studies using the floxed KOR 
mouse generated for these studies in combination with promoter-driven Cre viral 
vectors have the potential to elucidate the roles of KORs within particular cell 
populations and brain regions. 
 
4.2 KOR effects on VTA function 
Early investigations into the neural substrates of KOR-induced aversion using CPA 
identified the VTA as a key area of activation (Bals-Kubik et al., 1993).  Aversion was 
postulated to be the result of KOR-mediated decreases in DA release.  Indeed, KOR 
agonists decrease DA release in VTA cell cultures (Ronken et al., 1993; Dalman and 
O'Malley, 1999) and directly inhibit DA cell firing through GIRKs in slice (Margolis et al., 
2003).  In addition to postsynaptically inhibiting DA release through hyperpolarization, 
KOR activation in the VTA can induce presynaptic inhibition of somatodendritic DA at its 
release sites (Ford et al., 2007).  KORs can also regulate VTA activity through the 
control of glutamate input (Margolis et al., 2005) demonstrating the broad range of KOR 
control over DA function.  Dynorphin terminals synapse onto both TH-labeled 
(presumably DA neurons) and unlabeled dendrites as well as terminals and astrocytes 
in the VTA (Pickel et al., 1993) where KOR activation can produce differential 
responses.  Because several dynorphin-expressing nuclei project to the VTA including  
197 
 
those from the hypothalamus, AMY, CPu, and NAc (Fallon and Leslie, 1986), VTA cells 
expressing KORs may be involved in integrating information from multiple brain circuits 
or have unique responses based on input and/or projection target.  For example, KOR-
mediated inhibition of DA neurons varies as a function of projection target (Ford et al., 
2006; Margolis et al., 2006b; Margolis et al., 2008).  KORs are also located on the 
terminals of DA projections from the VTA to the NAc and PFC where they can 
presynaptically inhibit DA release (Di Chiara and Imperato, 1988; Werling et al., 1988; 
Spanagel et al., 1992; Carlezon et al., 2006; Grilli et al., 2009).  This complexity makes 
it difficult to clearly delineate the circuits underlying our present findings in mice injected 
with systemic KOR antagonists (which results in blockade of KORs throughout the 
brain) and DAT-KOR
lox/lox mice (which lack KORs on all DA neurons); however, 
accumulating evidence suggests that alterations in the function of the PFC in particular 
may regulate, at least in part, the anxiolytic-like effects observed in the current work. 
 
The PFC integrates information for cognitive processing and is involved in emotional 
learning and memory (Fuster, 2008).  DA plays a role in the regulation of PFC function; 
it is released into this region in response to stress, an effect thought to produce 
anxiolytic-like behavior in rodents (Thierry et al., 1976; Abercrombie et al., 1989; Deutch 
and Roth, 1990; Sorg and Kalivas, 1993; Feenstra et al., 2001).  In contrast, DA 
depletion in the PFC induces anxiogenic-like behavior in the EPM (Espejo, 1997; 
Fernandez Espejo, 2003).  Further support for a protective role of PFC DA is provided 
from studies of neuropeptide S, which produces anxiolytic-like effects thought to be 
secondary to increases in PFC DA release (Si et al., 2010).  Stress-induced 
enhancement of DA function in the PFC may result from direct activation of VTA  
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neurons by CRF, considering that CRF-R1 KO in DA neurons results in increased 
anxiety-like behavior accompanied by reductions in PFC DA release in response to 
stress (Refojo et al., 2011).  Thus KORs have the ability to modulate anxiogenic-like 
responses to stress through the control of DA release within the PFC (Margolis et al., 
2006b; Tejeda et al., 2010b).  Although the current work has more precisely determined 
the role of KORs in the VTA as compared to drug microinfusions by using Cre/loxP 
recombination to target DA neurons specifically, the heterogeneity of DA neuron 
subtypes expressing KORs in the VTA suggests that even more precise targeting of 
specific DA subpopulations may lead to a better understanding of the particular role of 
KORs within each component of the mesocorticolimbic system. 
 
4.3 Hypothetical framework to explain behavioral effects 
The paradigms of anxiety-like behavior that I used in this thesis (CRF-enhanced startle 
and footshock-potentiated startle) were chosen to elicit a sustained fear response that 
more accurately models clinical aspects of anxiety disorders as compared to cued fear 
conditioning, which elicits phasic fear and relies partly on distinct brain regions (Davis et 
al., 2010).  In models of both sustained and phasic fear, aversive stimuli activate the 
BLA which sends projections to the CeA and BNST.  The medial subregion of the CeA 
is responsible for rapid phasic fear responses, while activation of the lateral CeA elicits 
CRF release into the BNST producing a slower onset, sustained fear response (Davis et 
al., 2010).  This model is supported by work indicating that the BNST is critical for CRF- 
and light-enhanced startle—paradigms that produce sustained levels of fear throughout 
the test session—but not fear-potentiated startle—a paradigm in which startle is 
facilitated only following a short (3.7 sec) cue (Hitchcock and Davis, 1986; Hitchcock  
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and Davis, 1991; Lee and Davis, 1997; Walker and Davis, 1997).  Thus BNST activation 
is a key component for increases in startle reactivity in the CRF-enhanced and 
footshock-potentiated startle paradigms used in my dissertation. 
 
A highly simplified circuit hypothesized to underlie KOR effects on anxiety is illustrated 
in Fig. 6.1 (adapted from Davis (2010) and Meloni (2006)).  According to this model, 
sensory activation of the BLA by aversive stimuli would increase activity in the CeA 
through direct projections to this region.  The CeA sends abundant projections to the 
BNST that provide the primary source of CRF to this region (Sakanaka et al., 1986; Sun 
et al., 1991; Petrovich and Swanson, 1997; Dong et al., 2001a).  Stress would cause 
the release of CRF and subsequent activation of the BNST, a region rich in CRF-Rs 
(Wynn et al., 1984).  CRF and footshock-induced increases in startle would result, in 
part, from direct projections from the BNST to the PnC, a critical relay site in the startle 
pathway from ear to muscle (Davis et al., 1982; Rosen et al., 1991).  This response may 
be modulated by PFC effects on intercalated cell (ITC) masses—GABAergic neurons 
located between the BLA and CeA that inhibit AMY output (Millhouse, 1986; Pare et al., 
2004).  Direct projections from the PFC to the ITCs have been demonstrated in 
primates and rodents (McDonald et al., 1996; Chiba et al., 2001; Ghashghaei and 
Barbas, 2002), and regulate AMY output (Maren and Quirk, 2004; Pare et al., 2004).  
Indeed, stimulation of the PFC increases c-Fos labeling in the ITCs (Berretta et al., 
2005) and reduces the response of CeA output neurons to BLA activation (Quirk et al., 
2003). 
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In times of stress, PFC activation might occur following mesocortical DA release 
(Thierry et al., 1976; Roth et al., 1988) under the control of presynaptic KORs.  Release 
of dynorphin and activation of KORs may be especially prominent in response to 
repeated or prolonged stress, which would reduce DA release and subsequent PFC 
activity and lead to increases in anxiety-like behavior (e.g. enhanced startle).  Indeed, 
DA activity in the PFC changes with repeated stress (Tanaka et al., 2012).  Whereas 
acute defeat activates the mesocortical DA pathway, 10 days of defeat leads to an 
attenuation of DA turnover that is accompanied by increases in social avoidance and 
anxiogenic-like behavior (Tanaka et al., 2012).  Because KOR-induced decreases in DA 
release within the PFC (Margolis et al., 2006b) would presumably be absent in DAT-
KOR
lox/lox mice, the anxiolytic-like effects observed in footshock-potentiated startle in 
these mutants may result from DA-induced PFC activation of ITCs, the postulated “off” 
switch of the AMY (Quirk and Mueller, 2008).   
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Figure 6.1 Model illustrating the hypothetical involvement of mesocortical 
projections in stress-induced facilitation of the ASR.  Sensory stimuli associated 
with aversive events activate the BLA, which promotes CRF release in the BNST via the 
CeA, and activates the BNST directly.  In turn, the ASR is enhanced through direct 
BNST to PnC projections.  CeA output is inhibited by PFC-induced ITC activation, 
reducing BNST modulation of the acoustic startle pathway.  As ablation of KORs in the 
VTA attenuates the increases in startle produced by footshock, I hypothesize that 
disruption of mesocortical KOR function enhances DA release and PFC activation.  
KOR and CRF effects outside of the VTA (e.g. in the AMY, BNST and PnC) may also 
modulate this circuit and account for the differences observed in my pharmacological 
and genetic studies.  AMY, amygdala; ASR, acoustic startle reflex; BLA, basolateral 
nucleus of the amygdala; BNST, bed nucleus of the stria terminalis; CeA, central 
nucleus of the amygdala; CRF, corticotropin-releasing factor; CRN, cochlear root 
neurons; DA, dopamine; ITC, intercalated cell masses; KOR, kappa-opioid receptor; 
PFC, prefrontal cortex; PnC, caudal nucleus of the pontine reticular formation; VTA, 
ventral tegmental area 
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Figure 6.1 (Continued) Model illustrating the hypothetical involvement of mesocortical 
projections in stress-induced facilitation of the ASR 
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This hypothesized circuit may help clarify the results in KOR antagonist versus KOR-
deficient mice in CRF-enhanced and footshock-potentiated startle.  ICV CRF infusions 
like those used for my CRF-enhanced startle studies would be capable of directly 
activating CRF-Rs of the CeA, BNST and PnC (Wynn et al., 1984; Smagin et al., 2001), 
thus bypassing the anxiolytic-like effects of KOR ablation in DA neurons.  According to 
this putative scheme, CRF-enhanced startle would be equivalent in DAT-KOR
lox/lox mice 
and controls, as was observed.  Likewise, additional KOR antagonist effects outside of 
the mesocortical system would contribute to attenuation of startle as observed in my 
JDTic studies (Chapters 2 and 3).  As one example, amygdalar KORs regulate anxiety-
like behavior and are present on GABAergic terminal inputs to the BNST, where they 
inhibit GABA release that would tend to dampen BNST activation (Li et al., 2012).  Thus 
systemic blockade of KORs can have effects at multiple levels of the proposed circuit to 
reduce BNST activation and anxiogenic-like effects of stress on the ASR. 
 
It is important to note that in the proposed model of stress effects on the ASR, we would 
expect to see increased activation of VTA neurons that project to the PFC in JDTic-
treated mice; however, c-Fos expression studies (Chapter 2) indicate significant 
reductions.  However, there is emerging evidence that DA cells in the VTA have 
disparate projections that can respond to inputs independently.  In fact, some reports 
indicate an increase in VTA firing following social defeat stress in susceptible mice that 
confers vulnerability through actions that occur within the NAc (Krishnan et al., 2008; 
Cao et al., 2010).  As such, decreases in activation of this particular VTA projection 
would be beneficial (anxiolytic).  In the current work, I was unable to identify PFC-
projecting DA neurons specifically and therefore could not determine whether  
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mesocortical and mesolimbic DA neurons deviated in their response to JDTic as would 
be predict by this model.  c-Fos expression experiments in which VTA neurons are 
retrogradely labeled by projection target may help to clarify whether DA neurons 
projecting to the PFC are activated in response to stress. 
 
5. Conclusions and future directions 
The KOR system is implicated in anxiety-like behaviors particularly in response to 
stress.  While KOR antagonists produce anxiolytic-like effects on their own and block 
the effects of stress, KOR agonists mimic stress to induce depressive-and anxiogenic-
like behavior.  Previous work has shown that these effects rely, at least in part, on KOR 
activation within the AMY and serotonergic neurons of the DRN.  The work presented 
here offers the first data to demonstrate a role for KORs on DA neurons in stress-
induced anxiety-like behavior.  Together, these data suggest that the KOR system has 
broad control over neurotransmitter systems throughout the brain to regulate circuits 
involved in responses to stress.  While normal KOR function is important to antagonize 
other brain systems and maintain response adaptability (Pan, 1998), dysfunction in this 
system may be responsible for psychiatric disorders such as depression and anxiety. 
 
Here I propose that KOR control of DA release into the PFC may partly underlie the 
anxiolytic-like effects of KOR blockade.  To support this model, it will first be important 
to determine whether DA release is enhanced in DAT-KOR
lox/lox mice through 
microdialysis studies.  Further work using optogenetic techniques may clarify the role of 
the mesocortical KOR system in anxiety-like behavior through specific stimulation of 
these projections following KOR excision or rescue.  Such experiments can be achieved  
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through stimulation of the PFC after VTA expression of channelrhodopsin (Ch2) under 
the control of a DAT promoter in our DAT-KOR
lox/lox mice.  This would enable specific 
control of KOR-lacking DA projections from the VTA to PFC and would hypothetically 
reduce anxiety-like behavior.  Previously, optogenetic stimulation of the PFC has been 
shown to reduce some measures of anxiety-like behavior in mice (Covington et al., 
2010) providing some evidence that DA-induced activation of this area may produce 
similar results.  Such studies may lead us closer to the role of KORs within the complex 
circuitry underlying anxiety disorders.   
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Abstract 
Stress often disrupts behavior and can lead to psychiatric illness.  Considerable 
evidence suggests that corticotropin-releasing factor (CRF) plays an important role in 
regulating the effects of stress.  CRF administration produces stress-like effects in 
humans and laboratory animals, and CRF levels are elevated in individuals with stress-
related illness.  Recent work indicates that kappa-opioid receptor (KOR) antagonists 
can block CRF effects, raising the possibility that at least some of the effects of stress 
are mediated via KORs.  Here we examined the effects of CRF on performance in the 
5-choice serial reaction time task (5CSRTT), a test used to quantify attention in rodents, 
as well as functional interactions between CRF and KORs.  Male Sprague-Dawley rats 
were trained in the 5CSRTT and then each was implanted with an 
intracerebroventricular (ICV) cannula.  After recovery and re-stabilization of 
performance, they received a single intraperitoneal (IP) injection of vehicle or JDTic (10 
mg/kg), a KOR antagonist with long-lasting (>14 days) effects.  In subsequent sessions, 
rats received ICV infusions of CRF (0.25-1.0 µg) or vehicle and were tested 60 min 
later.  CRF dose-dependently disrupted performance as reflected by decreases in 
correct responding, increases in omission errors, increases in latencies to respond 
correctly, and increases in time to complete the session.  JDTic attenuated each of 
these CRF-induced deficits while having no effects on its own.  The persistent ability of 
JDTic to disrupt KOR function was confirmed using the tail immersion assay.  These 
findings indicate that KOR antagonists can prevent acute stress-related effects that 
degrade performance in tasks requiring attention. 
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Introduction 
Stress can have disruptive effects on behavior, cognition, and motivation (Knoll and 
Carlezon, 2010; Campeau et al., 2011).  Exposure to severe or repeated stress can 
cause psychiatric illnesses including anxiety and depressive disorders such as PTSD 
(Keane et al., 2006; Keller et al., 2007; Kessler et al., 2010). Stress-related illnesses are 
debilitating and burdensome because they tend to be persistent, resistant to treatment, 
and co-morbid with substance abuse disorders (Chilcoat and Breslau, 1998; Greenberg 
et al., 1999; Koob and Kreek, 2007).  Currently there are no treatments available that 
reliably block the effects of stress or have broad efficacy in reversing the long-term 
effects of prior stress exposure.  
 
There is considerable evidence that corticotropin-releasing factor (CRF) plays an 
important role in regulating stress effects.  CRF is a neuropeptide that is released in the 
brain in response to stress (Koob, 1999).  Administration of CRF produces many of the 
same physiological and behavioral effects as stress in people and laboratory animals 
(Hauger et al., 2009), and people with stress-related psychiatric illness have higher 
levels of CRF in cerebrospinal fluid (CSF) and blood (Bremner et al., 1997a; Sautter et 
al., 2003; de Kloet et al., 2008).  Although much is known about the neural mechanisms 
by which CRF regulates stress (Bangasser and Valentino, 2012), it has remained 
difficult to develop clinically effective anti-stress agents that act directly at CRF 
receptors (Zorrilla and Koob, 2010). 
 
Accumulating evidence suggests that important aspects of the stress-related effects of 
CRF are mediated by kappa-opioid receptors (KORs) (Bruchas and Chavkin, 2010;  
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Knoll and Carlezon, 2010), the receptor at which the endogenous opioid dynorphin acts 
(Chavkin et al., 1982).  For example, the prototypical KOR antagonist nor-
binaltorphimine (norBNI) blocks CRF-induced dysphoria in the place conditioning test 
(Land et al., 2008) and reductions in open arm time in the elevated plus maze (Bruchas 
et al., 2009).  Our group has shown in preliminary tests that JDTic, another highly 
selective KOR antagonist that is structurally unrelated to norBNI (Carroll et al., 2004), 
also blocks CRF-induced elevations in acoustic startle behavior (Van't Veer et al., 
2011).  The observations that CRF-induced phosphorylation of KORs is blocked by 
KOR antagonists (Land et al., 2008) and CRF-induced anxiety behavior is reduced in 
dynorphin knockout mice (Bruchas et al., 2009) provide molecular evidence for links 
between CRF and KOR systems.  Interactions between these systems have been 
thoroughly characterized within the raphe nucleus (Bruchas et al., 2011) but may also 
occur in other brain regions (Pliakas et al., 2001; Newton et al., 2002; Shirayama et al., 
2004; Knoll et al., 2011; Muschamp et al., 2011b).  The notion that KOR antagonists 
block the effects of stress fits well with other evidence that these agents have 
antidepressant-like (Pliakas et al., 2001; Newton et al., 2002; Mague et al., 2003; 
Shirayama et al., 2004) and anxiolytic-like effects including the ability to block 
acquisition of fear-potentiated startle (Knoll et al., 2007; Knoll et al., 2011), a procedure 
often used to study PTSD (Mahan and Ressler, 2012).  In addition, KOR agonists can 
produce key behavioral signs of stress (Mague et al., 2003; McLaughlin et al., 2003a; 
Todtenkopf et al., 2004; McLaughlin et al., 2006b).  When considered together, these 
findings raise the possibility that pretreatment with KOR antagonists could reduce or 
prevent effects of stress, representing an alternative approach to modulating the 
behavior-disrupting effects of CRF.  
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The present studies were designed to examine how CRF affects a subset of cognitive 
behaviors in rodents, and whether pretreatment with a KOR antagonist (JDTic) 
mitigates any stress-like effects.  Cognitive behavior was quantified using the 5-choice 
serial reaction time task (5CSRTT), a food-motivated test that is analogous to the 
continuous performance task used to study attention in humans (Rosvold et al., 1956; 
Robbins, 2002).  The 5CSRTT yields metrics that quantify attention, reaction time, 
motivation, and impulsivity (Robbins, 2002; Paine et al. 2007; Nemeth et al., 2010).  
Stress is known to degrade performance in tasks requiring attention or concentration in 
humans (Campeau et al., 2011), and poor concentration is one of the diagnostic criteria 
for stress-related psychiatric illnesses such as PTSD (American Psychiatric Association, 
2000).  Previous work has demonstrated that JDTic produces long-lasting (>14 days) 
disruptions of KOR function (Carroll et al., 2004) and that the behavioral effects of JDTic 
and norBNI are virtually identical (Knoll et al., 2007; Knoll and Carlezon, 2010).  To 
confirm that a single injection of JDTic produced disruption of KOR function for the 
duration of our tests in the 5CSRTT, we examined the ability of the KOR agonist 
U50,488 to produce antinociceptive effects in the tail immersion assay (Smith and 
French, 2002).   
 
Materials and Methods 
Rats:  A total of 14 male Sprague-Dawley rats (Charles River, Raleigh, NC; 250–275 g 
at the start of the experiment) were used.  Rats were housed two per cage upon arrival 
and kept on a 12-hour/12-hour light-dark cycle (lights on at 7:00 AM) and given 1 week 
to acclimate with free access to food (Purina Rat Chow; Ralston Purina, St. Louis, MO) 
and water.  Beginning 2 days before the start of training, the rats were food restricted to  
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85% of their free-feeding weight.  Experiments were conducted in accordance with the 
National Institutes of Health, and McLean Hospital guidelines for the care and use of 
laboratory animals. 
 
5CSRTT: The apparatus and training have been described previously (Paine et. al., 
2007).  Briefly, the operant chambers (Med-Associates, St. Albans, Vermont) were 
contained within sound-attenuating cubicles.  One wall contained five apertures capable 
of LED illumination and outfitted with infrared detectors to record nose-pokes.  The 
opposite wall contained a food reward receptacle also capable of illumination and nose-
poke detection that was connected to a pellet dispenser.  Rats were handled for 3 days 
before the start of training.  During the next 3 days, rats were trained to retrieve food 
pellets (45 mg; Bio-Serv, Frenchtown, NJ) from the food magazine.  Rats were then 
trained to nose-poke in one of five spatial locations within 5 sec of the presentation of a 
brief stimulus light (0.5 sec).  A timely response in this aperture resulted in delivery of 1 
food pellet.  Incorrect nose-pokes in the other apertures resulted in a 5-sec time-out.  
Similarly, failing to respond (omission) or responding during the 5-sec inter-trial interval 
(premature response) resulted in a 5-sec time-out.  Sessions were 90 trials or 30 min, 
whichever came first.  Performance measures of primary interest were: % correct 
((correct responses/[correct + incorrect+ omitted responses])*100), accuracy ((correct 
responses/[correct + incorrect responses])*100), % omissions ([total omissions/number 
of trials]*100; trials in which no response was emitted), latency to make a correct 
response (the time from the stimulus onset to a correct response; a putative indicator of 
speed of processing or decision-making), reward latency (the time from a correct 
response to the collection of the food pellet; a putative indicator of motivation),  
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premature responses (responses during the ITI; a putative indicator of impulsivity), and 
time to complete the task (a putative indicator of overall performance capabilities).  The 
criteria to advance to the next stages of the experiments were >60% correct responses 
and <20% omissions for 5 consecutive days. 
 
Stereotaxic Surgery:  Upon meeting performance criteria, rats underwent surgery to 
implant an intracerebroventricular (ICV) cannula.  Each rat was anesthetized with an 
intraperitoneal (IP) injection of pentobarbital (65 mg/kg) supplemented with 
subcutaneous atropine (0.25 mg/kg) to minimize bronchial secretions, and placed in a 
stereotaxic instrument (David Kopf Instruments, Tujunga, CA).  For each rat, a stainless 
steel guide cannula (23-gauge, Plastics One, Roanoke, VA) with a dummy stylet 
extending 1.5 mm beyond the tip was lowered into the right lateral ventricle at 
coordinates relative to bregma; anteroposterior = -0.8 mm, mediolateral = 1.3 mm, and 
lowered -3.5 mm ventral to dura.  Dental acrylic (Stoelting, Wood Dale, IL) secured the 
cannula to screws (Plastics One, Roanoke, VA) attached to the skull.  Rats were 
housed individually after surgery to recover for 5-7 days, and then tested until their 
performance had re-stabilized to baseline levels (±10%) while also fulfilling the basic 
response criteria (>60% correct responding, <20% omissions).  Microinfusions were 
performed by removing the dummy stylet and replacing it with a 30-gauge infusion stylet 
(Plastics One) attached to a Hamilton microsyringe (10 µl) by polyethylene tubing.  ICV 
infusions of CRF (0.25, 0.5 or 1.0 µg) or vehicle (artificial cerebrospinal fluid [aCSF]; 
Harvard Apparatus, Holliston, MA) were performed over a 2-min period at a rate of 0.5 
µL/min, with an additional 2 minutes of diffusion time before the stylet was removed and 
the dummy stylet was replaced.  Testing began 60 min after infusion.   
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5CRSTT Studies: Drugs and Design.  CRF was purchased from American Peptide 
(Sunnyvale, CA) and dissolved in aCSF.  JDTic was synthesized at Research Triangle 
Institute (Research Triangle Park, NC) and dissolved in 0.9% saline; 10 mg/kg (based 
on the salt form of the drug) was selected because this dose produces strong anxiolytic-
like effects in rats (Knoll et al., 2007).  Rats first received an infusion of aCSF to ensure 
the infusion procedure did not affect performance, and to obtain data to serve as 
baseline.  Forty-eight hr later, the rats received an injection of either JDTic (10 mg/kg, 
IP; n=7) or vehicle (1.0 mL/kg, IP, n=7).  A 24-hr pretreatment period was used before 
beginning behavioral testing to optimize KOR selectivity (Carroll et al., 2004; Knoll et al., 
2007).  Rats were subsequently tested with CRF in the following order: 0 (aCSF), 0.5, 
1.0 and 0.25 µg.  Rats did not receive subsequent treatments until their performance 
had re-stabilized to baseline levels (±10%) while also fulfilling the basic response 
criteria (>60% correct responding, <20% omissions). 
 
Tail Immersion Assay: Drugs and Design.  After the final test in the 5CSRTT, the ability 
of a single injection of JDTic to produce long-lasting disruptions of KOR function was 
assessed by quantifying KOR agonist-induced analgesia in the tail immersion assay 
(Smith and French, 2002).  A stopwatch was used to measure the latency at which each 
rat removed its tail from a 52°C (±1°C) water bath.  A baseline measurement was 
obtained before treatment with the KOR agonist (±)-trans-U50,488 methanesulfonate 
(15 mg/kg, IP, dissolved in 0.9% saline; dose based on the salt form of the drug).  
Latencies were re-assessed 60 min after KOR agonist treatment.  A cutoff time of 15 
sec was used to prevent tissue damage to the tail. 
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Histological analysis:  After the tail immersion assay, rats were overdosed with 
pentobarbital (130 mg/kg, IP) and perfused with 0.9% saline followed by 4% 
paraformaldehyde.  Brains were kept overnight in 30% glycerol before sectioning (40 
µm).  ICV cannula placements were verified in histological analyses by an observer 
unaware of the treatment conditions.  Data from rats in which the tip of the cannula was 
found to be embedded in brain tissue adjacent to the lateral ventricle, rather than being 
located within the lateral ventricle itself, were excluded from the statistical analyses 
since this could affect the quality of the ICV infusion. 
 
Statistics:  For the 5CSRTT, 2-way (treatment x session) analyses of variance 
(ANOVAs) with repeated measures were used to compare the effects of an ICV infusion 
alone (baseline) with the effects of the ICV infusion plus the pretreatment (saline or 
JDTic).  Separate 2-way (pretreatment x treatment) ANOVAs with repeated measures 
were used to compare the effects of various doses of CRF in saline- or JDTic-treated 
mice.  Analyses were performed for each individual metric.  For the tail immersion 
assay, a 2-way (pretreatment x treatment) ANOVA with repeated measures was used to 
examine the effects of prior treatment with JDTic on U50,488-induced antinociception, 
and a t-test was used to examine group differences in the timing of the tail immersion 
assay.  Significant interactions in the ANOVAs were further analyzed using Newman-
Keuls post hoc tests, whereas significant main effects in the absence of interactions 
were further analyzed using Simple Main Effects tests. 
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Results 
Three rats (1 vehicle, 2 JDTic) were excluded because histological analyses revealed 
that the tips of their guide cannula had been embedded in tissue adjacent to the lateral 
ventricle.  The tips of the ICV cannulas for the remaining 6 vehicle-treated rats and 5 
JDTic-treated rats were located entirely within the lateral ventricle (Fig. A.1) and thus 
data from these rats were included in the final statistical analyses.   
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Figure A.1 Representative micrograph of ICV cannula tract in cresyl violet-stained 
tissue.  Rats were excluded if the tip of the cannula was embedded in the brain tissue 
surrounding the lateral ventricle (LV).
LV 
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CRF produced JDTic-sensitive disruptions in performance in 4 of the 5CSRTT metrics: 
percent correct responding, percent omission errors, latency to make a correct 
response, and time to complete the task (Fig. A.2).  For correct responding, 
administration of JDTic did not produce any effects on its own (Fig. A.2A, left panel).  
However, the effects of CRF depended on an interaction of pretreatment (saline or 
JDTic) and treatment (CRF dose) (F[3,27]=3.60, P<0.05) (Fig. A.2A, right panel).  Post 
hoc analyses of within-subject effects revealed that CRF significantly reduced the 
percentage of correct responding at 0.5 µg and 1.0 µg doses (P’s<0.01) in saline-
treated rats, but only at the 1.0 µg dose (P<0.01) in JDTic-treated rats.  Between-group 
analyses revealed that correct responding was significantly higher in JDTic-treated rats 
than in saline-treated rats at the 0.5 µg dose of CRF (P<0.01).  Likewise, for omission 
errors, JDTic did not produce any effects on its own (Fig. A.2B, left panel), but the 
effects of CRF depended on a pretreatment x treatment interaction (F[3,27]=3.33, 
P<0.05) (Fig. A.2B, right panel).  Post hoc analyses of within-subject effects revealed 
that CRF significantly increased the percentage of omitted responses at 0.5 µg and 1.0 
µg doses (P’s<0.01) in saline-treated rats, but only at the 1.0 µg dose (P<0.01) in 
JDTic-treated rats.  Between-group analyses revealed that the percentage of omitted 
responses was lower in JDTic-treated rats than in saline-treated rats at the 0.5 µg 
(P<0.01) and 1.0 µg (P<0.05) doses of CRF.  While JDTic on its own did not have any 
effects on latency to make correct responses (Fig. A.2C, left panel), the effects of CRF 
depended on main effects of pretreatment (F[1,9]=5.82, P<0.05) and treatment 
(F[3,27]=9.48, P<0.01) (Fig. A.2C, right panel).  Post hoc analyses of between-group 
effects using Simple Main Effects tests revealed that the latencies to respond correctly 
were lower in JDTic-treated rats than in saline-treated rats at the 0.5 µg dose of CRF  
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(F[1,9]=10.9, P<0.01).  JDTic on its own also did not have any effects on time to 
complete the task (i.e., to finish the test session) (Fig. A.2D, left panel), but the effects 
of CRF depended on a pretreatment x treatment interaction (F[3,27]=3.00, P<0.05) (Fig. 
A.2D, right panel).  Post hoc analyses of within-subject effects revealed that CRF 
significantly increased the time to complete the task at the 0.5 µg (P<0.05) and 1.0 µg 
doses (P<0.01) in saline-treated rats, but not at any of the doses tested in the JDTic-
treated rats.  Between-group analyses revealed that time to complete the task was 
shorter in JDTic-treated rats than in saline-treated rats at the 0.5 µg dose of CRF 
(P<0.01).   
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Figure A.2 Effects of JDTic pretreatment on the ability of CRF to affect 
performance in the 5CSRTT.  Left panel represents effects of pretreatment alone on 
baseline A. Percent Correct Responses, B. Percent Omissions, C. Latency to Correct 
Responses (in sec), and D. Latency to Complete the Task (in sec); right panel 
represents effects after various doses of CRF.  *P<0.05, **P<0.01 within group 
comparisons, ^P<0.05, ^^P<0.01 between group comparisons, Newman-Keuls post hoc 
t-tests.
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In addition (Table A.1), CRF produced effects on other metrics that were not affected by 
JDTic treatment: there were main effects on accuracy (F[3,27]=3.56, P<0.05), latencies 
to collect the reward (food pellet) (F[3,27]=5.87, P<0.01), and number of premature 
responses (F[3,27]=3.33, P<0.05). 
 
In the tail immersion assay, latencies to remove the tail from the hot water depended 
upon a significant pretreatment x treatment interaction (F[1,9]=9.34, P<0.05) (Fig. A.3).  
Post hoc analyses of within-subject effects revealed that latencies were significantly 
higher 60 min after U50,488 (15 mg/kg, IP) in the saline-treated group (P<0.01) but not 
in the JDTic-treated group.  Between-group analyses revealed no group differences at 
baseline but significantly higher latencies in the saline-treated rats 60 min after U50,488 
treatment (P<0.01).  Rats in the JDTic-treated group received the tail immersion test 
11.0 (±1.6) days after pretreatment whereas rats in the saline-treated group received it 
15.8 (±6.4) days after pretreatment.  This difference was not statistically significant 
(t[9]=1.76, not significant); much of the variability in the saline-treated group was 
attributable to a rat that was resistant to re-stabilization after treatment with the 1.0 µg 
dose of CRF. 
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Table A.1 Additional 5CSRTT Metrics 
       
               
Metric  Group  Pretreat  aCSF  CRF 0.25  CRF 0.5  CRF 1.0  Statistics
a 
Accuracy  Vehicle  74.0 ± 4.6  77.7 ± 4.2  75.8 ± 4.4  69.0 ± 6.1  58.2 ± 6.6  F[3,27]=3.56 
  JDTic  76.2 ± 2.4  78.2 ± 4.3  81.6 ± 4.9  82.8 ± 2.3  67.8 ± 2.8  P<0.05 
Reward 
Latency  Vehicle  1.53 ± 0.10  1.65 ± 0.14  1.93 ± 0.33  2.09 ± 0.41  2.35 ± 0.36  F[3,27]=5.87 
  JDTic  1.52 ± 0.15  1.48 ± 0.11  1.59 ± 0.16  1.63 ± 0.17  2.40 ± 0.30  P<0.01 
Premature  Vehicle  21.8 ± 5.8  20.8 ± 10.2  15.4 ± 4.1  10.8 ± 1.6  9.7 ± 1.8  F[3,27]=3.33 
  JDTic  21.8 ± 6.8  17.2 ± 2.9  16.4 ± 3.7  4.4 ± 2.0  7.6 ± 1.7  P<0.05 
                       
                aMain effects of Treatment (CRF Dose).  No Main effects of Pretreatment or Interactions 
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Figure A.3 Effects of JDTic pretreatment on latency to withdraw the tail (in sec) in 
the tail immersion assay at baseline or 60 min after administration of the KOR-
selective agonist U50,488 (15 mg/kg, IP).  **P<0.01 within group comparisons, 
^^P<0.01 between group comparisons, Newman-Keuls post hoc t-tests.
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Discussion 
We report 3 important findings.  First, we show that administration of CRF, an approach 
known to mimic effects of stress in humans and laboratory animals (Bangasser and 
Valentino, 2012), can produce dramatic disruptions of performance in rats as measured 
in the 5CSRTT.  This finding is novel, considering that previous work suggests that CRF 
can enhance performance in the 5CSRTT at lower doses (0.1 µg) and shorter 
pretreatment times (20 min) (Ohmura et al., 2009), and suggests an inverted U-shaped 
function of CRF on cognitive behavior.  Second, we show that pretreatment with a 
single injection of JDTic, a highly selective KOR antagonist with long-lasting effects 
(Carroll et al., 2004), can reduce or prevent numerous acute stress-related effects that 
degrade performance in tasks requiring attention.  Finally, we confirm that the 
behavioral effects of JDTic are persistent in rats, producing a virtually complete 
blockade of KOR function for at least 11 days after administration.  These findings are 
broadly consistent with previous work indicating that KOR antagonists can block the 
effects of stress (Bruchas et al., 2010; Knoll et al., 2010), but extend it to a more 
complex aspect of cognitive behavior (attention/concentration) using a procedure that is 
directly analogous to that used to measure attention in humans (Robbins, 2002). 
 
The primary indicator that CRF disrupted performance in these studies is decreases in 
the percentage of correct responses.  CRF also increased the percentage of trials in 
which the rats failed to respond (omission errors) and increased the latency to make a 
correct response, an effect that may reflect reduced speed of processing or decision-
making (Robbins, 2002; Paine et al., 2007; Nemeth et al., 2010).  The fact that CRF 
increased the time required to complete the task (i.e., collect 90 rewards before the end  
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of the 30-min test session) likely reflects the accumulation of 5-sec time out periods 
after omitted responses and the small but significant increases in decision-making time 
over the course of the session.  Although some of these 5CSRTT metrics are clearly 
related (e.g., latencies to respond and time to complete the task), previous work 
demonstrates that key metrics can vary independently and that different drug classes 
can produce different patterns of alterations in responding (Paine et al., 2007; Nemeth 
et al., 2010).  Pretreatment with JDTic attenuated each of these CRF effects.  JDTic 
was most effective at intermediate doses of CRF that caused significant disruptions of 
behavior, but its effects were less evident at high doses of CRF that caused more 
profound stress-like behavior, suggesting lower efficacy in preventing the acute effects 
of extreme amounts or degrees of stress.  Importantly, JDTic did not have any effects of 
its own on any of these measures.  While some of the JDTic effects might be suggestive 
of behavioral activation, stimulant effects have not been observed with this class of 
drugs.  For example, we did not observe any effects of KOR antagonists on locomotor 
activity at doses that produce antidepressant-like or anxiolytic-like effects (Mague et al., 
2003; Knoll et al., 2007), or alterations in reward-driven behavior or response 
capabilities at doses that block the prodepressive-like effects of KOR agonists on 
motivation (Todtenkopf et al., 2004).  JDTic also blocks (rather than primes) stress-
induced reinstatement of cocaine self-administration in rats (Beardsley et al., 2005), 
another indicator of a lack of effects that would raise concerns about stimulant effects or 
abuse potential of this class of drugs.  The fact that JDTic did not attenuate the effects 
of CRF on accuracy, time to collect the reward, or premature responses reinforces the 
notion that individual 5CSRTT metrics are not inextricably linked to one another.  The 
CRF-induced reductions in accuracy reflect gradual increases in “commission errors”,  
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where the rat responds but at the incorrect aperture.  JDTic caused nominal reductions 
in the accuracy-disrupting effects of CRF, but these effects were not statistically 
significant.  Overall, this pattern of effects (increases in omission errors but not 
commission errors) resembles that seen in this test following administration of ketamine 
(Nemeth et al., 2010), a drug known to disrupt attention in humans (Knott et al., 2011).  
Both omission and commission errors can have significant adverse consequences 
during times of stress. 
 
The mechanisms by which KOR antagonists prevent the effects of stress in general or 
of CRF specifically are not fully understood.  There is no evidence from published 
studies that KOR antagonists bind to CRF receptors.  While it would be speculative to 
attribute our effects to actions in any particular brain area or circuit, there are some 
obvious candidates.  As one example, there is evidence that KOR antagonists produce 
anti-stress effects via interactions with the intracellular signaling molecule p38α MAPK 
(Bruchas et al., 2011).  Stress produces increases in the activity (phosphorylation) of 
p38α MAPK within the dorsal raphe nucleus (DRN), which sends serotonin (5HT)-
containing projections to forebrain areas critical for modulating fear and anxiety 
responses (Lowry et al., 2005).  This effect is mimicked by administration of U50,488, 
which produces dysphoria (see Carlezon et al., 2009), and is blocked by KOR 
antagonism.  Activation of p38α MAPK leads to increases in surface expression of 5HT 
transporters and, in turn, decreases in extracellular levels of 5HT.  Indeed, central 
administration of CRF inhibits DRN neurons and produces decreases in 5HT release 
(Price et al., 1998; Kirby et al., 2000).  Thus it is possible that the effects of JDTic 
reported here may be due to inhibition of CRF-induced decreases in 5HT via blockade  
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of CRF-regulating KORs within the DRN (see Bruchas et al., 2011; Muschamp et al., 
2011a).  Another possibility is that actions in striatal regions may contribute to these 
effects.  Lesions of the striatum, an area rich in dopamine (DA), degrade 5CSRTT 
performance (Rogers et al., 2001).  Previous work has shown that systemic DA receptor 
antagonism decreases premature responses and increases omissions and response 
latencies in the 5CSRTT (Harrison et al., 1997).  Similarly, depletion of DA from the 
striatum increases both response latencies and omissions (Cole and Robbins, 1989; 
Baunez and Robbins, 1999), a pattern of effects similar to that which we observed after 
CRF administration.  CRF stimulates dynorphin release (Nikolarakis et al., 1986; Song 
and Takemori, 1992), which can in turn inhibit DA release via KOR activation at 
terminals of midbrain DA neurons (Donzanti et al., 1992; Svingos et al., 1999), creating 
a hypo-dopaminergic state.  Additionally, there is evidence that the DRN sends direct 
projections to the striatum that regulate DA release: activation of 5HT receptors in the 
striatum increases extracellular concentrations of DA (Benloucif and Galloway, 1991; 
Benloucif et al., 1993) whereas CRF reduces 5HT release in the striatum (Price et al., 
1998), raising the possibility that CRF-induced decreases in 5HT may reduce DA 
activity in this region.  Blockade of KORs with JDTic either at DA nerve terminals or 
within the DRN may attenuate reductions in DA activity, thereby improving performance 
in the 5CSRTT.  These possibilities are not mutually exclusive; indeed, each may be 
only one of several mechanisms acting in concert, considering that stress can elevate 
dynorphin expression in areas including the ventral striatum (nucleus accumbens [NAc]) 
and hippocampus, and that microinjections of KOR antagonists into these regions is 
sufficient to produce antidepressant-like effects (Pliakas et al., 2001; Newton et al., 
2002; Shirayama et al., 2004; Muschamp et al., 2011b).  The NAc is of particular  
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interest because it is embedded within a complex circuitry that can influence the 
function of other brain areas implicated in motivation and emotion, such as the frontal 
cortex and amygdala (see Carlezon and Thomas, 2009).  It is not yet known if all of 
these effects can be tied together within a single neural circuitry model.  Clearly, a 
broad scope of additional work is needed to further characterize CRF-KOR interactions 
and determine if effects in the various behavioral tests are attributable to a uniform 
neural substrate or circuit.  
 
JDTic (10 mg/kg) was administered once, 24 hr before testing began, because this drug 
is known to have a slow onset and long duration of action (Carroll et al., 2004; Knoll et 
al. 2007; Knoll and Carlezon 2010).  Indeed, data from the present study confirm that 
JDTic can disrupt responsiveness to a KOR-selective agonist for at least 11 days.  The 
mechanism of this effect is not fully understood, but may involve ligand-directed 
signaling (also known as biased agonism), a process by which a drug can act as an 
antagonist of some downstream intracellular signaling pathways while simultaneously 
acting as an agonist at others.  The long-lasting effects of KOR antagonists in general 
may be related to their ability to activate c-Jun N-terminal kinase-1 (JNK), leading to a 
de-coupling of KORs from their intracellular signaling cascades (Melief et al., 2010; 
Melief et al., 2011), rather than long-term persistence of these drugs in the brain (Munro 
et al., 2012).  From a drug development perspective, such long-lasting effects may be 
ultimately desirable once safety and efficacy are established, but they complicate early-
phase clinical studies in humans (Carlezon et al., 2009).  Next-generation KOR 
antagonists that block p38α MAPK without stimulating JNK may be optimal as 
therapeutic agents.  
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These new findings supplement a growing body of evidence suggesting that KOR 
antagonists can block the effects of stress.  These agents produce antidepressant-like 
effects in models that depend upon stressful experiences such as inescapable 
swimming or shock to trigger a depressive-like state (Pliakas et al., 2001; Newton et al., 
2002; Mague et al., 2003).  They also produce anxiolytic-like effects in models where 
stress produces a resistance to exploring open spaces (elevated plus maze) or 
persistent fear behaviors in the presence of cues associated with prior pain or trauma 
(fear conditioning) (Knoll et al., 2007).  The fact that KOR antagonists produce both 
these antidepressant- and anxiolytic-like behaviors together gives them a unique profile, 
since acute administration of standard antidepressants tends to produce anxiogenic 
effects in rodent models that may reflect those often seen early in antidepressant 
treatment regimens in humans (Knoll et al., 2007). 
 
There are currently no methods to prevent the immediate effects of stress or the 
subsequent development of anxiety or depressive disorders.  In situations where stress 
can be predicted, the ability to intervene with a preventative measure in advance of 
stress exposure may promote short-term safety and long-term health.  The present 
studies indicate that pretreatment with a KOR antagonist can improve cognitive 
performance that is typically degraded under stress-like conditions, an effect that would 
be particularly desirable in humans when stress is accompanied by danger or the 
potential for harm.  Considering prior work showing that pretreatment with this same 
class of agents has anxiolytic effects and attenuates the development of conditioned 
fear (Knoll et al, 2007) in a rodent version of a method often used to study PTSD in 
people (Mahan and Ressler, 2012), these new findings provide further evidence that  
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KOR antagonists can prevent stress-induced processes that may render individuals 
vulnerable to acute injury and contribute to the development of psychiatric illness. 
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